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ABSTRACT 
Neisseria meningitidis is a major cause of meningitis and sepsis worldwide despite available 
polysaccharide and protein vaccines. Individuals with rare defects in the terminal complement 
pathway are susceptible to meningococcal disease but further genetic factors that contribute to 
disease susceptibility are less well understood. A genome wide association study has linked 
polymorphisms in the Complement Factor H (CFH) locus with meningococcal disease in the general 
population. CFH is a negative regulator of the alternative complement pathway whereas CFH-related 
proteins (CFHR), encoded in the CFH locus, act as antagonists of CFH. Investigations of the biological 
role of the CFHRs have been hampered by lack of reagents, therefore a panel of specific monoclonal 
antibody reagents to CFHR2-5 were generated and characterised. 
Previously, N. meningitidis has been shown to bind CFH via a surface exposed lipoprotein, factor H 
binding protein (fHbp), at high affinity. This study demonstrates that CFHR3 binds to the bacterial 
surface in a fHbp dependent-manner. Furthermore, CFHR3 competes with CFH for binding to fHbp. 
Bound CFHR3 increases susceptibility of N. meningitidis to complement-mediated lysis which was 
dependent on the sequence of the fHbp variant. The ability of N. meningitidis to evade the host 
immune system is likely to be determined by the relative levels of CFH and CFHR3 on the bacterial 
surface, providing a molecular mechanism for how variation in cfhr3 may predispose individuals to 
meningococcal disease. 
Furthermore this work demonstrates that Neisseria cinerea, which colonises the respiratory mucosa, 
expresses fHbp and binds CFH at similar affinities as meningococcal fHbp promoting bacterial survival 
in serum. The recently developed meningococcal vaccine, Bexsero®, includes fHbp as an antigen and 
antibodies elicited by Bexsero® are bactericidal against N. cinerea suggesting that the introduction 
of this vaccine could affect nasopharyngeal carriage of N. cinerea. 
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1. INTRODUCTION 
1.1 The Complement System: Pathway overview  
The Complement system is a crucial mechanism of host defence against pathogens and mediates 
both immunological and inflammatory responses [Dunkelberger, J. R. 2010]. Complement is able to 
discriminate self from non-self, eliminate cellular debris and apoptotic cells, and recognise foreign 
molecules including those on microbes [Medzhitov, R. 2002. Trouw, L. A. 2008. Ricklin, D. 2010]. The 
Complement system is comprised of over 50 fluid phase and membrane-associated proteins which 
are integrated in a tightly regulated proteolytic cascade, initiated through sequential cleavage of 
complement components and resulting in the activation of the innate immune system [Ricklin, D. 
2010]. Complement activation can be initiated by three pathways: through the recognition of foreign 
surfaces (alternative pathway, AP), antibody:antigen complexes (classical pathway, CP) or pathogen 
glycans (lectin pathway, LP), which ultimately lead to lysis or phagocytosis of the complement target 
[Pangburn, M. K. 1981. Bindon, C. I. 1988. Nadesalingam, J. 2005. Ricklin, D. 2010].  
1.1.1 The Classical pathway 
The fluid phase pattern recognition molecule (PRM) C1q initiates the CP by direct binding onto the 
surface of a pathogen or apoptopic cell, or by recognising immune complexes formed by IgM or IgG 
binding to an antigen [Collins, C. 2002. Bindon, C. I. 1988.]. The CP can also be initiated by pentraxins, 
e.g. C-reactive protein (CRP), pentraxin related protein 3 (PTX3) or serum amyloid P (SAP), binding 
phosphorylcholine or phosphorylethanolamine on microbes or apoptopic cells [Szalai, A. J. 2002; 
Jiang, H. X. 1991. Schwalbe, R. A. 1992]. C1q is present in serum in a complex with C1r and C1s, 
C1qr2s2 [Chen, C. H. 1998]. Binding of C1q results in cleavage of C1s by C1r, leading to the subsequent 
cleavage of C4, to C4a and C4b, by activated C1s [Lepow, I. H. 1963. Ziccardi, R. J. 1977. Bally, I. 2009]. 
The exposed thioester bond of C4b then covalently binds to the surface of the activating molecule, 
leading to opsonisation [Schreiber, R. D. 1974. Dodds, A. W. 1996]. Surface bound C4b recognises 
and binds C2 which is cleaved into C2a and C2b by C1s, [Müller-Eberhard, H. J. 1967. Nagasawa, S. 
1977]. C2a remains bound by C4b to form the CP C3 convertase, C4bC2a, which cleaves C3 to activate 
the AP and the terminal complement pathway. Figure 1.1 summarises the CP. 
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Figure 1.1: Activation of CP and LP 
The CP is initiated by the binding of the C1q complex; consisting of C1q (grey), two C1r molecules (blue) and two C1s 
molecules (green) to IgG or IgM on activating surfaces. Conformational changes in C1q result in the activation of the 
proteases C1r and C1s resulting in the cleavage of C4 by C1s. C4b is deposited on activator surfaces and binds C2 which is 
cleaved by C1s to C2a, that remains bound to C4b, and the C2b fragment is released. The C4bC2a complex is a C3 
convertase that can cleave C3. The LP is initiated by the binding of the MBL complex (red box) to carbohydrates on 
microbes. The MBL complex is structurally similar to the C1q complex of the CP. MASP1 and MASP2 are functionally similar 
to C1r and C1s respectively, which results in cleavage of C4 and C2 to form the C3 convertase. 
 
1.1.2 The Lectin pathway  
The LP is functionally similar to the CP as it results in the formation of the same C3 convertase, 
C4bC2a [Degn, S. E. 2012]. The LP is initiated by the recognition of mannose or N-acetylglucosamine 
by Mannan Binding lectin (MBL) or acetylated carbohydrates on pathogens by ficolins. MBL or ficolins 
assemble with MBL-associated serine proteases (MASPs) into a complex similar to the C1 complex 
of the CP [Matsushita, M. 1992. Sato, T. 1994. Thiel, S. 1997. Nadesalingam, J.  2005]. MASP-1 and 
MASP-2 are functionally and structurally similar to C1r and C1s, respectively, with MASP-2 
proteolytically cleaving both C4 and C2 leading to complement activation, whereas MASP-1 
promotes the LP by specifically cleaving C2 [Héja, D. 2012. Degn, S. E. 2012].   
1.1.3 The Alternative pathway 
The formation of the CP convertase by the CP or LP results in the cleavage of C3 into C3a and C3b, 
which exposes a thioester moiety in C3b, that covalently binds to an available amine or carbohydrate 
group. This results in the attachment of C3b on the surface of the activating molecule [Fearon, D. T. 
1975. Law, S. K. 1977. Pangburn, M. K. 1980. Sim, R. B. 1981. Fishelson, Z. 1984]. C3b then binds 
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Factor B (FB) which becomes susceptible to cleavage into Ba and Bb by the protease Factor D (FD) 
[Lesavre, P. H. 1978. Janssen, B. J. 2009. Hourcade, D. E. 2011]. Bb remains bound to C3b, forming 
the AP C3 convertase, C3bBb. The AP is also activated by C3 ‘tick-over’ which results from 
spontaneous hydrolysis of C3 to C3H2O, leading to the generation of the soluble C3 convertase 
(C3H2OBb) after binding and cleavage of FB [Pangburn, M. K. 1981]. The convertase is further 
processed to generate active C3b, leading to surface deposition of the complex [Hugli, T. E. 1975. 
Pangburn, M. K. 1981]. Further PRM-mediated activation of the AP can result from recognition of 
pathogen- or damage-associated molecular patterns (PAMPs or DAMPs, respectively) by properdin 
(P) which attracts C3b to targeted surfaces and also stabilises the AP C3 convertase, C3bBbP [Spitzer, 
D. 2007. Kimura, Y. 2008. Fearon, D. T. 1975.]. Once activated the AP acts as a positive amplification 
loop, accounting for 80-90% of total complement activation, regardless of the initiating pathway 
[Fung, M. 2001. Harboe, M. 2008]. The AP needs to be tightly regulated to avoid damage to host 
tissues and a number of proteins are involved in the negative regulation of the AP. Figure 1.2 
summarises C3 tick-over and activation of the AP. 
 
Figure 1.2: Initiation of the AP 
C3 ‘tick over’ occurs by the spontaneous hydrolysis of C3 (C3(H20)) resulting in binding and subsequent cleavage of FB by FD 
to form the fluid phase C3 convertase, C3H20Bb. The fluid phase C3 convertase cleaves C3 into C3b and C3a; C3b is deposited 
on activator surfaces. Deposited C3b binds FB making FB susceptible to cleavage by FD, resulting in the release of Ba and 
formation of the C3 convertase, C3bBb. Binding of Properdin (P) stabilises the C3 convertase. The C3 convertase cleaves 
further C3 molecules acting as a positive amplification loop (red dotted arrow) to increase C3 deposition on activator 
surfaces. 
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1.1.4 The Terminal complement pathway 
Formation of the C5 convertase, whereby an additional C3b molecule is incorporated into the CP or 
AP C3 convertase resulting in C4bC2aC3b and C3bBbC3b, respectively, occurs following deposition 
of increased amounts of C3b on a target surface [Daha, M. R. 1976. Medicus, R. G. 1976. Sim, R. B. 
1980. Pangburn, M. K. 2002]. The change of substrate from C3 to C5 initiates the Terminal Pathway 
(TP) through the cleavage of C5 to C5a and C5b, which results in binding of further complement 
molecules C6 and C7 (C5b-7) [Medicus, R. G. 1976]. The C5b-7 complex can then be inserted into a 
cell membrane where it associates with C8, causing the polymerisation of multiple C9 molecules to 
assemble into a pore, the membrane attack complex (MAC) [Müller-Eberhard HJ 1986]. Figure 1.3 
summarises the activation of the TP and formation of the MAC. 
 
Figure 1.3: Activation of the TP 
Binding of a further C3b molecule to the C3 convertase on an activating surface generates the C5 convertase, C3bBbC3b, 
and a switch in substrate from C3 to C5. The C5 convertase cleaves bound C5 to C5b and releases the C5a fragment. 
Bound C5b binds C6 and subsequently C7; the C5b-C7 complex binds to the membrane and recruits C8 and 
polymerisation of C9 to form the MAC, resulting in lysis of the cell. 
 
1.2 Complement Factor H protein family  
The human complement factor H (CFH) protein family are encoded by genes located within the 
Regulators of Complement Activation (RCA) gene cluster on chromosome 1q32. The protein family 
consists of six related proteins; Complement Factor H (CFH), the major negative regulator of the AP, 
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and five CFH Related proteins (CFHRs) encoded downstream of the CFH gene. The homology 
between CFH and the CFHRs is shown in Figure 1.4 together with their major known ligands.  
 
Figure 1.4: Homology of CFH and CFHR protein family 
CFH and CFHRs consist of between 4 and 20 CCP domains. Alignment of homologous CCP domains with CFH are shown; 
the percentage amino acid sequence identity with CFH is indicated in domains and sequence identity between homologous 
CFHR domains is indicated in red.  The complement regulatory domains of CFH, CCP domains 1-4 (blue) are not conserved 
in the CFHRs. Shared binding motifs between CCP domains of CFH and CFHRs for C3b, heparin and the regulatory activity 
of CFH are also indicated. Dotted lines for heparin and C3b binding sites between CCP domains 9-14 are not confirmed. 
Confirmed C-terminal C3b/GAG binding domains (green), CCP domains 3-4 of CFHR2 retain C3b binding but have lost GAG 
binding (light green). Group 1 CFHRs (CFHR1, -2, and -5) share a conserved dimerisation motif in the first N-terminal CCP 
domain (grey) whereas group 2 CFHRs (CFHR-3 and -4) lack the motif. 
 
1.2.1 Complement Factor H 
CFH (originally called β1H globulin) was identified in human serum by Nilsson and Muller-Eberhard 
in 1965, as an essential component of complement which functions in ‘immune haemolysis’ [Nilsson, 
U. R. 1965]. The CFH gene encodes for two proteins: CFH (155 kDa), and a truncated alternative 
splice variant, CFH Like 1 (CFHL1) (43 kDa), which is identical to Complement Control Protein (CCP) 
domains 1-7 of CFH but terminates in a unique amino acid sequence, Ser-Phe-Thr-Leu [Ripoche, J. 
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1988]. CFH is primarily produced in the liver by hepatocytes, and in addition is also produced by 
monocytes, thrombocytes, fibroblasts, endothelial cells, keratinocytes, and retinal pigment epithelial 
cells where it modulates local complement activation [Schulz, T. F. 1986. Halme, J. 2009. Whaley, K. 
1980. Devine, D. V. 1987. Katz, Y. 1988. Brooimans, R. A. 1990. Timár, K. K. 2006. Chen, M. 2007]. 
Circulating plasma concentrations of CFH vary between 116–562 μg/mL, i.e. 0.7–3.6 μM, (mean 
concentration of 2.1 μM) with differences seen depending on age and ethnic groups [Esparza-
Gordillo, J. 2004]. The major role of CFH is the regulation of the AP.  
1.2.1.1 CFH Structure  
CFH is composed of 20 domains termed Complement Control Protein modules (CCP), also referred 
to as Short Consensus Repeats (SCRs) or sushi domains [Kristensen, T. 1986. Ripoche, J. 1988]. CCP 
domains are found in other complement regulatory proteins encoded by the RCA gene cluster [Lintin, 
S. J. 1988. Klickstein, L. B. 1987]. Each CCP domain of CFH is approximately 60 amino acids in length, 
stabilised by two disulphide bonds, and has three to eight amino acids between neighbouring CCP 
domains [Klickstein, L. B. 1987. Ripoche, J. 1988]. Low resolution X-ray structures indicate that CFH 
is flexible and is bent back on itself in solution, enabling it to engage ligands such as C3b and heparin, 
and bring them into close proximity with each other [Aslam, M. 2001]. Three C3b binding sites have 
been mapped to CCP domains 1-4, 12-14 and 19-20 of CFH, with the major C3b binding sites in CCP 
domains 1-4 and 19-20 [Schmidt, C. Q. 2008A. Schmidt, C. Q. 2008B]. Polyanion binding sites, which 
engage sulphated glycosominoglycan or heparin on non-activating host surfaces, have been mapped 
to CCP domains 6-8 (with CCP domain 7 essential for this interaction), and domains 19-20 [Schmidt, 
C. Q. 2008A]. Another polyanion binding site was postulated to reside within CCP domains 9-15, 
although this has not been confirmed [Schmidt, C. Q. 2008B]. The complement regulatory functions 
of CFH can be attributed to CCP domains 1-4, while CCP domains 19-20 are essential for 
discriminating self from non-self surfaces. 
1.2.1.2 Role in complement regulation 
CFH has three mechanisms to down-regulate AP activation by acting as: (i) a co-factor for Factor I 
(FI) mediated proteolytic cleavage and inactivation of C3b to iC3b; (ii) competing with FB for binding 
to C3b, inhibiting the formation of both the AP C3 and C5 convertases; (iii) and accelerating the decay 
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of the AP C3 convertase by displacing bound Bb (Figure 1.5) [Weiler, J. M. 1976. Whaley, K. 1976. 
Pangburn, M. K. 1977]. The decay accelerating and FI cofactor activities of CFH reside in CCP domains 
1-4 [Gordon, D. L. 1995. Kühn, S. 1995.]. The AP C3 convertase has a short half-life of approximately 
90 seconds, unless stabilised by properdin which increases its half-life by 10-fold [Pangburn, M. K. 
1986]. However, in the presence of bound CFH, the half-life of the AP C3 convertase is decreased to 
approximately 0.1 seconds [Pangburn, M. K. 1986]. Once Bb is displaced by CFH, no further FB can 
bind to form further C3 convertases. In the presence of FI, C3b in the CFH:C3b complex undergoes 
proteolysis in which the α’-chain of C3b is cleaved to iC3b. CFHL1 retains co-factor and decay 
accelerating activities as the N-terminus is identical to CFH, although it lacks target recognition 
mediated by the C terminal domains of CFH [Kühn, S. 1995. Kühn, S. 1996]. Recent evidence 
demonstrates that CCP domain 4 of CFHL1 but not CFH, mediates attachment of CFHL1 to epithelial 
cells by a conserved sequence, Arg-Gly-Asp, and has been implicated as the major complement 
regulator protecting the Bruch's membrane in the human eye [Hellwage, J. 1997. Clark, S. J. 2015]. 
 
Figure 1.5: Regulation of the AP by CFH 
CFH consists of 20 CCP domains with regulatory activity localised in CCP domains 1-4 (red domains). CFH regulates the 
activation of the AP by three ways: 1) Cofactor activity; binding of CFH to C3b promotes cleavage of C3b by FI to the inactive 
form of C3b, iC3b. 2) CFH competes with FB for binding to C3b preventing formation of the C3 convertase. 3) Decay 
accelerating activity; CFH binds to the C3 convertase promoting the dissociation of Bb from the complex. 
 
1.2.1.3 The role of CFH in discriminating self from non-self surfaces 
C3b can be deposited on any surface, and therefore complement needs to be tightly regulated to 
avoid complement mediated attack of host cells. CFH is a key regulator of complement activation on 
host tissues due to its regulatory functions. Recognition of host cell surfaces by CFH is thought to be 
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mediated through sialic acids and glycosaminoglycans (GAG) i.e. heparin, heparan sulphate, and 
dextran sulphate [Jokiranta, T. S. 2005]. The polyanionic molecules on endothelial cells are generally 
host specific and have a 10-fold higher affinity for CFH than C3b, and therefore impair activation of 
complement [Fearon, D. T. 1978]. On host tissues, CFH can bind to human endothelial cells and 
basement membranes via CCP domain 20, while simultaneously binding C3b via CCP domain 19, and 
preventing complement-mediated attack via the regulatory CCP domains 1-4 [Jokiranta, T. S. 2005. 
Ferreira, V. P. 2006. Pickering, M. C. 2002. Kajander, T. 2011].  
1.2.1.4 Recruitment of CFH as a mechanism for complement evasion by bacterial pathogens 
The ability of pathogenic bacteria to evade the immune system is essential for survival within the 
host. Many pathogens have evolved mechanisms to circumvent the complement system.  Both Gram 
positive and Gram negative bacteria can recruit CFH to avoid complement-mediated attack by 
decreasing opsonisation and lysis [Lambris, J. D. 2008]. Table 1.1 summarises bacteria which are 
known to bind CFH. Two main binding sites, which are distinct from the regulatory CCP domains, are 
utilised by microbes to sequester CFH [Meri, T. 2013]. One binding site is located in CCP domains 6-
7, and is utilised by Streptococcus pyogenes, Neisseria meningitidis and Pseudomonas aeruginosa 
[Meri, T. 2013. Pérez-Caballero, D. 2004. Schneider, M. C. 2009. Kunert, A. 2007]. The other main 
interaction site is in the carboxy terminus of CFH in CCP domains 19-20; Streptococcus pneumoniae, 
Neisseria gonorrhoeae and Staphylococcus aureus utilise this second binding site [Meri, T. 2013. 
Hammerschmidt, S. 2007. Ngampasutadol, J. 2008. Haupt, K. 2008].  
Host endothelial cells bind CFH via a charged groove between CCP domains 6-7 and also via 19-20 
[Prosser, B. E. 2007]. Of note, N. meningitidis, binds CFH at the same site as host cells by CCP domains 
6-7, and engages the GAG binding site in CCP domain 7 via meningococcal factor H binding protein 
(fHbp) [Schneider, M. C. 2009. Meri, T. 2013]. fHbp forms a high affinity complex with CFH, while the 
closely-related organism, N. gonorrhoeae binds CFH via an outer membrane porin, PorB.1B [Ram, S. 
1998]. CFH binding to PorB.1.B is enhanced by sialylation of the lipooligosaccharide of the 
gonococcus [Ram, S. 1998]. 
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Bacterial spp. Ligand Ligand binding domain with CFH Reference(s) 
                       
  
1 2 3 4 5 6 7 8 9 # # # 
#  
# # # # # # # 
 
                       
Bordetella 
pertussis  
?     
                     Amdahl, H. 2011 
                         
Bordetella 
parapertussis 
?     
                     Amdahl, H. 2011 
                         
Borrelia 
burgdorferi  
CRASP-1 
[1] 
                     Siegel, C. 2010 
                     
 CRASP-2 
[1] 
                     Siegel, C. 2010 
                     
 OspE 
                      Hellwage, J. J. 
2001. 
Bhattacharjee, A. 
2013                       
Borrelia 
hermsii 
CRASP-1                    
  Rossmann, E. 
2007 
                     
Escherichia coli  Stx2 [1]      
                     Orth, D. 2009;                                         
Poolpol, K. 2014                           
Fusobacterium 
necrophorum 
? [1]     
                     Friberg, N. 2008 
                         
Haemophilus 
influenzae 
PH [1]       
                  Fleury, C. 2014 
                    
Neisseria 
gonorrhoeae 
PorB.1A 
[1] 
                        Ram, S. 1998. 
Ngampasutadol, J. 
2008                     
 PorB.1B 
[sia] 
                       Ram, S. 1998. 
Ngampasutadol, J. 
2008                     
Neisseria 
meningitidis 
fHbp      
                 Schneider, M. C. 
2009                     
 NspA      
                 Lewis, L. A. 2010 
                    
 PorB2 [1]      
                 Lewis, L. A. 2013 
                    
Leptospira 
interrogans  
Lig (A, B) 
[1] 
                          Castiblanco-
Valencia, M. M. 
2012                           
 LfHA                   
    
Verma, A. 2006 
                      
 LenA                  
      
Meri, T. 2005 
                       
 LenB [1]     
                   Stevenson, B. 
2007 
                       
Pseudomonas 
aeruginosa 
Tuf [1]      
                   Kunert, A. 2007 
                        
 LpD [1]       
                  Hallström, T. 2012 
                        
Rickettsia 
conorii 
OmpB** 
                                        
Riley, S. P. 2012 
                                        
Salmonella 
enterica 
Rck     
                     Ho, D. K. 2010 
                         
Staphylococcus 
aureus 
Sbi*                   
    
Haupt, K. 2008 
                      
 SdrE** 
                                        
Sharp, J. A. 2012 
                                        
Streptococcus 
agalactiae  
β protein        
                    Jarva, H. 2004 
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SHT** 
                                        Maruvada, R. 
2009                                          
Streptococcus 
pneumoniae 
CbpA      
                       Lu, L. 2006 
                            
 Hic 
                        
Jarva, H. 2002 
                        
 PspC 
                             Dave, S. 2004; 
Hammerschmidt, 
S. 2007; Duthy, T. 
G. 2002 
                             
Streptococcus 
pyogenes  
M protein 
[1] 
                      Kotarsky, H. 1998. 
Pérez-Caballero, 
D. 2004 
                      
 Fba [1] 
                      Pandiripally, V. 
2003                       
 Scl1.6; 
Scl1.55 
                       
Reuter, M. 2010 
                       
Streptococcus 
suis 
Fhb** 
                                        
Pian, Y. 2012 
                                        
Treponema 
denticola 
FhbB [1] 
                      McDowell, J. V. 
2005; Miller, D. P. 
2012                       
Yersinia 
enterocolitica 
YadA* 
                                        Schindler, M. K. 
2012                                         
 
Ail                       
Biedzka-Sarek, M. 
2008 
                    
Table 1.1: Recruitment of CFH by bacterial pathogens 
Reported domains of CFH (black line) which bind to the bacterial spp. indicated, with the known CFH receptor. Bacteria 
shown to bind CFH, but the domains of CFH that bind to the receptors have not been identified are indicated. 
* Complexes   ** Unknown CFH binding region   [1] Binds CFHL along with CFH   [sia] Requires siaylation for CFH binding 
Abbreviations: CRASP, complement regulator acquiring surface proteins; OspE, outer surface protein; Stx-2, Shiga toxins; 
PH, protein H; Por, Porin; fHbp, factor H binding protein; NspA, Neisserial Surface Protein A; Lig, Leptospiral 
Immunoglobulin-like;  Lfh, Leptospiral factor H binding protein; Len, Leptospiral Endostatin-Like Protein; Tuf, Translation 
elongation factor Tu; LpD, Dihydrolipoyl dehydrogenase; Omp, outer membrane protein; Rck, resistance to complement 
killing; Sbi, second immunoglobulin-binding protein; SHT, streptococcal histidine trial; CbpA, choline-binding protein; Hic, 
factor H binding inhibitor of complement; Psp, pneumococcal surface protein; Fba,  fibronectin binding protein; Scl, 
streptococcal collagen like protein; Fhb, factor H binding protein; YadA, Yersinia adhesin; Ail, attachment invasion locus 
protein.   
 
More recently, CFH has been shown to enhance the activity of the S. aureus immune evasion protein, 
Sbi [Haupt, K. 2008. Amdahl, H. 2013. Meri, T. 2013]. This staphylococcal protein inhibits binding of 
IgG to Fcᵧ receptors, and binds CFH and C3 in a tripartite complex [Burman, J. D. 2008. Haupt, K. 
2008]. Staphylococcal extracellular complement binding protein (Ecb) and to a more limited extent, 
extracellular fibrinogen-binding protein (Efb) also bind CFH and C3b in a complex. In contrast to Sbi, 
Ecb and Efb are secreted proteins and do not recruit CFH to the bacterial surface [Amdahl, H. 2013]. 
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Recent evidence has also shown that CFH binds to Yersinia enterocolitica by Yersinia adhesin A 
(YadA), in complex with C3b mediating enhanced resistance to serum [Schindler, M. K. 2012]. The 
identification of distinct molecules (Sbi, Ecb, Efb and YadA) in two bacterial species that bind CFH by 
alternative mechanisms that enhance down regulation of the AP emphasises the importance of 
recruitment of CFH to pathogenic bacteria [Meri, T. 2013]. 
Recruitment of CFH by pathogens can also promote bacterial invasion of host epithelial cells and 
attachment to neutrophils [Agarwal, V. 2010]. CFH is a ligand for human polymorphonuclear 
leukocytes via the intergrin, Complement Receptor 3 (CR3) [DiScipio, R. G. 1998]. S. pneumoniae 
recruits CFH to its surface by Pneumococcal Surface Protein C (PspC). Binding of CFH to S. 
pneumoniae enhances adhesion and internalisation by interactions with CR3, with CFH acting as a 
molecular bridge. [Agarwal, V. 2010]. A similar mechanism by N. gonorrhoeae also enhances 
adherence to cells expressing CR3 [Agarwal, S. 2010].  
1.2.2 Complement Factor H Related proteins  
All five CFHRs are structurally similar to CFH but are composed of four to nine CCP domains, which 
have varying sequence identity with CCP domains of CFH (Figure 1.4) [Díaz-Guillén, M. A. 1999]. 
cfhr1, cfhr2, cfhr3 and cfhr4 were identified as mRNA transcripts of human liver that hybridise to CFH 
cDNA. CFHR5 was initially identified by using a monoclonal antibody (mAb) raised against human 
glomerular preparations and mRNA transcripts were subsequently detected in human liver 
preparations [Estaller, C. 1991. Skerka, C. 1992. Skerka, C. 1993. Skerka, C. 1997. McRae, J. L. 2001].  
All CFHRs lack the regulatory domains of CFH (i.e. CCP domains 1-4), and therefore would be 
expected to lack FI cofactor and C3 convertase decay accelerating activity (Figure 1.4).   
CFHRs can be divided into two groups based on their structure and sequence [Skerka, C. 2013]. 
Group I, classified by their conserved N-terminus and ability to form dimers, consists of CFHR1, 
CFHR2 and CFHR5 [Goicoechea de Jorge, E. 2013]. CFHR3 and CFHR4 lack the dimerisation motif yet 
have a high sequence identity with each other and form group II. Structural studies demonstrate that 
CFHR1, -2 and -5 assemble as head-to-tail dimers with three key residues (Tyr34, Ser36 and Tyr39) 
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mediating this interaction [Goicoechea de Jorge, E. 2013]. Dimeric complexes can be isolated from 
serum, with the composition of dimers dependent on the relative abundance of each CFHR 
[Goicoechea de Jorge, E. 2013]. Dimerisation of the CFHRs increases their avidity for substrates such 
as C3b, and dimeric CFHR5 has also been demonstrated to have an increased ability to bind to 
activated murine C3 on the glomerular basement membrane compared to monomeric CFHR5 
[Goicoechea de Jorge, E. 2013]. It is not known whether CFHR3 and CFHR4 form dimers although 
both lack the key residues required for dimer formation found in Group I CFHRs. 
1.2.2.1 CFHR1 
CFHR1 is a five CCP domain protein with a high sequence identity to CCP domains 6-7 and 18-20 of 
CFH, and with CFHR2 and CFHR5 (Figure 1.4). CFHR1 occurs as two variants; CFHR1A has the amino 
acid sequence His-Leu-Glu in CCP domain 3, whereas this sequence is Tyr-Val-Gln in CFHR1B [Skerka, 
C. 1991. Susukida, R. 2007. Abarrategui-Garrido, C. 2009]. CFHR1 also circulates in the blood stream 
as two isoforms, CFHR1α with a single glycosylation site, while CFHR1β is glycosylated at residues 
Asn 126 and Asn 194 [Skerka, C. 1991. Liu, T. 2005]. Predicted to be the most abundant of the CFHRs, 
the serum concentration of CFHR1 is approximately 70–100 μg/ml (1.6–2.4 μM) [Heinen, S. 2009].  
1.2.2.2 CFHR2 
CFHR2 is composed of four CCP domains homologous to CCP domains 6-7 and 19-20 of CFH. Serum 
CFHR2 concentrations are estimated to be approximately 50 µg/ml (1.2 µM) [Goicoechea de Jorge, 
E. 2013]. CFHR2 exists as two isoforms; CFHR2 is unglycosylated, whereas CFHR2α is glycosylated at 
position Asn 126 [Skerka, C. 1992. Chen, R. 2009]. 
1.2.2.3 CFHR3 
CFHR3 consists of five CCP domains homologous to CCP domains 6-8 and 19-20 of CFH. Initial 
estimates of the serum concentration of CFHR3 indicate it is present at similar levels as CFHR1 i.e. 
50–80 µg/ml (1–1.6 µM) [Fritsche, L. G. 2010]. However many available antibodies against CFHR3 
cross react with CFHR4 due to the high amino acid identity between CFHR3 and CFHR4 [Fritsche, L. 
G. 2010. Skerka, C. 2013]. Therefore estimates of CFHR3 levels may be inaccurate and the actual 
concentration may be significantly lower. Indeed, recent estimates of serum CFHR3 levels suggest 
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that the circulating concentration of CFHR3 is approximately 100-fold lower, and range from 0–2.7 
µg/ml with a mean of 0.69 µg/ml (18.7 nM) [Pouw, R. B. 2016]. Like CFHR4, CFHR3 lacks an N terminal 
dimerisation motif, while multiple isoforms of CFHR3 have been detected in sera indicating four 
potential glycosylation variants [Skerka, C. 1993. Chen, R. 2009].  
1.2.2.4 CFHR4 
cfhr4 encodes for two alternative splice variants, CFHR4A and CFHR4B. CFHR4A is a nine CCP domain 
protein resulting from an internal duplication, with identical CCP domains 1-3 and 5-7 [Józsi, M. 
2005]. CFHR4B is an alternative splice variant of CFHR4 composed of five CCP domains. The CCP 
domains of CFHR4B and domains 5-9 of CFHR4A are also homologous to CCP domains 6, 8, 9 and 19-
20 of CFH. Serum concentrations of both isoforms of CFHR4 have been estimated to be 
approximately 25 µg/mL [Hebecker, M. 2012].  
1.2.2.5 CFHR5 
CFHR5 forms heterodimers with CFHR1 and CFHR2 [Goicoechea de Jorge, E. 2013]. CFHR5 is 
composed of nine CCP domains which are homologous to CCP domains 6-7, 10-14 and 19-20 of CFH. 
Serum concentrations have been estimated at 3–6 μg/ml (0.05–0.09 μM) [McRae, J. L. 2005]. 
1.3 CFHRs and interactions with the Complement system  
The complexity of studying CFHRs is evident from the literature in which CFHRs have been proposed 
to act as negative complement regulators, given their sequence identity with CFH, while recent 
evidence indicates that CFHRs enhance complement activation [Heinen, S. 2009. Hebecker, M. 2012. 
Goicoechea de Jorge, E. 2013. Tortajada, A. 2013]. 
1.3.1 Interaction of CFHRs and the pentraxins 
The monomeric pentraxin CRP binds phospholipids from damaged or aptoptotic cells, inducing an 
inflammatory response by recruiting C1q and activating the CP [Volanakis, J. E. 1979; Volanakis, J. E. 
1981]. CRP also binds CFH independently of Ca2+ via CCP domains 7 and 8-11, modulating localised 
complement activation [Jarva, H. 1999]. Both CFHR4A and CFHR4B bind pentameric CRP in the fluid 
phase in the presence of Ca2+ via CCP domain 1; the difference in binding region between CFH and 
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CFHR4 may explain why CFH binds monomeric CRP whereas CFHR4 binds pentameric CRP [Mihlan, 
M. 2009. Hebecker, M. 2010.]. Binding of CFHR4A to CRP also initiates the CP by increasing 
deposition of C4 and C3 [Hebecker, M. 2010.]. CRP also activates the AP by binding C3b, and 
mediating the opsonisation of biological surfaces and modulates complement activation [Hebecker, 
M. 2010.].  CFHR5 binds CRP via CCP domains 5-7 and is predicted to be recruited to sites of host 
tissue damage and potentially enhance complement activation [McRae, J. L. 2005. Kopp, A. 2012]. 
PTX3 has been shown to bind CFH and CFHL in a Ca2+ dependent manner by CCP domain 7 and 19-
20 of CFH, leading to clearance of apoptopic cells [Deban, L. 2008. Kopp, A. 2012]. PTX3 bound to 
extracellular matrix components prevents complement activation by binding CFH, whereas damaged 
tissues are unprotected by regulators [Deban, L. 2008. Kopp, A. 2012]. PTX3 also binds CFHR1 by CCP 
domains 4-5 which are related to CFH CCP domains 19-20 [Kopp, A. 2012]. More recent evidence 
suggests that CFHR5 competes with CFH for binding to PTX3 and CRP enhancing C1q binding and 
results in increased deposition of C3b on surfaces [Csincsi, ÁI. 2015]. Therefore the balance between 
pentraxins, CFH, CFHR1 and CFHR5 will determine the level of complement activation on surfaces. 
Currently there is no evidence that CFHRs -2, -3, or -4 bind PTX3 [Csincsi, ÁI. 2015]. 
1.3.2 CFHR interactions with C3 and function 
CFHR1, CFHR3, CFHR4A, CFHR4B and CFHR5 have been shown to bind C3b, iC3b and C3d but lack 
both cofactor activity for FI and decay accelerating activity [Heinen, S. 2009. Hellwage, J. 1999. 
Hebecker, M. 2012.  Eberhardt, H. U. 2013. Goicoechea de Jorge, E. 2013]. At non-physiological 
concentrations, (e.g. 10 µM) or extended incubation times (e.g. 5 hours), CFHR3 and CFHR4B have 
weak FI cofactor activity, but this is unlikely to be biologically relevant [Hellwage, J. 1999. Hebecker, 
M. 2012.]. Other studies have used high concentrations of CFHR3 (1.8 µM) and CFHR5 (0.15 µM) to 
demonstrate weak FI cofactor activity [Fritsche, L. G. 2010. McRae, J. L. 2005]. CFHR1 has been 
proposed to act as a complement regulator by directly binding C5 or C5b-6 and preventing MAC 
formation [Heinen, S. 2009]. Subsequent studies have shown that CFHR3 also prevents the 
generation of C5a [Fritsche, L. G. 2010.]. Conversely Goicoechea de Jorge, E. et al could not 
demonstrate any significant interaction between CFHR1 with C5 at physiological protein 
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concentrations and instead demonstrated a novel role for CFHR1, CFHR2 and CFHR5. These CFHRs 
were shown to activate complement and increase erythrocyte lysis which was further enhanced by 
dimerisation of CFHRs [Goicoechea de Jorge, E. 2013]. Furthermore, CFHR1, CFHR2 and CFHR5 act 
as competitive antagonists of CFH by competing for binding C3b [Goicoechea de Jorge, E. 2013]. The 
ability of CFHR1, CFHR2 and CFHR5 to act as antagonists of CFH has been confirmed by others 
[Tortajada, A. 2013].  
CFHR5 is also a PRM which specifically binds to necrotic endothelial cells and recruits properdin, by 
CCP domains 1-2 [Chen, Q. 2016]. Multimerisation of CFHR5 increases binding to cell surfaces and 
enhances properdin binding due to increased avidity [Chen, Q. 2016]. Therefore while CFH is 
essential for discriminating self from non-self, the CFHRs can help fine-tune complement regulation 
to maintain tissue homoeostasis.  
1.4 Association of CFHRs with human disease 
The CFH/CFHR gene locus is susceptible to gene rearrangements including replication, deletion, and 
duplication as well as mutations and polymorphisms. Rearrangements of this region are associated 
with human diseases, providing some insights into the function of CFHRs.  
Lack of CFHR1, through ΔCFHR3/CFHR1 or ΔCFHR1/CFHR4, and gene fusions of CFH/CFHR1 or 
CFH/CFHR3 predispose individuals to atypical haemolytic-uraemic syndrome (aHUS) associated with 
the appearance of auto-antibodies against CFH (DEAP HUS) [Holmes, L. V. 2013. Zipfel, P. F. 2007. 
Moore, I. 2010. Dragon-Durey, M. A. 2009. Francis, N. J. 2012; Francis, N. J. 2012]. The 
ΔCFHR3/CFHR1 deletion also confers protection against age-related macular degeneration (AMD) 
and IgA nephropathy [Hughes, A. E. 2006. Gharavi, A. G. 2011]. Both a duplication of CCP domains 1-
4 of CFHR1 and CFHR3/CFHR1 gene fusions are associated with the development of C3 
glomerulonephritis (C3GN) [Tortajada, A. 2013. Malik, T. H. 2012]. A recent genome wide association 
study (GWAS) of susceptibility to meningococcal disease identified a single nucleotide polymorphism 
(SNP) in cfhr3 which is associated with a decreased risk of developing meningococcal disease [Davila, 
S. 2010]. This GWAS study is discussed in further detail in section 1.7.5.3. Furthermore, the same 
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cfhr3 SNP (rs426736) was identified in meningococcal GWAS study was also associated with leprosy 
caused by Mycobacterium leprae [Zhang, D. F. 2014].  
Polymorphisms in cfhr5 are associated with dense deposit disease (DDD) characterised by dense 
deposits of C3 in the glomerular basement membrane of the kidneys, whereas an internal 
duplication of cfhr5 is associated with nephropathy in a family of Cypriot origin [Abrera-Abeleda, M. 
A. 2006. Gale, D. P. 2010]. Loss of function mutations in cfhr5 have also been reported in aHUS 
patients [Maga, T. K. 2010. Westra, D. 2012]. In one study, individuals with sequence variants in cfhr5 
were reported to have a significant increased risk of AMD, whereas another study reported that the 
risk of AMD was unchanged [Zhang, H. 2008. Narendra, U. 2009]. Recently a single nucleotide 
insertion in cfhr5 resulting in a premature stop codon presented with C3 deposits in the kidneys 
which were consistent with C3 glomerulopathy suggesting this sequence variant was a risk factor for 
developing chromic kidney disease. [Vernon, K.A. 2012]. 
1.5 CFHR interactions with bacterial pathogens 
There are several examples of CFHRs recruited to the surface of pathogens, although in many 
instances the consequences of CFHR binding remain unknown. PorB.1A and sialylated PorB.1B of 
N. gonorrhoeae bind CFHR1 preferentially over CFH and CFHL1; however, no role for CFHR1 binding 
was determined [Ngampasutadol, J. 2008]. Of note, CFHR binding to pathogens is often mediated by 
the same proteins that recruit CFH. A notable exception is Borrelia burgdorferi which binds CFHR1, 
CFHR2, CFHR5 and CFH by distinct proteins. Complement regulator-acquiring surface proteins 
(CRASPs) of B. burgdorferi are complement evasion molecules which act by binding CFH [Haupt, K. 
2007]. CRASPs have also been shown to bind preferentially to CFH or CFHRs, with CRASP-3 and -5 
binding CFHR1, CFHR2 and CFHR5 rather than CFH, while CRASP-4 preferentially binds CFHR1 and 
CFHR2 [Haupt, K. 2007. Siegel, C. 2010. Hammerschmidt, C. 2012]. Recruitment of CFHR1, CFHR2 
and CFHR5 does not enhance serum resistance of B. burgdorferi in the absence of CFH [Siegel, C. 
2010]. Competition of CFHR1 with CFH for binding to Shiga toxin 2 of Enterohamorrhagic Escherichia 
coli via CCP domains 3-5 has been shown to decrease C3b cleavage [Poolpol, K. 2014]. Table 1.2 
summarises the bacteria which bind CFHRs. 
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Pathogen CFHR Ligand CFHR Binding domain CFH Reference(s) 
      
Borrelia burgdorferi  CFHR1 
CFHR2 
CFHR5 
CRASP-3 CFHR2- SCR 4 Yes 
(Weak) 
Haupt, K. 2007; 
Siegel, C. 2010 
 
CFHR1 
CFHR2 
CFHR5 
CRASP-4 
 
Yes 
(Weak) 
Haupt, K. 2007; 
Hammerschmidt, C. 
2012 
 
CFHR1 
CFHR2 
CFHR5 
CRASP-5 
 
Yes Haupt, K. 2007; 
Siegel, C. 2010 
Borrelia hermsii CFHR1 CRASP-1 SCR  5 Yes Rossmann, E. 2007 
Escherichia coli (EHEC) CFHR1 Stx2 SCRs 3–5 Yes Poolpol, K. 2014;  
Fusobacterium 
necrophorum 
CFHR1 
CFHR4 
? ? Yes Friberg, N. 2008 
Leptospira interrogans  CFHR1 LigA, LigB SCRs 1–2; SCRs 3–5 Yes Castiblanco-
Valencia, M. M. 
2012  
CFHR1 LfHA SCRs 3–5 Yes Verma, A. 2006 
 
CFHR1 LenA SCRs 3-5 Yes Meri, T. 2005 
 
CFHR1 LenB SCRs 1-2 Yes Stevenson, B. 2007 
Neisseria gonorrhoeae CFHR1 PorB.1A SCRs 4-5 Yes Ngampasutadol, J. 
2008 
 
CFHR1 PorB.1B [sia] SCRs 4-5 Yes Ngampasutadol, J. 
2008 
Pseudomonas aeruginosa CFHR1 Tuf SCRs 3–5 Yes Kunert, A. J. 2007 
  
LpD SCRs 3–5 Yes Hallström, T. 2012 
Staphylococcus aureus CFHR1 Sbi SCRs 4-5 Yes Haupt, K. 2008 
Streptococcus pyogenes  CFHR1 
CFHR3 
M protein SCRs 1-2; SCRs 1-2 Yes Kotarsky, H. 1998 
 
CFHR1 Scl1.6; 
Scl1.55 
SCRs 3-5 Yes Reuter, M. 2010 
 
Table 1.2: Recruitment of CFHRs by bacterial pathogens 
 Bacterial species and the receptors which bind CFHRs are indicated along with the known CCP domains which bind to the 
receptor. If the receptor also binds CFH this is also indicated. 
[sia]    Requires siaylation for CFHR1 binding 
Abbreviations: CRASP, complement regulator acquiring surface proteins; Stx-2, Shiga toxins; Lig, Leptospiral 
Immunoglobulin-like; Lfh, Leptospiral factor H binding protein; Len, Leptospiral Endostatin-Like Protein; Tuf, Translation 
elongation factor Tu; LpD, Dihydrolipoyl dehydrogenase; Por, Porin; Sbi, second immunoglobulin-binding protein; Scl, 
streptococcal collagen like protein. 
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1.6 Neisseria 
The genus Neisseria are Gram negative β proteobacteria and includes two human specific pathogens, 
N. meningitidis and N. gonorrhoeae. N. meningitidis is the major causative agent of meningitis and 
septicaemia while the gonococcus causes the sexually transmitted infection, gonorrhoea and is a 
major health concern due to the emergence of multi-drug resistance [Unemo, M. 2012]. The genus 
Neisseria also includes a number of other closely-related commensal species [Knapp, J. S. 1988]. 
1.6.1 Commensal Neisseria 
Commensal Neisseria spp. are common inhabitants of the mucosal and dental surfaces of the human 
upper respiratory tract [Gold, R. 1978. Knapp, J. S. 1988. Sáez Nieto, J. A. 1998. Zaura, E. 2009. 
Kristiansen, P. A. 2012. Kraal, L. 2014. Sheikhi, R. 2015]. Some species of Neisseria have been isolated 
from other mammalian and non-mammalian hosts [Liu, G. 2015]. Frequent co-colonisation of 
multiple Neisseria spp. has been observed in carriage studies [Knapp, J. S. 1988. Sáez Nieto, J. A. 
1998]. Horizontal gene transfer between these related organisms has made classifying Neisseria into 
distinct species problematic [Bowler, L. D. 1994; Zhou, J. 1997. Smith, N. H. 1999]. Several methods, 
including DNA-DNA hybridisation, 16s rRNA sequencing and Multi Locus Sequence Typing (MLST), 
have been utilised to designate the different species [Tønjum, T. 1989; Harmsen, D. 2001; Bennett, 
J. S. 2007; Maiden, M. C. 1998]. More recently, whole genome sequencing (WGS) approaches have 
been employed to distinguish and classify commensal Neisseria [Bennett, J. S. 2012].  
The commensal Neisseria, Neisseria lactamica and Neisseria polysaccharea have been shown by 
DNA-DNA hybridisation and by WGS to be closely related to N. meningitidis and N. gonorrhoeae 
[Guibourdenche, M. 1986; Bennett, J. S. 2012]. Although more distinct than N. lactamica and N. 
polysaccharea, N. cinerea is also related to the proteotypic Neisseria pathogens as shown by DNA-
DNA hybridisation [Guibourdenche, M. 1986]. While commensal Neisseria are generally considered 
to be harmless inhabitants of the human nasopharynx, there are case reports of commensal 
Neisseria causing disease in immuno-compromised individuals [Knapp, J. S. 1988. Liu, G. 2015]. 
However, N. polysaccharea, which is the most closely related to N. meningitidis and N. gonorrhoeae, 
has fewer case reports than N. lactamica and N. cinerea [Bennett, J. S. 2012]. Disease caused by N. 
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lactamica and N. cinerea has a range of presentations including meningitis, septicaemia and 
peritonitis [Kirchgesner, V. 1995. Everts, R. J. 2010. Taegtmeyer, M. 2006]. 
In comparison with N. meningitidis and N. gonorrhoeae, the commensal Neisseria are less well 
studied. However, N. lactamica has been assessed for its ability to generate natural immunity and N. 
lactamica derived antigens from outer membrane vesicles (OMV) have been evaluated for the 
prevention of meningococcal disease [Gold, R. 1978. Evans, C. M. 2011. Vaughan, T. E.  2006. 
Gorringe, A. R. 2009]. 
1.7 Neisseria meningitidis 
N. meningitidis is an obligate human pathogen and present in the nasopharynx of approximately 10% 
of the population [Stephens, D. S. 2007]. The bacterium is the major causative agent of meningitis 
and septicaemia with a case fatality rate of between 5-20% [Stephens, D. S. 2007]. Meningococcal 
disease has a rapid onset with non-specific early symptoms, and is often mistaken for viral infection 
[van Deuren, M. 2000]. Non-specific symptoms progress within a few hours and later patients can 
present with a purpuric skin rash, photophobia and neck stiffness which are characteristic of 
meningococcal disease. N. meningitidis can also cause uncommon clinical presentations including 
pericarditis, conjunctivitis, sinusitis, arthritis and urethritis [Tzeng, Y. L. 2000]. 
1.7.1 Classification  
N. meningitidis is classified into serogroups based on its polysaccharide capsule; 13 serogroups of N. 
meningitidis have been identified (A, B, C, E, H, I, K, L, M, W, X, Y and Z). Serogroups A, B, C, W, X and 
Y account for the majority of disease [Frasch, C. E. 1985. Pollard, A. J. 2000. Jódar, L. 2002. Stephens, 
D. S. 2007]. The capsular polysaccharide of serogroups B and C strains consist of α-2-8 and α-1-9-
linked polysialic acid, respectively, while serogroups W and Y express alternating sequences of D-
galactose or D-glucose with sialic acid. The serogroup A capsule does not contain sialic acid but is 
composed of α 1-6 linked mannosamine phosphate [Liu, T. Y. 1971a. Liu, T. Y. 1971b. Bhattacharjee, 
A. K. 1976]. Meningococcal isolates are further classified based on the outer membrane proteins, 
PorA and PorB, into serosubtypes and subtypes, respectively [Frasch, C. E. 1985. van Deuren, M. 
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2000]. The properties of meningococcal lipopolysaccharide determine the immunotype of strains; 
so far 12 immunotypes have been identified [Tsai, C. M. 1987. Scholten, R. J. 1994]. 
Meningococcal surface proteins can undergo antigenic or phase variation, which complicates the 
classification of N. meningitidis in epidemiological studies [Caugant, D. A. 1998]. In addition, many 
carriage isolates do not express a capsule and therefore cannot be classified by serogrouping. 
Alternative methods for classifying N. meningitidis have been developed to overcome the issue of 
antigenic and phase variation. Multi Locus Sequence Typing (MLST, http://pubmlst.org) analyses the 
nucleotide sequence of seven genes with housekeeping functions (abcZ, adk, aroE, fumC, gdh, pdhC, 
and pgm) [Maiden, M. C. 1998]. A second classification system, Multilocus Enzyme Electrophoresis 
(MLEE), is based on the migration metabolic enzymes [Selander, R. K. 1986]. MLST has the advantage 
over MLEE that it can be standardised between laboratories [Maiden, M. C. 1998]. Recently WGS has 
been employed to characterise meningococcal isolates that are closely related [Lucidarme, J. 2015]. 
1.7.2 Pathogenesis  
N. meningitidis is transmitted between individuals by aerosol spread or direct contact with secretions 
from the oropharynx and nasopharynx [Tzeng, Y. L. 2000].  Colonisation is an essential step in N. 
meningitidis pathogenesis, and initial adhesion to epithelial cells is mediated by bacterial type four 
pili (Tfp) [Kellogg, D. S. 1963. Nassif, X. 1993]. Tfp are hair-like filaments which project from the 
bacterial surface, and are important for colony formation, aggregation, and uptake of exogenous 
DNA [Lappann, M. 2006. Seifert, H. S. 1990]. There are several proposed epithelial host receptors for 
Tfp. For example, CD46, a membrane bound CP and AP regulator, has been proposed to mediate 
Tfp:epithelial cell attachment [Källström, H. 1997. Johansson, L. 2003]. However, CD46 is expressed 
mostly on the basolateral side of epithelial cells and knock down of CD46 did not affect gonococcal 
adhesion to epithelial cells [Maisner, A. 1997. Kirchner, M. 2005]. Tfp have also been shown to 
mediate the adherence of meningococci via the platelet activating factor receptor (PAFr) on human 
bronchial epithelial cells, although this has not been confirmed by others [Jen, F. E. 2013].  
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Meningococcal binding to epithelial cells is a two-step process. Tfp are required for the initial 
engagement of epithelial cells, while other adhesins mediate subsequent intimate adherence. 
Downregulation of the meningococcal polysaccharide capsule is essential for intimate adherence 
and temperature has been shown to be a key cue for the bacterium as capsule expression is lower 
at cooler temperatures, such as encountered by the bacterium in the nasopharynx [Hammerschmidt, 
S. 1996. Loh, E. 2013. Barnwal R, P. 2016]. The class five outer membrane opacity proteins, Opa and 
Opc mediate intimate adherence by binding members of the CD66 family, i.e. carcinoembryonic 
antigen cell adhesion molecules (CEACAMs) [Virji, M. 1996a. Virji, M. 1996b]. Of note, interactions 
between Opc and CEACAMs require high level expression of Opc [Sarkari, J. 1994]. Neisseria adhesin 
A (NadA) has also been implicated in the initial attachment of meningococci to epithelial cells by 
binding to β1-integrins [Capecchi, B. 2005. Nägele, V. 2011]. Several other adhesins have been 
identified including the Adhesion and penetrating protein and Meningococcal surface fibril (Msf) 
[Serruto, D. 2003. Turner, D. P. 2006]. Of note, Msf has been suggested to bind the TP regulator, 
vitronectin [Griffiths, N. J. 2011].  
Bacterial microcolonies form on the apical surface of epithelial cells, whereby the meningococcus 
multiplies and spreads over the cell. From this site, the bacterium can invade epithelial cells and then 
pass to the sub-epithelial layer by transversing the epithelial layer [Kirchner, M. 2005. Stephens, D. 
S. 1983. Sadlon, T. A. 1994. Sutherland, T. C. 2010].  
Dissemination of N. meningitidis, in the circulation and its interactions with both epithelial and 
endothelial cells at the blood brain barrier are critical steps in meningococcal pathogenesis. Tfp 
interactions with CD147 initiate bacterial adherence to the endothelium and are important for 
meningococcal colonisation of the microvasculature [Bernard, S. C. 2014]. Engagement of CD147 
initiates a signalling cascade involving the β2-adrenergic receptor (β2-AR), and leads to tight junction 
remodeling, allowing N. meningitidis to transverse the brain endothelial layer by a paracellular route 
[Coureuil, M. 2010. Lécuyer, H. 2012]. Both Opc and Opa also mediate intimate adhesion of bacteria 
to endothelial cells [Meyer, T. F. 1999]. Furthermore, Opc can bind vitronectin which acts as a 
molecular bridge by binding to αvβ3 integrin on the apical surface of endothelial cells [Virji, M. 1994].  
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The clinical presentation of N. meningitidis infection occurs after the bacterium enters the 
bloodstream. Within the circulation, bacteria reach high densities of up to 109/ml [Hackett, S. J. 
2002]. The release of pro-inflammatory chemokines and cytokines, including interleukins -1, -6 and 
-8, and TNF-α, along with high levels lipopolysaccharide, lead to tissue damage and meningococcal 
sepsis [Brandtzaeg, P. 1989]. When bacteria cross the blood brain barrier, release of pro-
inflammatory cytokines into the subarachnoid space result in inflammation of the meninges and 
meningitis [Brandtzaeg, P. 1992]. The pathophysiological factors which govern meningococcal 
disease progression are not limited to the interaction between bacteria with epithelial and 
endothelial cells, but also include the ability of the meningococcus to survive and replicate in the 
bloodstream.  
1.7.3 Epidemiology  
Meningococcal disease occurs worldwide but its prevalence varies depending on geographic 
location, age and season. There are estimated to be 1.2 million cases of meningococcal disease 
worldwide each year with 135,000 deaths [Stephens, D. S. 2007].  
Epidemics occur every 5-10 years within the ‘meningitis belt’ in sub-Saharan Africa with 
approximately 500 cases per 100,000 population. Serogroup A meningococci are largely responsible 
for these outbreaks, and to a lesser extent cause epidemics in China and Russia [Maiden, M. C. 1998. 
Wang, J. F. 1992. Greenwood, B. 1999. Greenwood, B. M. 1987]. The high incidence of 
meningococcal disease in Africa coincides with the beginning of the dry season with humidity and 
dust associated with an increase in meningococcal disease [Molesworth, A. M. 2003]. 
In contrast, serogroup B disease is prevalent in Europe, while serogroups B, C and Y predominate in 
the USA [Jackson, L. A. 1995. Brooks, R. 2006]. The incidence of serogroup C disease fell in the UK 
following the introduction of a polysaccharide conjugate vaccine in 1999-2000 [Balmer, P. 2002. 
Maiden, M. C. 2008. Campbell, H. 2009]. Generally, outbreaks of meningococcal disease in 
developed countries are small and sporadic, affecting approximately 1 in 100,000 of the population 
[Achtman, M. 1995]. Epidemics of meningococcal disease have also been associated with the 
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movement of populations. For example, the 1987 Hajj pilgrimage to Mecca resulted in the spread of 
a virulent form of serogroup W N. meningitidis by returning pilgrims [Schwartz. D. 1987]. Therefore 
all individuals attending the Hajj pilgrimage are vaccinated against N. meningitidis serogroup A, C, W, 
Y with a conjugate vaccine. 
1.7.4 Natural immunity against N. meningitidis 
Both N. meningitidis and commensal Neisseria spp. can colonise the human nasopharyengeal 
mucosa. Carriage of N. lactamica is high in infants and declines with age. Conversely, carriage of N. 
meningitidis is low in infancy and steadily rises in childhood and adolescence [Gold, R. 1978. 
Cartwright, K. A. 1987. Olsen, S. F. 1991. Bennett, J. S. 2005]. Incidence rates of meningococcal 
disease peak between 6 months and 2 years of age, coinciding with the waning of maternal 
antibodies and before the induction of bactericidal antibodies [Goldschneider, I. 1969a. 
Goldschneider, I. 1969b]. The level of serum bactericidal and cross-reactive IgG antibodies against 
N. meningitidis also increases with age in children even though meningococcal carriage remains low, 
suggesting that N. lactamica may protect against meningococcal disease [Gold, R. 1978. Cann, K. J. 
1989]. Furthermore, individuals colonised by N. lactamica showed reduced carriage of N. 
meningitidis which also indicates that N. lactamica can inhibit colonisation of N. meningitidis [Gold, 
R. 1978. Bennett, J. S. 2005]. Human challenge with N. lactamica sought to determine the 
mechanism for the induction of natural immunity against N. meningitidis [Evans, C. M. 2011; Deasy, 
A. M. 2015]. Individuals colonised by N. lactamica generated cross-reactive salivary IgA and serum 
IgG antibodies against serogroup B meningococci supporting the hypothesis that colonisation by N. 
lactamica contributes to natural immunity against the meningococcus [Evans, C. M. 2011. Gold, R. 
1978]. However, serum antibodies of N. lactamica carriers lacked bactericidal activity and 
furthermore, did not prevent colonisation of N. meningitidis [Evans, C. M. 2011]. A subsequent 
human challenge study observed a reduction in meningococcal carriage by both displacement of 
meningococci from the nasopharynx and further prevents meningococcal acquisition; potentially 
this can be achieved by altering conditions in the nasopharynx to favour N. lactamica colonisation 
[Deasy, A. M. 2015. Andrade, J. R. 1986. Vaughan, A. T. 2009. Wong, H. E. 2011].  
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1.7.5 Susceptibility to meningococcal disease 
The molecular mechanisms which predispose some individuals to meningococcal disease are not 
fully understood. Age is an important determinant with the highest incidence of meningococcal 
disease seen in children between 6 and 24 months of age [Goldschneider, I. 1969. Moore, P. S. 1989]. 
Complement plays an important role in protection from meningococcal disease as individuals lacking 
complement components are highly susceptible to invasive disease and often have recurrent 
infections [Figueroa, J. E. 1991]. 
1.7.5.1 Complement deficiencies 
Individuals with rare, inherited deficiencies of complement components, particularly of the AP or TP, 
are predisposed to meningococcal disease [Figueroa, J. E. 1991]. Some deficiencies influence the 
severity of disease, while individuals with other defects suffer from recurrent infections [Pickering, 
M. C. 2008. Kuijpers, T. W. 2010]. 
Individuals with deficiencies in MAC components, i.e. C5-C9, tend to suffer from recurrent 
meningococcal infections of mild to moderate severity [Pickering, M. C. 2008. Barroso, S. 2010. 
Kuijpers, T. W. 2010; Orren, A. 2012]. Deficiency of any MAC component prevents formation of the 
MAC lytic pore on the bacterial surface. Of note, lack of C9 results in a reduction of complement 
mediated lysis, even though the C5-C8 complex can still lyse bacteria albeit to a lesser extent 
[Miyagawa, S. 1996]. These defects are rare in the general population but a higher prevalence is seen 
in certain ethnic groups. For example, C5, C6 and C8 deficiency is reported to be higher in the US, 
with a high prevalence of C6 deficiency in African Americans originally from South Africa (1 in 1600) 
[López-Lera, A. 2009. Orren, A. 2012. Zhu, Z. 2000. Pickering, M. C. 2008. Kojima, T. 1998. Tedesco, 
F. 1990.]. Cases of C7 deficiency have been reported worldwide, whereas the prevalence of C9 
deficiency is higher in individuals of Japanese ancestry (0.095%) [Rameix-Welti, M. A. 2007. Barroso, 
S. 2006. Nishizaka, H. 1996. Fernie, B. A. 1996. Thomas, A. D. 2012. Barroso, S. 2010. Kuijpers, T. W. 
2010. Khajoee, V. 2003. Fukumori, Y. 1989]. 
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Deficiencies of components or regulators of the AP, such as Properdin and FD, also increase 
susceptibility to meningococcal disease. Properdin, stabilises the C3 convertase, while FD cleaves FB 
during the formation of the AP C3 convertase [Sjöholm, A. G. 1982. Braconier, J.H. 1983. Söderström, 
C. 1989. Sprong, T. 2006]. Deficiency of the complement regulators, CFH and FI, leads to a reduction 
in C3 levels with a clinical pathology similar to C3 deficiency [Zipfel, P. F. 1999. Vyse, T. J. 1994]. This 
is due to uncontrolled complement activation, resulting in excessive C3 cleavage in the fluid phase. 
Conversely, a SNP (C246T) in CFH which results in increased circulating CFH concentrations is also 
associated with predisposition to meningococcal disease [Haralambous, E. 2006].  Increased levels 
of CFH could render the bacterium less susceptible to complement mediated lysis [Haralambous, E. 
2006]. 
Some studies have linked polymorphisms in the promoter of the mbl gene or in the gene itself to 
increased susceptibility to meningococcal disease [Bax, W. A. 1999. Hibberd, M. L. 1999. Kuipers, S. 
2003]. However, this was not confirmed in a subsequent study [Kuijper, E. J. 1999].  
1.7.5.2 Terminal complement inhibitors 
Eculizumab (Soliris®; Alexion Pharmaceuticals, Inc.) is a humanised mAb used to treat paroxysmal 
nocturnal hemoglobinuria and aHUS [Dmytrijuk, A. 2008. Kelly, R. J. 2011. Mache, C. J. 2009. Zuber, 
J. 2012]. Eculizumab binds C5 at high affinity, preventing both C5 cleavage by the C3 convertase and 
MAC formation [Dmytrijuk, A. 2008]. As deficiencies in TP components are linked with increased risk 
of meningococcal infection, therapies which inhibit the TP also predispose individuals to 
meningococcal disease [Figueroa, J. E. 1991. Struijk, G. H. 2013]. Due to the higher risk of 
meningococcal disease, patients are immunised against N. meningitidis prior to starting Eculizumab 
treatment [Dmytrijuk, A. 2008. Zlamy, M. 2012]. 
1.7.5.3 Genome Wide Association Studies (GWAS) 
A GWAS study published in 2010 by Davilla et al. identified SNPs in CFH (rs1065489) and CFHR3 
(rs426736) associated with meningococcal disease from 475 cases and 4,703 controls [Davila, S. 
2010]. CFH SNP (rs1065489) coding for a nonsynonymous substitution resulted in a lower risk of 
meningococcal disease. Of note, sub-Saharan African populations have the highest incidence of 
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meningococcal disease, also had the lowest frequency of the CFH (rs1065489) polymorphism [Frazer, 
K. A. 2007]. Furthermore, CFHR3 (rs426736) polymorphism also conferred a meningococcal disease 
risk reduction for minor allele carriers [Davila, S. 2010]. These findings were replicated in a further 
Western and South European cohort of 968 cases and 1,376 controls [Davila, S. 2010]. Of note, a 
SNP in CFHR1 (rs16840658) was also strongly associated with meningococcal disease in the original 
and western European cohorts but failed genotyping in the southern European cohort [Davila, S. 
2010]. Previous genetic studies had identified a SNP in the promotor region of NFκB (rs3753394) 
correlated with CFH levels but in the GWAS study by Davilla et al. this SNP showed a non-significant 
trend for association with disease in the southern and western Europe cohorts, potentially due to 
meningococcal strain differences [Haralambous, E. 2006]. A subsequent study confirmed the 
association of SNPs in CFH (rs1065489) and CFHR3 (rs426736) with meningococcal disease from a 
central European cohort of 248 patients and 835 controls [Biebl, A. 2015]. However, the molecular 
mechanisms underlying these findings have not been examined. 
1.7.6 Complement evasion by N. meningitidis 
When N. meningitidis enters the blood stream it is subject to complement-mediated attack which 
leads to bacterial lysis and clearance. The bacterium has evolved several mechanisms to avoid the 
human complement system. 
1.7.6.1 Surface structures that facilitate complement evasion 
Expression of a polysaccharide capsule is important for serum resistance of N. meningitidis with 
almost all clinical isolates being encapsulated, whereas 50% of colonising N. meningitidis are 
unencapsulated [Jarvis, G. A. 1987. Claus, H. 2002]. The mechanisms by which the capsule protects 
N. meningitidis from complement are not fully understood, although it is thought to prevent 
insertion of the MAC [Drogari-Apiranthitou, M. 2002]. Furthermore, the chemical composition of the 
capsule may affect complement susceptibility; serogroup A strains bind more C3 and C4 compared 
with strains expressing sialic acid containing capsules (such as serogroups B and C). [Drogari-
Apiranthitou, M. 2002. Ram, S. 1999]. Capsule expression has been shown to be upregulated in 
response to increasing ambient temperature possibly during transition from the nasopharynx to the 
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blood stream, resulting in enhanced resistance against complement [Loh, E. 2013. Barnwal, R. P. 
2016]. Other studies have also indicated that increased capsule expression resulting from an IS1301 
insertion in the capsule biosynthesis locus can downregulate the AP and reduce C3 binding [Uria, M. 
J. 2008].  
Lipopolysaccharide (LPS) is a major component of the outer membrane of N. meningitidis which also 
enhances resistance of the meningococcus to complement; strains with truncated LPS have 
decreased serum resistance [Geoffroy, M. C. 2003]. In addition the availability of micronutrients, 
particularly lactate, can also facilitate complement resistance as lactate can be converted into 
phosphoenol pyruvate, which is a precursor of sialic acid, a constituent of the capsule in many strains, 
and incorporated into LPS [Exley, R. M. 2005].  
1.7.6.2 Acquisition of complement regulators 
Factor H binding protein (fHbp) is a surface expressed lipoprotein (approximately 27 kDa) which was 
identified by reverse vaccinology as a candidate for meningococcal vaccines [Pizza, M. 2000. 
Masignani, V. 2003]. It is a highly variable protein which can be grouped into three distinct variants 
[Brehony, C. 2009]. fHbp binds CFH at high affinity (~3 nM KD) by mimicking host glycosaminoglycans 
binding of CFH  [Schneider, M. C. 2009]. The atomic structure of the CFH:fHbp complex indicates that 
fHbp binds CFH via CCP domains 6 and 7 [Schneider, M. C. 2009]. All three fHbp variants can bind 
CFH at similar high affinities independent of serogroup and sialyation of LPS [Madico, G. 2006. 
Schneider, M. C. 2006. Johnson, S. 2012. van der Veen, S. 2014]. Binding of CFH on the surface of N. 
meningitidis reduces C3b deposition and increases survival of the bacterium in whole blood and 
resistance against complement-mediated lysis [Madico, G. 2006. Schneider, M. C. 2006]. fHbp is 
upregulated in response to increasing temperature. Therefore the bacterium would express more 
fHbp when in the blood stream than in the nasopharynx [Loh, E. 2013. Loh, E. 2016]. 
Some N. meningitidis strains have been isolated from individuals which lack expression of fHbp 
[Lucidarme, J. 2011]. Further research has identified other receptors for CFH on the bacterial surface. 
Neisserial surface protein A (NspA) was identified in a Δfhbp which bound CFH, and binding was 
enhanced by sialylation of LPS [Lewis, L. A. 2010. Lewis, L. A. 2012]. More recent evidence has also 
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suggested that N. meningitidis binds CFH via the abundant meningococcal porin, PorB2, although 
this was only shown in a strain deficient in both NspA and fHbp [Lewis, L. A. 2013]. CFH binding to 
both NspA and PorB2 enhances resistance to complement-mediated lysis. 
C4 binding protein (C4bp) is a major negative regulator of the CP which acts by accelerating the decay 
of the CP C3 convertase and a co-factor for FI cleavage of C4b [Gigli, I. 1979]. Meningococcal PorA 
loops 1 and 4 act as receptors for C4bp on the surface of N. meningitidis with binding increasing 
resistance to complement-mediated lysis [Jarva, H. 2005]. Of note, encapsulated strains had a 
significant reduction in the amount of bound C4bp therefore the relevance of C4bp binding to N. 
meningitidis is unclear; furthermore experiments were performed at non-physiological NaCl 
concentrations [Jarva, H. 2005]. 
N. meningitidis has been shown to bind vitronectin by both the Neisseria opacity protein, Opc, and 
Msf [Hubert, K. 2012. Griffiths, N. J. 2011]. Soluble vitronectin is an inhibitor of the TP and reduces 
the formation and insertion of the MAC by occupying the membrane binding site of the C5b-7 
complex and preventing C9 polymerisation [Millis, L. 1993]. Interestingly, circulating concentrations 
of vitronectin are reduced in the acute phase of meningococcal disease [Høgåsen, K. 1994]. Opc 
binds vitronectin by sulphated tyrosines and facilitates bacterial adherence to human brain 
endothelial cells, whereas Msf is a homologue of the autotransporter adhesion, Hsf, from 
Haemophilus influenzae, which binds to integrins on epithelial cells [Prince, S. M. 2002. Hubert, K. 
2012. Peak, I. R. 2000]. Vitronectin interactions with Opc and Msf decrease MAC deposition and 
enhance N. meningitidis resistance to complement-mediated lysis [Hubert, K. 2012. Griffiths, N. J. 
2011. Hill, D. J. 2015]. 
1.7.6.3 Protease activity against complement components 
The autotransporter protease, NalP, has previously been shown to process proteins on the surface 
of N. meningitidis, cleaving proteins involved in biofilm formation [Roussel-Jazédé, V. 2013]. This 
serine protease also cleaves C3, into C3a-like and C3b-like components, with the C3b-like component 
rapidly degraded by CFH and FI [Del Tordello, E. 2014]. Generation of the C3b-like component also 
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results in reduced deposition of C3b on the bacterial surface and enhanced survival in normal human 
serum (NHS) [Del Tordello, E. 2014]. 
1.7.7 N. meningitidis vaccines 
Even with effective antibiotic treatment, meningococcal disease has a fatality rate of approximately 
6-10%, with 4.3-11.2% of survivors suffering from long term sequelae [Harrison, L. H. 2001. Goldacre, 
M. J. 2003. Robbins, J. B. 2003. Edmond, K. 2010]. Vaccination is a key preventative strategy against 
meningococcal disease. Effective vaccines not only protect immunised individuals, but can also 
provide herd immunity [Maiden, M. C. 2002. Ramsay, M. E. 2003. Maiden, M. C. 2008]. This is 
particularly evident from the implementation of polysaccharide conjugate vaccines against 
meningococcal C strains in the UK and meningococcal A strains in Africa [Campbell, H. 2009. Sow, S. 
O. 2011. Sambo, L. 2015]. Vaccines available against N. meningitidis are reviewed below. 
1.7.7.1 Correlates of protection 
The establishment of a serological correlate of protection against N. meningitidis was essential for 
the development of meningococcal vaccines [Gotschlich, E. C. 1969]. Serum bactericidal activity 
(SBA) is the accepted ‘gold standard’ for evaluating the protective efficacy of meningococcal vaccines 
and is correlated with natural immunity against meningococcal disease [Goldschneider, I. 1969]. 
There is an inverse correlation between the age-related incidence of meningococcal disease and the 
presence of SBA [Goldschneider, I. 1969]. In the laboratory, SBA measures the ability of antibodies 
in sera to lyse bacteria via the CP in the presence of an exogenous source of complement. The 
dilution of serum that results in at least a 50% reduction in bacteria is defined as the SBA titre 
[Goldschneider, I. 1969; Holst, J. 2003; Borrow, R. 2006]. An SBA titre of ≥4 using human serum as 
the complement source, or ≥8 using rabbit serum correlates with protection against meningococcal 
disease [Goldschneider, I. 1969. Borrow, R. 2006. Santos, G. F. 2001]. 
1.7.7.2 Polysaccharide vaccines 
Capsular polysaccharides of serogroups A and C were initially investigated as vaccine targets largely 
due to the success of pneumococcal polysaccharide vaccines [Gotschlich, E. C.  1969a. Gotschlich, E. 
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C. 1969b. Finland, M. 1935. Finland, M. 1931. Francis, T. 1930]. Polysaccharide vaccines are effective 
in adults and older children but fail to induce an immune response in children less than two years of 
age as polysaccharides do not induce a T-cell dependent immune responses [Artenstein, M. S.  1970. 
Gold, R. 1971. Wahdan, M. H.  1977. Wahdan, M. H.  1973. Gold, R. 1975]. Furthermore, 
polysaccharide vaccines have no effect on meningococcal carriage [Gotschlich, E. C. 1969.  
Artenstein, M. S.1970. Sivonen, A.1981]. Despite these drawbacks, bivalent (serogroups A and C), 
trivalent (serogroups A, C and W), and tetravalent (serogroups A, C, W and Y) vaccines were licensed 
in the 1970s to control sporadic outbreaks and immunise individuals at high risk of developing 
meningococcal disease [Vodopija, I. 1983. Reingold, A. L. 1985. Peltola, H. 1985. Frasch, C. E.1989]. 
Following the success of the Haemophilus influenzae type B (Hib) glycoconjugate vaccine, in which 
the H. influenzae capsular polysaccharide is conjugated to diphtheria toxoid resulting in the induction 
of a T-cell dependent immune response and reduction in carriage [Eskola, J. 1993; Adams, W. G. 
1993. Conjugation of meningococcal polysaccharides to carrier proteins including diphtheria and 
tetanus toxoids were trialed and elicited higher antibody titres than observed with polysaccharide 
vaccines [Beuvery, E. C. 1983. Richmond, P. 1999. Southern, J. 2009. Borrow, R. 2010]. Introduction 
of a serogroup C conjugate vaccine in the UK during an epidemic of serogroup C disease during the 
1990s reduced carriage and invasive serogroup C disease by 89-94% [Balmer, P. 2002. Maiden, M. 
C. 2008. Campbell, H. 2009]. Furthermore, the vaccine induces T-cell dependent responses, resulting 
in immunological memory [Trotter, C. L. 2004. Pollard, A. J. 2009]. Implementation of the conjugated 
serogroup C polysaccharide vaccines in other countries lead to similar reductions in disease [de 
Greeff, S. C. 2006. Cano, R. 2004. Bettinger, J. A. 2009]. The success of conjugate polysaccharide 
vaccines is particularly evident by the reduction of carriage, with herd immunity almost eliminating 
serogroup A meningococcal disease in Africa (MenAfiVac) [Sow, S. O. 2011. Sambo, L. 2015. 
Kristiansen, P. A. 2012. Daugla, D. M. 2014]. Multivalent polysaccharide conjugate vaccines have 
been formulated and licensed covering seroroups A, C, W and Y [Campbell, J. D. 2002. Shao, P. L. 
2009]. 
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1.7.7.3 Challenges for meningococcal B vaccines 
The capsular polysaccharide of serogroup B N. meningitidis is identical to the α(2-8) N-acetyl 
neuraminic acid (polysialic acid) that is present on human tissues [Finne, J. 1983]. The capsule elicits 
a poor immune response even after conjugation to carrier proteins, and antibodies recognise host 
tissue [Finne, J. 1987. Jennings, H. J. 1981]. Therefore vaccination with the serogroup B capsule could 
generate auto-antibodies [Finne, J. 1987. Jennings, H. J. 1981]. Consequently, vaccines to prevent 
serogroup B disease must not be capsule based. Outer membrane vesicle (OMV) vaccines have been 
developed, and successfully used during epidemics [Kelly, C. 2007]. SBA responses from detergent 
extracted OMVs are mostly directed against the highly variable PorA and are not cross protective 
[Fredriksen, J. H. 1991. Holst, J. 2009. Tappero, J. W. 1999. Tondella, M. L. 2000]. To broaden the 
protection of OMV based vaccines, OMVs were extracted from multiple meningococcal strains or 
from strains expressing more than one PorA. However, antigenic diversity of PorA means that these 
vaccines are unlikely to induce broad protection [Tondella, M. L. 2000. Holst, J. 2005. Sandbu, S. 
2007. van der Ley, P. 1995. Cartwright, K. 1999. Holst, J. 2007].  
1.7.7.4 Recombinant protein vaccines against meningococcal B 
To develop broadly protective vaccines against serogroup B N. meningitidis, new strategies were 
employed largely following the publication of the complete genome sequence of the serogroup B 
meningococcal strain, MC58 [Tettelin, H. 2000]. The open reading frames (ORF) encoding predicted 
surface exposed proteins were identified, amplified and expressed in E. coli [Pizza, M. 2000]. The 
recombinant proteins were purified and used to immunise mice prior to identifying antigens that 
elicit SBA [Pizza, M. 2000]. This approach was termed reverse vaccinology and has been utilised to 
identify vaccine targets in other pathogens [Talukdar, S. 2014. Chiang, M. H. 2015. Meunier, M. 
2016]. Reverse vaccinology and further subsequent studies identified fHbp, Neisserial adhesin A 
(NadA), and Neisseria heparin binding antigen (NHBA) as broadly protective antigens which induce 
SBA in a panel of meningococcal isolates [Masignani, V. 2003. Fletcher, L. D. 2004. Giuliani, M. M. 
2005. Comanducci, M. 2002. Welsch, J. A. 2003. Giuliani, M. M. 2006]. Two additional proteins, 
GNA1030 and GNA2091 were included in meningococcal B vaccines as fusion proteins with NHBA 
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and fHbp, respectively, due to these proteins inducing strong immune responses [Pizza, M. 2000. 
Giuliani, M. M. 2006]. The Food and Drug Administration (FDA), due to the promising 
immunogenicity data in phase II clinical trials, has recently approved two vaccines for the prevention 
of serogroup B meningococcal disease under the accelerated approval pathway [Gossger, N.  2012. 
Santolaya, M. E. 2014. Esposito, S. 2012. Richmond, P. C. 2012. Vesikari, T. 2016]. Bexsero® was 
licensed in Europe in January 2015 and contains fHbp, NadA, NHBA and OMVs from NZ98/24 which 
caused the New Zealand epidemic outbreak [Oster, P. 2005]. Pfizer have developed Trumenba® 
released in the US in November 2014, containing two lipidated fHbps. Previous studies have shown 
that lipidation of fHbp enhances immune responses in mice [Fletcher, L. D. 2004]. Of note, these 
vaccines are not restricted to serogroup B meningococcal strains, but have the potential to protect 
against several meningococcal serogroups. The effect of these meningococcal B vaccines on 
meningococcal carriage are unknown; although a reduction in carriage of all meningococcal 
serogroups (but not serogroup B) was observed in university students after immunisation with 
Bexsero® but this requires further evaluation [Read, R. C. 2014]. 
1.7.7.5 Components of licensed meningococcal B vaccines 
1.7.7.5.1 fHbp  
To date, over 1,000 unique meningococcal fHbp sequences have been identified 
(http://pubmlst.org/neisseria/fHbp/) and can be divided into three variant groups (V1, V2, and V3) 
[Masignani, V. 2003. Brehony, C. 2009].  Generated bactericidal responses can provide cross 
protective SBA across strains expressing fHbp subvariants within the same variant group but are not 
cross protective between variant fHbp groups [Seib, K. L. 2011]. fHbp is a surface exposed lipoprotein 
composed of two β-barrels arranged as a bi-lobed structure anchored to the bacterial membrane by 
a lipid group covalently bound to the initial cysteine residue [Mascioni, A. 2009. Schneider, M. C. 
2009]. The C-terminal β-barrel is highly structured with the N-terminus having more pronounced 
flexibility in V2 fHbp compared to V1 and V3 fHbp [Johnson, S. 2012]. fhbp expression occurs under 
the control of two independent promotors;  a bicistronic or long transcript originating from the 
upstream gene encoding fructose-1,6-bisphosphate (fba), and a monocistonic or short transcript 
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from its own promotor [Oriente, F. 2010]. Early investigations identified putative Fur and FNR box 
motifs in the fhbp promotor suggesting that fHbp is regulated by iron and/or oxygen concentrations 
[Masignani, V. 2003. Oriente, F. 2010. Sanders, H. 2012]. More recent evidence indicates that fhbp 
transcription is upregulated in iron-rich conditions [Sanders, H. 2012]. Furthermore, fHbp has been 
shown to be regulated by temperature involving anti-ribosomal binding sites within the ORF [Loh, E. 
2013. Loh, E. 2016]. Previous analysis of fHbp determined that different N. meningitidis isolates 
express varying levels of fHbp on the surface [Donnelly, J. 2010]. Moreover, polymorphisms in the 
promotor region of fhbp can determine the level of fHbp expression, and isolates expressing V1 fHbp 
have significantly higher fHbp levels than V2 or V3 expressing isolates [Biagini, M. 2016]. fHbp 
expression levels have also been determined as affecting susceptibility of meningococcal isolates to 
SBA, as the amount of antigen on the bacterial surface correlates with higher SBA responses; 
therefore fHbp expression levels may determine the efficacy of fHbp meningococcal vaccines 
[Donnelly, J. 2010. Biagini, M. 2016]. 
1.7.7.5.2 NadA 
NadA is a trimeric autotransporter which is anchored to the outer membrane, and implicated in 
adhesion and invasion of bacteria [Comanducci, M. 2002. Malito, E. 2014. Capecchi, B. 2005. Nägele, 
V]. The nadA gene is present in approximately 50% of N. meningitidis isolates and is associated with 
hypervirulent linages, including the ET-5 complex, the ET-37 complex, and cluster A4 [Comanducci, 
M. 2004]. Interestingly, NadA is rarely associated with meningococcal carriage isolates [Comanducci 
M, 2002. Comanducci, M. 2004]. There are currently five known variants of NadA, NadA-1 to NadA-
5; NadA-1 to NadA-3 are associated with disease isolates and generate a cross-reactive SBA response 
whereas NadA-4 and Nad-A5 are more commonly associated with carriage isolates [Comanducci M, 
2002. Comanducci, M. 2004]. Moreover, SBA elicited by NadA-4 is not cross-reactive against NadA-
1 to NadA-3 [Comanducci, M. 2004]. 
1.7.7.5.3 NHBA 
NHBA is a surface exposed lipoprotein which binds heparin via an Arg-rich repeat region and 
contributes to serum resistance [Pizza, M. 2000. Serruto, D. 2010] Furthermore, it is likely that NHBA 
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binds host glycosaminoglycans, e.g. heparin sulphate, contributing to bacterial adhesion and 
colonisation [Casellato, A. 2014]. Post-translational cleavage of NHBA by NalP adjacent to the Arg-
rich region, releases a small NHBA fragment that has been shown to increase endothelial 
permeability by disrupting tight junctions, resulting in vascular leakage [Casellato, A. 2014]. nhba is 
present in all N. meningitidis isolates with the N- and C-termini conserved [Bambini, S. 2009. 
Jacobsson, S. 2009. Lucidarme, J. 2010]. Sera from meningococcal convalescent patients recognise 
NHBA and have SBA responses against this protein [Serruto, D. 2010. Giuliani, M. M. 2010. Plested, 
J. S. 2008]. Furthermore, vaccine induced antibodies can elicit cross-protective responses against 
strains expressing a range of NHBA peptides [Giuliani, M. M. 2006]. 
1.7.7.6 Improving immunogenicity of meningococcal vaccines 
Further developments in meningococcal vaccination have involved the optimisation and the 
evaluation of new vaccine candidates. fHbp specifically binds to human CFH and is a major 
component of the two licensed serogroup B N. meningitidis vaccines [Granoff, D. M. 2009. 
Masignani, V. 2003. Fletcher, L. D. 2004. Giuliani, M. M. 2006]. Further studies in human CFH 
transgenic mouse models demonstrated that CFH binding to fHbp impairs immune responses 
[Beernink, P. T. 2011. Johnson, S. 2012]. Therefore non-functional fHbps have been generated by 
introducing amino acid substitutions that disrupt the CFH-fHbp interactions [Schneider, M. C. 2009. 
Johnson, S. 2012. Pajon, R. 2012. van der Veen, S. 2014]. Non-functional V1 fHbps elicit similar or 
higher SBA than the wild-type protein, with similar results obtained with V2 and V3 [Beernink, P. T. 
2011. Johnson, S. 2012. Pajon, R. 2012. van der Veen, S. 2014].  
Sequence analysis of N. gonorrhoeae identified a homologue of fHbp designated GHfp (gonococcal 
homologue of fHbp) which does not bind CFH [Hadad, R. 2012. Jongerius, I. 2013]. Interestingly, a 
frameshift caused by an insertion of a single base (G) at position 40 results in the loss of the lipo-box 
motif (LXXC) of GHfp and a further eight-base insertion after position 70 re-establishes the correct 
frame resulting in protein translation [Hadad, R. 2012. Muzzi, A. 2013]. Sequence analysis indicates 
that GHfp belongs to V3 fHbp [Jongerius, I. 2013]. Although GHfp has been postulated to bind 
siderophores in vitro, the exact function of this protein in the gonococcus has yet to be established 
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[Veggi, D. 2012]. Furthermore, Ghfp elicits cross-protective immune responses against strains 
expressing any of the three fHbp variants although SBA titres were higher for V2 and V3 fHbp 
[Jongerius, I. 2013]. Furthermore, GHfp engineered to express heterologous epitopes from V1 fHbp 
elicit higher SBA titres for V1 fHbp with similar immune responses for V2 and V3 fHbp [Rippa, V. 
2015]. 
Other vaccine candidates are also currently under investigation including NspA, which is a well-
conserved outer membrane protein that induces SBA [Lewis, L. A. 2010. Lewis, L. A. 2012. Martin, D. 
1997. Cadieux, N. 1999. Martin, D. 2000]. Unfortunately, vaccination with NspA in human volunteers 
does not elicit bactericidal antibodies potentially due to NspA binding CFH [Beernink, P. T. 2011. 
Halperin, S. A. 2007].  Examination of serological responses to ferric enterobactin receptor (FetA) of 
convalescent patients prompted the evaluation of FetA as a vaccine antigen [Sanders, H. 2015]. Initial 
trials in animal models indicated that bactericidal antibodies could be generated against FetA in 
OMVs [Sanders, H. 2015]. Subsequent Phase I clinical trials also generated significant SBA titres 
[Sanders, H. 2015. Marsay, L. 2015]. 
1.7.7.7 Conservation of meningococcal vaccine antigens 
There are high rates of genetic exchange between Neisseria spp. that colonise human mucosal 
surfaces, highlighted by the presence of multiple genes encoding meningococcal virulence factors, 
including FetA, Tfp, Opas, and iron transport [Stabler, R. A. 2005. Snyder, L. A. 2006. Bennett, J. S. 
2009. Marri, P. R. 2010. Wörmann, M. E. 2016]. High rates of recombination between Neisseria spp. 
are likely due to the conservation of a 10 bp DNA uptake sequence (GCCGTCTGAA) which contributes 
to the transformation of N. meningitidis and N. gonorrhoeae [Liu, S. V. 2002. Snyder, L. A. 2007. 
Cehovin, A. 2013. Marri, P. R. 2010]. Therefore commensal Neisseria spp. might act as reservoir for 
virulence-associated factors [Marri, P. R. 2010]. More recent studies have evaluated the presence 
and conservation of antigens in the licensed meningococcal B vaccine, Bexsero® within Neisseria to 
assess the potential effect of this vaccine on the commensal flora [Muzzi, A. 2013]. The conservation 
of the antigens in Bexsero® is discussed below. 
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1.7.7.7.1 fHbp 
fHbp gene is present in N. cinerea and N. polysaccharea, but not in other commensal species [Muzzi, 
A. 2013]. Sequence analysis established that N. cinerea encodes a V1 fHbp whereas the N. 
polysaccharea fHbp belongs to V3 fHbp. Some strains of N. polysaccharea contain fHbp with a 
frameshift mutation [Muzzi, A. 2013]. The expression and function of fHbp from N. cinerea and N. 
polysaccharea has not been evaluated. 
1.7.7.7.2 NadA 
nadA is not present in N. gonorrhoeae or other Neisseria spp. although some N. cinerea isolates 
harbour fragments of nadA with only one isolate having an intact nadA homologue [Comanducci, M. 
2004. Hadad, R. 2012. Muzzi, A. 2013]. The N. cinerea nadA gene is related to alleles nadA4 and 
nadA5 from N. meningitidis [Comanducci, M. 2004. Muzzi, A. 2013]. 
1.7.7.7.3 NHBA 
Besides being present in all N. meningitidis isolates, nhba homologues are present in N. gonorrhoeae, 
N. polysaccharea, and N. lactamica. Conversely, nhba is not present in N. cinerea [Hadad, R. 2012. 
Muzzi, A. 2013]. Two functional motifs have been described for NHBA, the lipo-box, which is 
conserved across the Neisseria genus, and the Arg-rich, heparin-binding motif (RFRRSARSRRS) 
[Serruto, D. 2010]. The initial three amino acids (RFR) of the Arg-rich motif are were not conserved 
between species while the central six residues (RSARS) are conserved [Muzzi, A. 2013].  
1.8 Neisseria cinerea 
N. cinerea is a Gram negative diplococcus originally isolated in 1906 and designated Micrococcus 
cinereus [von Lingelsheim, W. 1906]. Isolates of N. cinerea have previously been misidentified as 
Moraxella catarrhalis and Neisseria pseudocatarrhalis prior to being correctly identified as N. cinerea 
in 1962 [Berger, U. 1962. Knapp, J. S. 1984].  
1.8.1 N. cinerea carriage 
N. cinerea frequently colonises the oropharynx of adults and children [Knapp, J. S. 1988. Sheikhi, R. 
2015]. Initial studies of N. cinerea colonisation rates in the US suggests that approximately 27% of 
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adults are colonised by N. cinerea [Knapp, J. S. 1988]. More recent studies in adults suggest that the 
colonisation is lower (approximately 10%) whereas estimated carriage rates of N. cinerea from 
children in Iran are approximately 1.6% [Sáez Nieto, J. A. 1998. Sheikhi, R. 2015]. Although there are 
limited studies, it appears that N. cinerea colonisation rates are lower in childhood and increase with 
age [Gold, R. 1978. Goldschneider, I. 1969. Cartwright, K. A. 1987. Sheikhi, R. 2015].   
1.8.2 Infections caused by N. cinerea 
Instances of disease caused by N. cinerea are mainly associated with immuno-compromised patients 
[Kochi, C. V. 1999]. Positive blood cultures for N. cinerea have been obtained from patients with 
meningitis, nosocomial pneumonia, peritonitis, bacteraemia and tricuspid valve endocarditis [Kochi, 
C. V. 1999. Kirchgesner, V. 1995. von Kietzell, M 2016. Boyce, J. M. 1985. Taegtmeyer, M. 2006. 
Southern, P. M. 1987. Benes, J. 2003]. Furthermore, N. cinerea has been isolated from newborns and 
is associated with conjunctivitis and purulent ophthalmia [Au, Y. K. 1990]. 
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2. AIMS 
N. meningitidis is a common commensal of the human nasopharynx of between 10-40% of the 
population but in rare instances can cause systemic disease [Stephens, D. S. 2007]. The genetic 
factors which contribute to an individual’s likelihood of developing systemic disease vs. 
asymptomatic carriage are not known, although individuals with rare defects in the AP or TP have 
approximately 7,000-10,000 fold increased risk of developing meningococcal disease [Figueroa, J. E. 
1991. Ram, S. 2010]. GWAS have identified SNPs in CFH and CFHR3 which are associated with 
meningococcal disease although the molecular mechanisms underlying these findings have yet to be 
defined [Davila, S. 2010. Biebl, A. 2015]. Understanding the function of the CFHRs has been 
hampered by the lack of reagents to study these proteins. Therefore, to determine a molecular 
mechanism for host susceptibility to meningococcal disease, novel reagents need to be generated. 
My initial aims are to: 
1. Generate and characterise specific mAbs against CFHRs.  
2. Determine if N. meningtidis binds CFHR3 and Investigate the biological relevance of N. 
meningitidis binding CFHR3.  
Multi-component protein based vaccines, which include fHbp, have been licensed against serogroup 
B N. meningitidis [Pizza, M. 2000. Masignani, V. 2003. Fletcher, L. D. 2004]. fhbp has been identified 
in N. gonorrhoeae and commensal Neisseria spp. including N. cinerea [Hadad, R. 2012. Muzzi, A. 
2013]. N. cinerea also colonises the human respiratory tract therefore implementation of protein 
based vaccines containing fHbp could affect the nasopharyngeal flora. My final aims were to: 
3. Determine if N. cinerea expresses fHbp and if expressed fHbp is functionally similar to 
meningococcal fHbp.  
4. Evaluate the immune response elicited by Bexsero® against N. cinerea.  
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3. MATERIALS AND METHODS 
3.1. Antibodies 
Antibodies used throughout this study are listed in Table 3.1. 
Antibodies Description Isotype 
Reference/ Catalogue 
number 
HSL-1* mouse monoclonal raised against CCP domains 
4-5 of CFHR3 
IgG1κ This Study 
CFHR1 mouse monoclonal against Glu19-Ala328 of 
CFHR1 
IgG2B R&D, MAB4247 
CFHR2 mouse monoclonal raised against CFHR2 
 
Gift Paul Morgan 
CFHR4 mouse monoclonal against Glu20-Glu331 of 
CFHR4 
IgG1 R&D, MAB5980 
CFHR5 goat polyclonal raised against Glu19-Glu569 of 
CFHR5 
- R&D, AF3845 
CFHR5 mouse monoclonal raised against Glu19-Glu569 
of CFHR5 
IgG1 R&D, MAB3845 
fHbp mouse polyclonal sera raised against fHbp V1 - [Johnson, S. 2012] 
GHfp mouse polyclonal sera raised against GHfp - [Jongerius, I. 2013] 
RecA rabbit polyclonal raised against E.coli RecA - Abcam, ab63797 
OX24 mouse monoclonal which recognises an epitope 
in CCP domain 5 of CFH 
IgG1κ [Sim, E. 1983] 
CFH goat polyclonal raised against CFH - Calbiochem, 341276 
HRP-mouse IgG goat anti-mouse immunoglobulins antibody 
conjugated to HRP 
- Dako, P0447 
HRP-Goat IgG rabbit anti-goat immunoglobulins antibody 
conjugated to HRP 
- Dako, P0160 
HRP-rabbit IgG goat anti-rabbit IgG antibody conjugated to HRP - Santa Cruz, sc-2004 
647-mouse IgG goat anti-mouse IgG (H+L) conjugated to Alexa 
Fluor® 647  
- LifeTech, A-21235  
488-mouse IgG goat anti-mouse IgG (H+L) conjugated to Alexa 
Fluor® 488 
- LifeTech, A-11029  
 
Table 3.1: Antibodies 
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3.2. Mouse immunisations 
All animal experiments were carried out under protocols reviewed and approved by the Home Office, 
United Kingdom under licence number PPL 30/3194.  
3.2.1 Generation of mAbs 
 Antigens used are listed in Table 3.2 and were conjugated to keyhole limpet hemocyanin (KLH) 
carrier (Imject™ mcKLH, PBS, Pierce) via N-hydroxysuccinimide ester cross-linking according to the 
manufacturer’s instructions. Female BALB/c mice (Charles River, Margate; >8 weeks of age) were 
immunised with 50 g of antigen emulsified in an equal volume of TitreMax®Gold (Sigma, UK) and 
administered subcutaneously on day 1. Two subsequent immunisations were administered 
intraperitoneally (IP) on days 15 and 29 with 50 g of antigen in PBS. A booster of 100 g of antigen 
was given by IP in PBS three days prior to cell fusion on day 43. Mice were sacrificed by cervical 
dislocation and the spleens removed. Blood was collected by cardiac puncture.  
CFHR Antigen (Sequence) 
Spleen 
number 
CFHR2 Recombinant CFHR2(3,4) 1 
Recombinant CFHR2(3,4) 2 
CFHR3 Recombinant CFHR3(4,5) 1 
Recombinant CFHR3(4,5) 2 
CFHR4 Peptide (ENSRAKSNGM) 1 
Peptide (ENSRAKSNGM) 2 
CFHR4 Recombinant CFHR4(4,5) 1 
Recombinant CFHR4(4,5) 2 
CFHR5 Peptide (IAGVNIKTLLKLSG)  1 
Peptide (IAGVNIKTLLKLSG) 2 
CFHR5 Recombinant CFHR5(8,9) 1 
Recombinant CFHR5(8,9) 2 
 
Table 3.2: Summary of antigens used in the generation of mouse anti-human CFHR mAbs 
J.C. and P.W. expressed and purified recombinant CFHR CCP domains (CCP domains in subscript) 
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Recombinant C-terminal CCP domains of CFHR2-CFHR5 were expressed using pET-15b vectors in E. 
coli BL21 (D3). Peptides were designed to regions with low sequence identity with other CFHRs and 
CFH. Both recombinant proteins and synthetic peptides were conjugated to KLH prior to immunising 
two BALB/c mice per antigen. 
Antigens were conjugated to KLH prior to immunisation by Dr. Joseph Caesar, University of Oxford. 
CFHR CCP domains used for immunisations and screening were expressed and purified by Dr. Joseph 
Caesar and Dr. Philip Ward, University of Oxford. 
3.2.2 Generation of immune sera 
Eight female BALB/c mice (6-8 week old, Charles Rivers, Margate) were immunised with recombinant 
V1.1 fHbp or N. cinerea fHbp (20 µg) absorbed to aluminium hydroxide (final composition; Al(OH)3 
0.5 mg/ml, Histidine-HCL 10 mM) by mixing overnight at 4OC, or with Bexsero® (total protein 20 µg). 
The antigens were given by IP on days 0, 21 and 35. Sera was collected on day 49 by terminal 
anaesthesia and cardiac puncture. 
3.3. Monoclonal antibody production 
3.3.1. Media and supplements for mAb production 
Buffers and media used to prepare mAbs are listed in Table 3.3. 
 Media 
Foetal 
bovine 
serum 
Penicillin/ 
Streptomycin 
L-glutamine 
Ultroser 
G 
HAT* HT** DMSO 
Myeloma media 
RPMI 
1640 
10% 
50 units/ml / 
50 µg/ml  
2 mM - - - - 
HEPES buffered 
fusion media 
with FBS 
RPMI 
1640, 
HEPES 
10% 
50 units/ml / 
50 µg/ml  
4 mM - - - - 
HEPES buffered 
fusion media 
w/o FBS 
RPMI 
1640, 
HEPES 
- 
50 units/ml / 
50 µg/ml  
4 mM - - - - 
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Fusion Recovery 
media 
RPMI 
1640 
10% 
50 units/ml / 
50 µg/ml  
2 mM 1% - - - 
Hybridoma 
Selection media 
RPMI 
1640 
10% 
50 units/ml / 
50 µg/ml  
2 mM 1% 2% - - 
Hybridoma 
Competent 
media 
RPMI 
1640 
10% 
50 units/ml / 
50 µg/ml  
2 mM 1% 1% - - 
Freezing media - 85% - - - - - 15% 
Hybridoma 
recovery media 
RPMI 
1640 
10% 
50 units/ml / 
50 µg/ml  
2 mM - - 1% - 
 
Table 3.3: Media and supplements used in the generation of mAbs 
* HAT supplement (50x) is a mixture of sodium hypoxanthine (5 mM), aminopterin (20 µM) and thymidine (0.8 mM) 
** HT supplement (50x) is a mixture of sodium hypoxanthine (5 mM), and thymidine (0.8 mM) 
 
3.3.2. Spleen preparation prior to cell fusion 
Spleens were washed in 5 ml of HEPES buffered fusion media containing 10% FBS, then placed in a 
petri dish containing 5 ml of fresh HEPES buffered fusion media containing 10% FBS. The spleen was 
dissected into two and plasma cells were dissociated from the spleen using tweezers. Plasma cells 
were pelleted by centrifugation at 280 x g for 5 minutes, then resuspended in 10 mls of HEPES 
buffered fusion media without FBS if immediately proceeding with fusion protocol, or in 3 mls of 
freezing media for long term storage. Prior to cell fusion, frozen plasma cells were thawed and 
immediately placed into 15ml of HEPES buffered fusion media with FBS prior to pelleting at 280 x g 
for 5 minutes. Plasma cells were resuspended in 10 mls of HEPES buffered fusion media without FBS 
prior to cell fusion.  
3.3.3. Cell fusion 
NS0 myeloma cells were grown in myeloma media to confluency. Three days prior to cell fusion the 
myeloma cells were diluted 1:40 to ensure that cells were in exponential growth at the time of fusion. 
Plasma cells (108) and NSO myeloma cells (107), or alternatively a ratio of 1 myeloma cell to every 10 
43 
plasma cells, were combined and washed in 30 ml of HEPES buffered fusion media without FBS and 
pelleted for 10 minutes at 280 x g. The supernatant was removed and the cell pellet was dissociated 
by gentle tapping. All further steps were conducted in a 37oC waterbath. Cell fusion was initiated by 
the addition of 1.2 ml of polyethylene glycol (PEG 1500, Roche, UK) over one minute with continual 
agitation. While continuing to agitate the cells, 7 ml of HEPES buffered fusion media without FBS was 
added slowly over seven minutes; cell fusion was halted with 8 ml of HEPES buffered fusion media 
with FBS.  Fused cells were then pelleted at 280 x g for 5 minutes, and the cells resuspended in 10 
ml, of fusion recovery media. The fused cells were then added to 190 ml of fusion recovery media, 
and 1 ml plated into each well of eight 24-well plates. After 24 hours, 1 ml of hybridoma selection 
media was added to each of the wells. Cells were then incubated for seven to ten days prior to 
screening for positive clones.  
3.3.4. Cloning hybridomas by limiting dilution 
Hybridomas were thawed a few days prior to cloning to ensure that cells were in exponential growth. 
Cells were enumerated and 10 μl of cells were placed in 10 ml of cloning media (hybridoma 
competent media with 1% or 2% Condimed, Roche, 11088947001) then cells were diluted to 5 
cells/ml in a total volume of 16 ml of cloning media. 200 μl of solution containing diluted hybridomas 
was added to 80 wells of a 96-well plate then incubated for five to seven days. Each well was 
screened under a microscope to identify those containing single colonies prior to screening for 
specific mAbs in the media. Cells were sequentially expanded into T-75 tissue culture flasks for 
storage and mAb production.  
3.3.6. Monoclonal antibody isotyping 
The isotype of mAbs was determined using a mouse isotyping kit (AbD Serotec, UK, catalogue 
number MMT1) according to manufacturer’s instructions. In brief, microparticle beads coupled to 
anti-mouse kappa and anti-mouse lamda mAbs bind to murine antibodies. The isotyping strip 
contains immobilised goat anti-mouse antibodies specific for mouse IgG1, IgG2a, IgG2b, IgG3, IgM 
and IgA along with a second strip with immobilised antibodies specific for mouse lamda and kappa 
light chains. Tissue culture supernatants containing mAbs were diluted in PBS to approximately 1 
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μg/ml, and 200 μl of mAb was incubated with the microparticle beads at room temperature for one 
minute. The test strips were then added to the mAb conjugated microparticle beads; blue aggregates 
form after 5-10 minutes incubation where the microparticle beads are bound by the specific 
isotyping antibodies. 
3.3.7. Monoclonal antibody production and purification 
Hybridoma cell cultures were transferred to serum free or ultra-low bovine IgG prior to antibody 
production. Cells were grown in hybridoma competent media without antibiotics or Ultroser G 
serum substitute. Cells were then serially diluted into hybridoma recovery media and subsequently 
serially diluted into myeloma media without antibiotics. Hybridoma cells were then adapted to 
growth in either RPMI-1640 with L-glutamine with either 10% ultra-low IgG FBS (Life Technologies, 
16250078) or 5% FreeAdd serum replacement (BioWest, S6000) prior to harvesting tissue culture 
supernatant for mAb purification. Cell debris was removed by centrifugation at 3,500 x g and the 
supernatant passed through a 0.22 μm filter prior to antibody purification. Antibodies were purified 
using Pierce™ Protein G Agarose resin (ThermoScientific, 20398) according to manufacturer’s 
instructions. Antibodies were eluted with 0.1 M glycine, pH 2.5 and dialysed overnight into Tris pH 
7.5, then further purified by size exclusion chromatography (Superdex HiLoad 16/600 200pg, GE 
Healthcare, Little Chalfont, UK, buffer 50 mM Tris pH 7.5, 150 mM NaCl). 
3.4. Enzyme-linked immunosorbent assay (ELISA) 
Primary antibodies were used at the following concentrations: hybridoma tissue culture 
supernatants, neat; anti- fHbp polyclonal sera, 1:100; anti-CFH, 1:1,000 (Calbiochem). Goat anti-
mouse HRP (Dako, UK) and rabbit anti-goat HRP (Dako, UK) secondary antibodies were used at a final 
concentration of 1:5,000. 
3.4.1 mAb screening 
To identify positive hybridomas wells, ELISA plates (F96 maxisorp, Nunc) were coated with 50 μl of 
unconjugated immunising antigen in PBS (5 μg/ml) for 1 hour at room temperature. Plates were 
washed with PBS 0.05% Tween 20 prior to blocking with 2% skimmed milk in PBS 0.05% Tween 20 
overnight at 4oC. Plates were stored at -20oC prior to screening. To determine the specificity of mAbs 
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produced by hybridomas, ELISA plates were coated with the two C-terminal CCP domains of CFH or 
CFHR1-CFHR5 (5 μg/ml, 50 μl per well) prior to blocking and stored as described for the immunising 
antigen. To evaluate the immunogenicity of whole IgG and antibody Fab fragments, ELISA plates 
were coated with CFHR3(4,5) (1 μg/ml, 50 μl per well) overnight at 4oC. Plates were washed with PBS 
0.05% Tween 20 prior to blocking with 2% skimmed milk in PBS 0.05% Tween 20 for 1 hour at 37oC. 
Blocking buffer was removed prior to washing with PBS 0.05% Tween 20 and labelling protocol 
followed as below. 
For ELISAs, plates were incubated with neat hybridoma culture supernatant, or purified Fab fragment 
for 1 hour at room temperature prior to washing with PBS-0.05% Tween 20. Plates were incubated 
with HRP-conjugated goat anti-mouse for a further hour. After washing, antibody recognition was 
detected using ELISA substrate and stop solution (Roche) according to manufacturer’s instructions. 
Plates were read at ODA450nm using SpectraMax M5 spectrophotometer (Molecular Devices) 
3.4.2. Evaluation of CFH binding 
To determine CFH binding, 96 well microplates (F96 maxisorp, Nunc) were coated with recombinant 
fHbp (3 μg/ml, 50 μl per well) overnight at room temperature. All further incubation steps were 
performed for one hour at 37oC. Plates were washed with PBS 0.05% Tween 20 prior to blocking with 
3% bovine serum albumin (BSA) in PBS with 0.05% Tween 20. Plates were incubated with full length 
recombinant CFH (Sigma) in two fold dilutions from 10 μg/ml, and binding was detected with anti-
CFH antibody (Calbiochem) and HRP-conjugated rabbit anti-goat antibody (Dako). CFH binding was 
visualised with substrate and stop solution (Roche) according to manufacturer’s instructions, and the 
ODA450nm measured (SpectraMax M5, Molecular devices). Statistical significance was tested using a 
unpaired student t-test (GraphPad Prism v.6.0) to compare means ± S.D using a p<0.05 cutoff for 
significance. 
3.4.3. Evaluation of immunogenicity sera 
To analyse the immunogenicity of sera generated from mice immunized with either recombinant 
fHbp or Bexsero®, ELISA plates were coated with recombinant V1.1 fHbp, V1.110 fHbp and BSA (2.5 
μg/ml, 50 μl per well) overnight at room temperature. Pooled mouse sera was used as primary 
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antibody with three-fold dilutions from a starting dilution of 1:300. All incubation steps were 
performed for one hour at 37oC and plates were blocked with 3% bovine serum albumin (BSA) in PBS 
with 0.05% Tween 20. Antibody binding was detected with secondary HRP-conjugated goat anti-
mouse antibody (Dako) and visualised as above.  
3.5. Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE)  
SDS-PAGE analysis of proteins was performed according to the method described by Sambrook et al. 
[Sambrook, J. 1989]. Reagents used to prepare both 12% and 16% polyacrylamide gels are shown in 
Table 3.4. 
  
Stacking 
Gel 
Resolving Gel 
    4% 12% 16% 
30% Acrylamide (ml) Severn Biotech, 20-2600-05 1.3 4.0 5.3 
0.5 M Tris pH 6.8 (ml) Sigma, T1503 2.5 - - 
1.5 M Tris pH 8.8 (ml) Sigma, T1503 - 2.5 2.5 
10% SDS (μl) Sigma, L3771 100.0 100.0 100.0 
dH2O (ml) - 6.1 3.4 2.1 
TEMED (μl) Sigma, T9281 10.0 5.0 5.0 
10% APS (μl) Sigma, A3678 50.0 50.0 50.0 
Total volume (ml) 
 
10.0 10.0 10.0 
 
Table 3.4: Reagents for the preparation of polyacrylamide gels 
 
SDS-PAGE was performed using the Mini-PROTEAN® Tetra Vertical Electrophoresis Cell (BioRad) and 
polyacrylamide gels were run in SDS buffer (200 mM glycine, 248 mM Tris, 34 mM SDS) at 100 V until 
the gel front reached the bottom of the gels. 
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3.6. Western Blotting 
Primary antibodies were used at the following concentrations: hybridoma tissue culture 
supernatants, 1:2; anti- fHbp V1.1 polyclonal sera, 1:1,000 [Johnson, S. 2012]; anti- GHfp polyclonal 
sera, 1:10,000 [Jongerius, I. 2013]; anti-fHbp polyclonal sera, 1:1,000 (this study); anti-RecA, 1:5,000 
(Abcam, Cambridge); anti-CFH, 1:10,000 (Calbiochem). Secondary antibodies were used at a final 
concentration of 1:10,000; goat anti-mouse HRP (Dako, UK), rabbit anti-goat HRP (Dako, UK) and 
goat anti-rabbit HRP (Santa Cruz Biotechnology, Germany). 
After SDS-PAGE, proteins were transferred to immobolin P polyvinylidine fluoride (PVDF) membranes 
(Millipore, USA) using the Trans-Blot® SD semi-dry transfer system (Biorad, USA). PVDF membranes 
were activated in methanol prior to equilibrating membranes and Whatman paper in Transfer buffer 
(48 mM Tris base, 39 mM Glycine, 20% methanol (v/v), pH8.3). The transfer sandwich was assembled 
into the Trans-Blot® drawer with four sheets of Whatman paper, activated PVDF membrane, 
polyacralyamide gel, and finally four further sheets of Whatman paper. Protein transfer was 
performed at 15V for 30 minutes. Membranes were blocked in 3% (w/v) dry milk/PBS with 0.05% 
(v/v) Tween-20 overnight, then incubated with primary antibodies for 60 minutes. Membranes were 
washed three times with PBS with 0.05% (v/v) Tween-20 and incubated for a further hour with HRP-
conjugated secondary antibodies. Binding was detected with ECL Western Blotting Detection kit 
(Amersham, USA) or ECL Prime Western Blotting Detection kit (Amersham, USA). All antibodies were 
diluted in 1% (w/v) dry milk/PBS. 
3.6.1. mAb specificity screening 
To determine specificity of the mAbs, the two C-terminal CCP domains of CFH and CFHR1-CFHR5 (10 
μg/ml), and NHS (1 in 200) diluted in 1x SDS-PAGE sample buffer (100 mM Tris-HCl, pH 6.8, 20 μM β-
mercaptoethanol, 4% SDS, 0.2% bromophenol blue, 20% glycerol) were separated on 16% 
polyacrylamide gels with PageRuler Plus Prestained protein marker (ThermoScientific) or All blue 
protein ladder (BioRad) prior to western blot analysis. Membranes were probed with hybridoma 
tissue culture supernatant and detected with HRP conjugated goat anti-mouse secondary antibody 
(Dako, 1/10,000). 
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3.6.2. Detection of fHbp 
For the preparation of whole cell lysates, bacteria were grown overnight on BHI and resuspended in 
PBS. The concentration of the bacterial suspension was quantified by measuring the A260 nm of 20  
μl of the bacterial suspension mixed with 980 μl of P2 lysis buffer (0.1 M NaOH, 1% SDS; Qiagen) using 
a UVVIS spectrophotometer (Shimadzu). The bacterial suspension was adjusted to 109 colony-
forming units (c.f.u.) ml−1, centrifuged at 16,000 x g for 5 minutes, and resuspended in 100 μl of SDS-
PAGE sample buffer, and boiled for 10 min prior to loading 10 μl for analyses by SDS-PAGE. 
For the detection of fHbp, bacterial whole cell lysates or recombinant fHbp (10 μg/ml in SDS-PAGE 
sample buffer) were separated on 12% polyacrylamide gels. After transferring to a PVDF membrane, 
membranes were probed with anti-fHbp V1.1 sera [Johnson, S. 2012], anti-Ghfp [Jongerius, I. 2013] 
or anti-fHbp polyclonal sera (this study) prior to detection with a HRP conjugated goat anti-mouse 
secondary antibody. For whole cell lysates, RecA was used as a loading control and detected with 
HRP conjugated goat anti-rabbit secondary antibody. Alternately, polyacrylamide gels were stained 
with Coomassie blue (0.2% Coomassie Blue R-250, 40% ethanol (v/v), 10% acetic acid (v/v), 50% d 
H20) for 10 minutes then de-stained overnight in dH20. 
3.6.3. Evaluation of CFH binding 
For far western blot analysis, whole cell lysates or recombinant proteins were separated on 12% 
polyacrylamide gels as for the detection of fHbp prior to transferring to a PVDF membrane. 
Membranes were then initially incubated with NHS (1:200 diluted in 1% (w/v) dry milk/PBS) for 60 
minutes and then washed with PBS with 0.05% (v/v) Tween-20. CFH binding was then detected with 
anti-CFH pAb and HRP conjugated rabbit anti-goat secondary antibody as described above. 
3.7. Bacterial strains and growth 
N. meningitidis and N. cinerea (Table 3.5) were grown on brain heart infusion (BHI) agar (Oxoid) or 
BHI broth supplemented with Levinthal’s base (500 ml defibrinated horse blood, autoclaved with 1 l 
BHI broth). Bacteria grown on solid media were incubated overnight at 37oC in the presence of 5% 
CO2. Liquid culture were inoculated with 109 bacterial per 10ml and grown with shaking at 180 r.p.m.  
at specified temperatures to OD A600 ~0.5 unless otherwise specified.  
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E. coli was grown in Luria-Bertani (LB) broth or on LB agar. Liquid cultures were grown in 5ml of 
media inoculated from a single colony overnight at 37oC with shaking at 180 r.p.m. Bacteria grown 
overnight in liquid cultures were diluted the next day, 1 in 100 into fresh media for protein 
expression.  
N. meningitidis 
Strain 
fHbp 
variant 
group 
fHbp 
sub- 
variant 
Year Country cc 
Serogroup: 
serotype: 
serosubtype 
Reference 
H44/76 1 1 1976 Norway 32 B:15:P1.7,16 
[Maiden, 
M. C. 1998] 
H44/76Δfhbp - - - - 32 B:15:P1.7,16 
[Lucidarme, 
J. 2011]  
M1239 3 28 1994 USA 41/44 B:14:P1.23,14 
[Masignani, 
V. 2003] 
M1239Δfhbp - - - - 41/44 B:14:P1.23,14 
[Jongerius, 
J. 2013] 
M1239Δfhbp::fhbp 
V1.1 
1 1 - - 41/44 B:14:P1.23,14 
[Jongerius, 
J. 2013] 
M1239Δfhbp::fhbp 
V1.14 
1 14 - - 41/44 B:14:P1.23,14 This study 
M1239Δfhbp::fhbp 
V2.22 
2 22 - - 41/44 B:14:P1.23,14 This study 
M1239Δfhbp::fhbp 
V3.28 
3 28 - - 41/44 B:14:P1.23,14 This study 
M1239Δfhbp::fhbp 
V3.28T286A 
3 28 - - 41/44 B:14:P1.23,14 This study 
NZ98/254 1 14 1998 
New 
Zealand 
41/44 B:4:P1.4 
[Martin, D. 
R. 1998] 
FAM18 2 22 1983 USA 11 C:2a:P1.5,2 
[Feavers, I. 
M.1999] 
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N. cinerea 
CCUG 346 T 1 110 Unknown Unknown ND 
ND: 
P1.ND,ND 
[Bennett, J. 
S. 2012] 
CCUG 346 TΔfhbp - - - - ND 
ND: 
P1.ND,ND 
This study 
CCUG 346 
TΔfhbp::N.c. fhbp 
1 110 - - ND 
ND: 
P1.ND,ND 
This study 
CCUG 25879 1 564 1989 Sweden ND 
ND: 
P1.ND,ND 
[Bennett, J. 
S. 2012] 
CCUG 27178 A 1 110 1983 Unknown ND 
ND: 
P1.ND,ND 
[Bennett, J. 
S. 2012] 
CCUG 53043 1 534 2006 Sweden ND 
ND: 
P1.ND,ND 
[Bennett, J. 
S. 2013] 
CCUG 5746 1 563 1977 Sweden ND 
ND: 
P1.ND,ND 
[Bennett, J. 
S. 2012] 
 
Table 3.5: N. meningitidis and N. cinerea strains 
Year and country of isolation, clonal complex (cc), and serogroup:serotype:serosubtype classification along with fHbp 
variant familiy and subvariant group are shown. 
3.8. Antibiotics 
Antibiotics were used at the concentrations listed in Table 3.6. Stock solutions of kanamycin (1 
mg/ml) and carbenicillin (1 mg/ml) were prepared in dH2O passed through a 0.22 μm filter prior to 
storage at -20oC. Erythromycin (100 μg/ml) was prepared in ethanol prior to storage at -20oC. 
 
Kanamycin 
(µg ml-1) 
Erythromycin 
(µg ml-1) 
Carbenicillin (µg 
ml-1) 
N. meningitidis 100 2 - 
N. cinerea 100 10 - 
E. coli 50 - 100 
 
Table 3.6: Concentration of antibiotics 
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3.9. Molecular Cloning 
The genome sequences of the Neisseria strains analysed in this work are publicly available online in 
the PubMLST Neisseria BIGSdb (http://pubmlst.org/neisseria/).  
3.9.1. Genomic DNA preparation 
Genomic DNA was isolated from Neisseria strains using the Wizard® Genomic DNA Purification Kit 
(Promega). Briefly, bacteria were grown overnight on BHI agar prior to resuspending in 600 µl Nuclei 
lysis solution. Bacteria were incubated at 80oC for 5 minutes and allowed to cool to room 
temperature. Protein was precipitated with the addition of 200 µl of Protein precipitation solution 
prior to centrifuging a 15,000 x g for 3 minutes. The supernatant was then added to 600 µl 
isopropanol, and the DNA pelleted at 15,000 x g for 5 minutes, then further washed in 600 µl of 70% 
ethanol. DNA was again pelleted and allowed to dry. DNA was resuspended in 100 µl of dH2O with 1 
µl of RNAase. 
3.9.2. Polymerase Chain Reaction (PCR) 
For fhbp amplification from Neisseria genomic DNA, reaction mixtures contained 1 pmol/ μl of each 
primer (Primers listed in table 3.7 and synthesized by Sigma), 1.5 mM MgCl2 (Roche), 200 μM dNTPs 
(New England Biolabs), 2 U Expand High fidelity DNA polymerase (Roche), and 0.1 volume 
polymerase buffer (Roche) in a total volume of 25 μl. The conditions for thermal cycling were an 
initial denaturation step of 94oC for 5 minutes, followed by 30 cycles of 94oC for 30 seconds, 55oC for 
30 seconds and 72oC for 80 seconds (Expand High fidelity DNA polymerase extension time 1 kb/min) 
and a final extension step at 72oC for 7 minutes. Taq DNA polymerase (1 kb/min extension time; 
Sigma) was used for the amplification of fHbp prior to sequencing. 
To generate N. cinerea Δfhbp, the PCR volume was increased to 50 μl; Herculase II Fusion DNA 
polymerase (Agilent) was used for amplification and extension times adjusted accordingly (15 sec/ 
min). 
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Primer  
fHbp 
variant 
group 
fHbp amplified 
(strain) 
Primer sequence (restriction site 
underlined) 
Restric
tion 
site 
Reference 
pgcc4V1.1 F 1.1 H44/76 CGGTTAATTAAGGAGTAATTTTTG
TGAATCGAACTGCCTTCTGCT 
PacI [Jongerius, I. 
2013] 
pgcc4V1.1 R 1.1 H44/76 CGGTTAATTAATTATTGCTTGGCG
GC 
PacI 
 
pgcc4V1.14 F 1.14 NZ98/254 CGGTTAATTAAGGAGTAATTTTTG
TGAACCGAACTGCC 
PacI 
 
pgcc4V1.14 R 1.14 NZ98/254 CGGTTAATTAATTATTGCTTGGCG
GCAAGAC 
PacI 
 
pgcc4V2.22F 2.22 FAM18 CGGTTAATTAAGGAGTAATTTTTG
TGAACCGAACTGCCTTCTGCT 
PacI 
 
pgcc4V2.22R 2.22 FAM18 CGGTTAATTAACTACTGTTTGCCG
GCGATGC 
PacI 
 
pgcc4V3.28 F 3.28 M1239 CGGTTAATTAAGGAGTAATTTTTG
TGAATCGAACTGCCTTCTGCT 
PacI 
 
pgcc4V3.28 R 3.28 M1239 CGGTTAATTAACTACTGTTTGCCG
GCGATGC 
PacI 
 
pncc1V1.110 F 1.11 CCUG 346 T CGGTTAATTAAGGAGTAATTTTTG
TGAACC 
PacI 
 
pncc1V1.110 R 1.11 CCUG 346 T CGGTTAATTAATTATTGCTTGGCG
GC 
PacI 
 
FfhbpV1.110 1.11 CCUG 346 T GCCATATGATGGCCGCCGACAT NdeI 
 
RfhbpV1.110 1.11 CCUG 346 T GCCTCGAGTTGCTTGGCGGCAAG
GCCGATAT 
XhoI 
 
F N.cΔfhbp  - H44/76Δfhbp GCCATATGGCTGAAAGTCATCAA
CGAAT 
NdeI 
 
R N.cΔfhbp  - H44/76Δfhbp GCCTCGAGGTGCAATACAAAATG
CCGTCCGAACGGTAA 
XhoI   
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Mutagenesis primers       
Primer name 
fHbp 
variant 
group 
Modification Primer sequence    Reference 
V3.28T286A F 3.28 T286A AGCGAAGAAAAAGGCgctTACCA
CCTCGCCCTT 
 
[van der Veen, 
S. 2014] 
V3.28T286A R 3.28 T286A AAGGGCGAGGTGGTAagcGCCTT
TTTCTTCGCT 
 
[van der Veen, 
S. 2014] 
V1.1I311A F 1.1 I311A AAAACCGTAAACGGCgcaCGCCA
TATCGGC 
 
[Johnson, S. 
2012] 
V1.1I311A R 1.1 I311A GCCGATATGGCGtgcGCCGTTTAC
GGTTTT 
  [Johnson, S. 
2012] 
 
Table 3.7:  Primers 
Lower case bases indicate target site for site-directed mutagenesis 
 
Plasmids were purified from E. coli using the GenElute Plasmid Miniprep kit (Sigma) according to 
manufacturer’s instructions and were analysed by gel electrophoresis. DNA was combined with gel 
loading buffer (0.25% bromophenol blue, 0.25% xylene cyanol FF, 30% glycerol) and resolved on 1% 
agarose (Sigma) gels with 1x Tris Acetate EDTA (TAE) buffer (Tris 0.4 M, EDTA 0.01 M, acetic acid 0.2 
M, Syber Safe DNA stain (1:10,000). DNA was visualised by UV illumination using a Safe Imager™ 2.0 
Blue Light Transilluminator. 
3.9.3. Site directed mutagenesis 
Alanine substitution mutants, V1.11311A and V3.28T286A fHbp, were generated from either the 
complementation or expression plasmids using QuikChange II Site-Directed Mutagenesis Kit 
(Aglilent) according to manufacturer’s instructions. Briefly, reaction mixtures contained 35 ng DNA 
template, 100 ng/μl of both forward and reverse primers (Primers listed in Table 3.6 and synthesised 
by Sigma), 800 μM dNTPs (New England Biolabs), 2.5 U PfuUltra HF DNA polymerase, and 0.1 volume 
reaction buffer in a total volume of 50 μl. Conditions for thermal cycling were an initial denaturation 
step of 95oC for 30 seconds; followed by 18 cycles of 95oC for 30 seconds, 55oC for 60 seconds and 
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68oC for either 11 minutes or 7 minutes for PGCC4/ PNCC1 or pET-21b, respectively (extension time 
1 kb/min) and a final extension step at 68oC for 10 minutes. Following amplification, reaction 
mixtures were incubated with DpnI for 1 hour at 37oC to digest methylated DNA prior to transforming 
into E. coli DH5α. 
3.9.4. Bacterial transformation 
PCR products or linearised plasmid DNA was transformed into Neisseria by spot transformation as 
follows. Neisseria were harvested from overnight growth on BHI agar into PBS and a 10 μl aliquot 
was placed onto BHI agar and allowed to dry. DNA (approx. 500 ng) was added to the bacteria and 
allowed to dry. Bacteria were incubated at 37oC, 5% CO2 for 5 h for meningococcal strains or 
overnight for N. cinerea. Transformants were selected by streaking bacterial growth onto BHI agar 
containing antibiotics. Transformants were verified PCR and sequenced.  
For E. coli transformations, ligation reactions were added to 50 μl of DH5α or BL21(DE3)Lys 
(Promega) competent cells and incubated on ice for 30 minutes. Cells were heat shocked for 45 
seconds at 37oC and immediately incubated on ice for 2 minutes, then 800 μl of LB broth was added 
to the cells and incubated at 37oC with continuous agitation (180 r.p.m) for one hour prior to plating 
on selective media. 
3.9.5. Construction of complemented N. meningitidis and N. cinerea strains 
Complemented Neisseria strains were constructed by amplifying fhbp using Expand High Fidelity 
DNA polymerase (Roche, UK) from genomic DNA isolated from Neisseria strains listed in Table 3.4 
using primers listed in Table 3.6. PCR products were ligated into either pGCC4 for N. meningitidis or 
pNCC1 for N. cinerea with T4 DNA ligase [Mehr, I. J. 1998. Wörmann ME. 2016]. In brief, ligations 
were performed using a 1:5 ratio of insert to vector with 4 μl 5x T4 ligase buffer and 1 μl T4 DNA 
ligase (1 U/μl) (LifeTechnologies, 15224017) in 20 μl. Ligation reactions were incubated at 16oC 
overnight prior to transformation into E. coli DH5α. Complemention plasmids are listed in Table 3.8. 
Prior to transforming Neisseria strains, plasmids were linearised by ClaI digestion to remove plasmid-
encoded kanamycin resistance, the construct was gel extracted and then the linearised fragments 
were then transformed into N. meningitidis strain or N. cinerea strain.  
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E. coli strain Plasmid Insert Modification 
Antibiotic 
resistance 
cassette 
Reference 
DH5α pGCC4 V1.1 - kan/ erm [Jongerius, I. 2013] 
DH5α pGCC4 V1.1I311A I311A kan/ erm This study 
DH5α pNCC1 V1.110 - kan/ erm This study 
DH5α pGCC4 V1.14 - kan/ erm This study 
DH5α pGCC4 V2.22 - kan/ erm This study 
DH5α pGCC4 V3.28 - kan/ erm This study 
DH5α pGCC4 V3.28T286A T286A kan/ erm This study 
 
Table 3.8: Neisseria complementation plasmids 
 
3.9.6. Generation of fHbp expression constructs  
V1.1 and V1.1I311A fHbp expression constructs were generated in a previous study [Johnson, S. 2012]. 
fhbp was amplified from N. cinerea CCUG 346 T using primers, Ffhbpv1.110 and Rfhbpv1.110 (Table 3.7). The 
resulting product was ligated into a pET-21b expression vector using containing a C-terminal His-Tag 
using T4 ligase, prior to transformation into E. coli BL21 (DE3) (Agilent). fHbp expression constructs 
are listed in Table 3.9. 
pET-21b expression vector containing N. cinerea CCUG 346 T fHbp V1.110 was generated by Katy 
Poncin under my direct supervision. 
Strain Plasmid Insert Modification 
Antibiotic 
resistance 
cassette 
Reference 
BL21(DE3)Lys pET21b V1.1  fHbp 
 
carb [Johnson et al. 2012] 
BL21(DE3)Lys pET21b V1.1I311A fHbp I311A carb [Johnson et al. 2012] 
BL21(DE3)Lys pET21b V1.110  fHbp   carb This study 
 
Table 3.9: Plasmids used for protein expression in E. coli 
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3.9.7. Generation of N. cinerea CCUG 346 TΔfhbp  
N. cinerea strain CCUG 346 TΔfhbp was constructed by insertional inactivation of fhbp with a cassette 
encoding kanamycin resistance. N.c Δfhbp forward primer and N.c Δfhbp reverse primer (Table 3.6) 
were used to amplify fhbp and flanking sequences from N. meningitidis strain H44/76Δfhbp. N. 
cinerea CCUG 346 T was then transformed with a linear PCR fragment as described previously for N. 
meningitidis [Wörmann, M. E. 2016]. 
N. cinerea strain CCUG 346 TΔfhbp was generated and contructed by Katy Poncin under my direct 
supervision. 
3.10. Sequence analysis and model predication of N. cinerea fHbp 
N. cinerea fhbp sequences were extracted from whole genome sequences available in the PubMLST 
BIGSdb database (http://pubmlst.org/neisseria/). Alignments of N. cinerea fhbp sequences against 
fhbp from N. meningitidis H44/76 were generated with Clustal OMEGA (http://www.ebi.ac.uk/); 
residues were numbered according to V1.1 fHbp sequence [Johnson, S. 2012]. A model of N. cinerea 
fHbp was generated using the iTASSER server [Zhang Y. 2008]; V1.1 fHbp (Schieider, PBD: 2W80) was 
used as the threading template and the resulting model illustrated in PyMol 
(https://www.pymol.org/). The resulting model has a high confidence with a C-score of 1.68.  
3.11. fHbp purification 
For protein expression, E. coli with expression plasmids (Table 3.8) were grown in liquid medium to 
an OD A600 of 0.4–0.8, then isopropyl-β-d-thiogalactopyranoside (IPTG) (Sigma) was added to a final 
concentration of 1 mM. After four hours, bacteria were harvested by centrifugation at 5,000 x g for 
30 min at 4oC and suspended in NPI-20 (50 mM NaH2P04, 300 mM NaCl, 20 mM imidazole, pH 8.0) 
with EDTA-Free protease inhibitors (Roche). Cells were lysed in an EmulsiFlex-C5 homogenizer 
(Avestin) at 15,000 lb/in2. Lysates were centrifuged at 50,000 x g for 30 min at 4°C and recombinant 
proteins purified by affinity chromatography with a 1 ml HisTrap column (GE Healthcare) and eluted 
with NPI-200 (50 mM NaH2PO4, 300 mM NaCl, 300 mM imidazole, pH 8.0). Proteins were dialysed 
against 25 mM Tris, pH 8.5 at 4oC overnight prior to further purification by anion exchange 
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chromatography using an AKTApurifier (GE Healthcare). Proteins were loaded onto a HiTrapQ HP 
column (GE Healthcare) and were eluted in salt gradient against 25 mM Tris, pH 8.5, 1 M NaCl prior 
to dialysing overnight against PBS. Protein concentrations were estimated using a Nanodrop 2000c 
spectrophotometer (Thermo Scientific). 
3.12. Surface Plasmon Resonance (SPR) 
SPR was performed using a BiaCore 3000 instrument (GE Healthcare). Purified fHbp was immobilised 
on a CM5 sensor chip to approximately 800 reaction units (RU) by amine coupling (GE Healthcare). 
Unreacted groups on the CM5 sensor chip were inactivated with ethanolamine. HBS-EB (HBS buffer 
0.01 M Hepes, 150 mM NaCl, 3 mM EDTA, pH7.4) was used throughout. Increasing concentrations 
of CFH(6,7) (0.5 nM-32 nM) were injected over the chip surface at a flow rate of 40 µl /min using the 
KINJECT command with a dissociation time of 300 seconds. Flow cells in CM5 sensor chip were 
washed with 1 M glycine pH 3.0 between injections. KD values were calculated and analysed with 
BIAevaluation software. Kinetic data was referenced against both a blank cell and subtraction of a 
blank injection (HSB-EB). Binding data was collected in triplicate from two independent experiments. 
3.13. Flow cytometry 
N. meningitidis (1×109) were fixed in 1 ml of 3% paraformaldehyde for two hours then washed with 
PBS prior to staining whereas N. cinerea were fixed in 1 ml of 3% paraformaldehyde for 15 minutes 
after staining to prevent bacterial aggregates from forming.  
Primary antibodies were used at the following concentrations: HSL-1 hybridoma tissue culture 
supernatant, neat; anti- fHbp V1.1 polyclonal sera, 1:1,000 [Johnson, S. 2012]; anti- GHfp polyclonal 
sera, 1:10,000 [Jongerius, I. 2013]; anti-CFH, 1:10,000 (OX24). Alexa Fluor®-conjugated secondary 
antibodies were used at a final concentration of 1:1,000: goat anti-mouse Alexa Fluor® 647 
(Molecular probes, Life technologies) and goat anti-mouse Alexa Fluor® 488 (Molecular probes, Life 
technologies). 
fHbp (N. meningitidis and N. cinerea) was detected using anti-fHbp V1.1 sera and goat anti-mouse 
IgG-Alexa Fluor 647 conjugated antibody. Samples were run on a FACSCalibur (BD Biosciences), and 
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at least 104 events recorded before results were analysed by calculating the geometric mean FL-4 in 
FlowJo vX software (Tree Star). Statistical significance was tested using the unpaired student t-test 
comparison as implemented in GraphPad Prism v.6.0 (GraphPad Software Inc.) to compare means ± 
S.D using a p<0.05 cutoff for significance. 
3.13.1. Evaluation of CFHR3 and CFH binding 
To evaluate CFHR3 binding, 5x107 CFU/ml were resuspended in 10 μl of NHS or 10 µl of 
ΔCFHR3/CFHR1 sera for 30 min at room temperature. After two washes in 0.05% BSA, binding was 
detected following incubation with 50 μl mAb anti-CFHR3 antibody mAb (HSL-1) for 30 min at 4°C in 
of PBS. Cells were washed twice in 0.05% BSA, then resuspended in 50 μl of goat anti-mouse IgG-
Alexa Fluor 647 conjugate and incubated for 30 min at 4°C.  
To evaluate CFH binding, 5x107 CFU of bacteria were resuspended in 10 μl of heat inactivated NHS 
(HI-NHS) or CFH depleted sera for 30 min at room temperature. NHS was heat inactivated for 1 hour 
at 56oC. Binding was detected with an anti-CFH mAb (OX24) and goat anti-mouse IgG-Alexa Fluor 
647 conjugate antibody and analysed as for CFHR3 binding. 
3.13.2 Competition assay 
To evaluate the influence of CFHR3 on CFH, 5x107 CFU/ml of N. meningitidis M1239 were incubated 
with 10 µl of ΔCFHR3/CFHR1 sera and two-fold dilutions of recombinant full length CFHR3 (from 1 
µM) for 30 min at room temperature. CFHR3 binding was detected with HSL-1 or an anti-human CFH 
mAb (OX24), followed by incubating with goat anti-mouse IgG-Alexa Fluor 647 conjugated antibody 
prior to analysis by flow cytometry. Maximum fluorescence for CFHR3 was normalised to the results 
obtained following addition of 1 μM exogenous CFHR3 while the maximum fluorescence for CFH was 
normalised to results without CFHR3. Statistical significance was tested using the one‐way ANOVA 
multiple comparisons as implemented in GraphPad Prism v.6.0 (GraphPad Software Inc.) to compare 
means ± S.E.M. using a p< 0.01 cutoff for significance  
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3.14. Bacterial serum survival assay 
NHS was obtained by collecting venous blood and allowing it to coagulate at room temperature for 
60 minutes before centrifuging at 3,000 x g for 20 minutes at 4°C. Sera was heat inactivated at 56oC 
for 30 minutes prior to use. 
N. meningitidis and N. cinerea were grown overnight on BHI agar; media was supplemented with 1 
mM IPTG (final concentration) for complemented strains. 104 CFU of bacteria were incubated in 
dilutions of NHS (0-70% NHS as specified) for 30 minutes at 37oC in the presence of CO2. Bacterial 
survival was determined by plating onto BHI agar in triplicate. The percentage survival was calculated 
by comparison with results of samples containing no sera. Statistical significance was tested using an 
unpaired student t-test (GraphPad Software Inc). To analyse AP activation, NHS was preincubated 
with 5 mM MgCl2 and 10 mM EGTA to inhibit the CP and LP [Des Prez, R. M. 1975]. Percentage 
bacterial survival and significance was analysed as described above.  
3.14.1. Evaluating the effect of CFHR3 on bacterial survival 
N. meningitidis was grown overnight on BHI agar, and resuspended in PBS then diluted to 1 x 105 
CFU/ml in DMEM (Sigma). A total of 1x 104 CFU of bacteria were pre-incubated with 1 µM CFHR3, 1 
µM CFHR3 domains or PBS for 10 minutes prior to incubation with 5% NHS or 5% HI-NHS for 30 
minutes at 37oC in the presence of CO2. Bacterial survival was determined by plating onto BHI agar. 
Relative survival was calculated from samples containing no CFHR3 and incubated with heat-
inactivated sera and expressed as percentage survival. Statistical significance was tested using the 
unpaired student t-test comparison as implemented in GraphPad Prism v.6.0 (GraphPad Software 
Inc.) to compare means ± S.D using a p<0.05 cutoff for significance. Serum concentration and 
incubation times are as specified unless otherwise stated. 
For assays of the AP, bacteria were grown on BHI agar supplemented with 1mM IPTG. The other 
complement pathways were inhibited with 5mM MgCl2/ 10mM EGTA, and bacteria were incubated 
with 25% NHS. Analysis was performed as before. Serum concentrations and incubation times are as 
specified unless otherwise stated. 
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3.15. Serum Bactericidal Assay (SBA) 
For serum bactericidal assays, 5x104 CFU/ml of N. cinerea were mixed with an equal volume of baby 
rabbit complement (Cedarlane) diluted 1:10 in SBA buffer (Dulbecos phosphate buffered saline 
containing 0.1% (wt/vol) glucose, 1 mM CaCl2, 0.5 mM MgCl2). Sera was pooled from all mice and 
heat inactivated for 1 hour at 56oC prior to being added to wells in two-fold dilutions starting at 1:8. 
Control wells contained either no serum or no complement. Following incubation for one hour at 
37°C, 10 µl from each well was plated onto solid BHI media in triplicate, and the number of surviving 
bacteria determined after overnight growth. The SBA was expressed as the reciprocal of the highest 
dilution of sera required to kill more than 50% of bacteria.  
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4. GENERATION AND CHARACTERISATION OF CFHR MONOCLONAL 
ANTIBODIES 
4.1 Introduction 
The CFH family of proteins consists of CFH, the major regulator of the AP, and five CFHR proteins, 
CFHR1-CFHR5 [Skerka, C. 2013]. The CFHRs are closely related to CFH and composed of between 4-
9 CCP domains. These CCP domains have a high degree of amino acid sequence identity (between 
36-100%) with CFH and other CFHRs suggesting the CFHRs CCP domains have related functions 
(Figure 1.4) [Díaz-Guillén, M. A. 1999. Skerka, C. 2013]. Whereas the role of CFH in regulating 
complement by distinguishing self from non-self surfaces and down regulating the AP C3 activation 
is well established, the function of CFHRs is poorly understood [Jokiranta, T. S. 2005. Weiler, J. M. 
1976. Whaley, K. 1976. Pangburn, M. K. 1977]. Recent evidence suggests that contrary to CFH, the 
CFHRs lack co-factor activity for FI and decay accelerating activity, which have been attributed to 
CCP domains 1-4 of CFH; all the CFHRs lack homologous CCP domains [Heinen, S. 2009. Hellwage, J. 
1999. Hebecker, M. 2012. Eberhardt, H. U. 2013]. Furthermore, CFHR1, CFHR2 and CFHR5 have been 
shown to act as antagonists of CFH by competing with CFH for C3b, promoting complement 
activation [Goicoechea de Jorge, E. 2013. Tortajada, A. 2013]. Therefore the CFHRs are thought to 
act by fine-tuning complement activation on surfaces.  
The importance of CFHRs is highlighted by genetic variation across the CFH locus as polymorphisms 
are associated with several human diseases. For example, individuals homozygous for a 
CFHR3/CFHR1 deletion (ΔCFHR3/CFHR1) are susceptible to aHUS yet are protected from AMD and 
IgA nephropathy [Holmes, L. V. 2013. Zipfel, P. F. 2007. Moore, I. 2010. Dragon-Durey, M. A. 2009. 
Francis, N. J. 2012. Hughes, A. E. 2006. Gharavi, A. G. 2011]. Susceptibility to C3GN is associated with 
a CFHR3/CFHR1 fusion or an internal duplication of CFHR1, while duplications of CFHR5 are also 
associated with DDD [Tortajada, A. 2013. Francis, N. J. 2012. Malik, T. H. 2012. Abrera-Abeleda, M. 
A. 2006]. A GWAS has also identified SNPs in CFHR3 which are associated with protection against 
meningococcal disease [Davila, S. 2010].  
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To further understand the pathogenesis of these human diseases and how CFHRs contribute to 
disease susceptibility and progression, the physiological role of each CFHR needs to be defined.  
 
Figure 4.1: Available antibodies cross-react with other CFH family members 
Western blot analysis of the two C-terminal CCP domains of CFH and CFHR1-CFHR5 using available mAbs and pAbs. 
Coomassie blue stain was used to determine protein loading.   
 
Studies of CFHRs have been hampered by the lack of specific reagents. Antibodies raised against 
either CFH or the CFHRs often cross-react with other family members due to their high amino acid 
and structural identity (Figure 4.1) [Skerka, C. 2013]. This is highlighted by the finding that auto-
antibodies against CFH also recognise CFHRs [Kopp, A.2012. Blanc, C. 2012]. Cross-reactivity has 
limited purification of individual CFHRs from serum and measurements of their levels in circulation. 
Estimated levels of CFHRs in plasma have been reported to be equimolar to CFH (116-562 ug/ml, 
0.7-3.6 uM); CFHR1 levels have been estimated to range between 70-100 ug/ml (1.6-2.4 uM) 
[Esparza-Gordillo, J. 2004. Heinen, S. 2009]. However, CFHR1 can form homo- and heterodimers with 
CFHR2 and CFHR5 which may affect protein estimations. Dimerisation and sequence similarity may 
have led to overestimation of CFHR concentrations [Goicoechea de Jorge, E. 2013]. Recent data using 
two cross reactive antibodies indicates that CFHR3 is approximately 132-fold lower than CFH levels, 
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ranging between 0-2.7 μg/ml (0-0.05 μM) whereas previously the circulating plasma concentration 
was estimated to range between 50-80 ug/ml (1-1.6 μM) [Pouw, R. 2016. Fritsche, L. G. 2010].  
Several strategies can be used to generate specific reagents that distinguish between CFHRs and 
CFH. The first is to generate polyclonal antibodies (pAbs); serum from immunised animals contains 
a heterogeneous mixture of antibodies that recognise multiple epitopes on the target molecule. The 
heterogeneity of epitopes recognised by pAbs offers an increased chance of recognising the native 
protein even following post-translational modification. The disadvantage of pAbs is cross-reactivity 
with related proteins. In contrast, the generation of mAbs provides an unlimited supply of a clonal 
antibody often with reproducible specificity for a single antigen, which is ideal for identifying CFHRs.  
The generation of an effective immune response is essential for producing mAbs. Therefore antigens 
must be capable of stimulating both T and B cell responses [MacLennan, I. C. 1997]. Poor immune 
responses are often observed when immunising with proteins that are closely related to those found 
in mice, therefore the immunising protein or peptide needs careful consideration [Stollar, B. D. 1970. 
Stollar, B. D. 1978]. Human CFH and murine CFH (mCFH) share approximately 63% amino acid 
identity, while mice also have five predicted CFHR proteins, CFHRa-CFHRe [Vik, D. P. 1988. Vik, D. P. 
1990. Hellwage, J. 2006]. CFHRb and CFHRc are homologues of CFHR1 and/or CFHR2 and CFHR5 
respectively, based on the organisation of CCP domains, whereas CFHRa and CFHRd are predicted to 
be pseudogenes [Hellwage, J. 2006]. There is evidence that CFHRe is transcribed but no protein has 
been detected [Vik, D. P. 1990]. The amino acid sequence identity of CCP domains between CFHRb 
and CFHR1/ CFHR2 (34-72%), and CFHRc and CFHR5 (36-63%) are sufficiently different to enable the 
generation of specific antibodies [Hellwage, J. 2006].  
The main aim of this chapter was to generate specific mAbs against human CFHRs to allow further 
understanding of the role of CFHRs and to estimate circulating CFHR levels, detect their tissue 
localisation, and determine the effect of polymorphisms and copy number variation (CNV) on 
disease. Furthermore, mAbs could be used to purify CFHRs from complex mixtures such as sera.  
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4.2 Results 
mAbs generated in this study were analysed for their specificity against recombinant CFH and CFHRs 
and were further characterised to determine recognition of proteins in NHS. The mAb production 
and screening strategy is shown in Figure 4.2. 
 
Figure 4.2: Schematic representation of mAb generation and identification 
Approximate time frames for the completion of each phase is indicated, with mAb development taking approximately 28-
42 weeks. 
4.2.1 Generation of anti-human CFHR antibodies 
Currently available antibodies against CFH and CFHRs have been shown to cross-react with other 
family members due to their high amino acid and structural identity hampering the further study of 
CFHR function (Figure 4.1). Therefore, the initial aim of this thesis was to generate a panel of mAb 
reagents which specifically recognise CFHRs.  The two C-terminal CCP domains of CFHR2-CFHR5 were 
chosen as antigens for the generation of mAbs due to their lower sequence similarity with the related 
CCP domains in CFH and CFHRs (Figure 1.4). Peptides were also designed to surface epitopes of 
CFHR4(3) and CFHR5(6) as an alternative strategy:  CCP domain 3 of CFHR4 is homologous to CCP 
domain 9 of CFH (amino acid identity of 57%) with no homologous domains in other CFHRs, whereas 
CFHR1-CFHR4 do not have a homologous CCP domain to domain 6 of CFHR5 which has 47% 
sequence identity with CCP domain 13 of CFH (Figure 4.3). The following peptides were used for 
immunisation; ENSRAKSNGM for CFHR4 and IAGVNIKTLLKLSG for CFHR5. Of note, the chosen 
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peptide sequences have no similarity to murine sequences using BLAST searches against the mouse 
genome. The protein and peptide antigens used here were conjugated to the carrier molecule, KLH, 
to enhance immune responses. The immunogenicity of the antigens was also enhanced by the 
addition of adjuvant (TitreMax Gold ™), which slowly releases the antigen at the site of immunisation 
(subcutaneous) and induces a strong inflammatory response during the primary immunisations 
[Bennett, B. 1992]. 
 
 
Figure 4.3: Peptides used to generated mAbs against CFHR4 and CFHR5 are surface localised 
Structural prediction of (A) CFHR4(3) and (B) CFHR5(6) (space filled models) with CCP domain 9 and 13 of CFH, respectively, 
used as a threading template (grey, ribbon model). The peptides used to generate mAbs are shown in blue. Models 
generated using the I-TASSER server and figure drawn using Pymol 
 
For each antigen (Table 3.2), two female BALB/c were immunised according to the schedule shown 
in Figure 4.4a, then plasma cells were isolated from each mouse. Cells were either directly fused with 
the mouse myeloma cell line, NS0, according to the protocol summarised in figure 4.4b, or stored in 
liquid nitrogen prior to fusion. A single fusion was performed to generate antibodies specific for 
CFHR2 and CFHR3. Few specific antibodies were generated in initial fusions following immunisation 
with CFHR4 and CFHR5 peptides. Therefore, cell fusions were also performed from mice immunised 
with recombinant C-terminal CCP domains of CFHR4 and CFHR5. The second fusion for CFHR4 
yielded no specific antibodies, whereas the second fusion for CFHR5 resulted in specific mAbs. The 
results of screening are summarised in Table 4.1. 
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Figure 4.4: Schematic showing the generation of mAbs 
(A) BALB/c mice were immunised with antigen conjugated to KLH subcutaneously in TitreMax® gold, then twice 
intraperitoneally followed by a booster immunisation three days prior to cell fusion. (B) Splenic plasma cells were isolated 
and fused with mouse myeloma cells and resulting hybridomas were selected from unfused plasma cells and mouse 
myeloma cells with HAT prior to screening for mAb specificity.
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Table 4.1: Summary of the selection of mouse anti-human CFHR mAbs in each phase of production 
* Not all positive clones from Phase III-a were analysed for their specificity although all were stored.  
** For CFHR5(8,9), six clones identified in Phase III-a were tested for specificity in Phase III-b and –c. Recombinant C-terminal CCP domains of all CFHRs and CFH showed some protein degradation. Therefore 
only clones that potentially recognised CFHR5 in NHS were screened again in Phase III-b. 
† CFHR2-63a was not successfully cloned by limiting dilution after two attempts under different conditions.  
†† CFHR5-80b was identified as having an IgMκ isotype was not pursued further due to instability and inconsistent results.
    Phase II-a Phase II-b Phase III-a Phase III-b Phase III-C Phase IV Phase V 
Spleen 
number 
Fusion 
antigen 
Initial well 
screening 
Initial colony 
screening 
Specificity 
screening by 
ELISA 
Specificity 
screening by 
Western blotting 
Specificity 
screening by 
Western blotting of 
NHS 
Cloning by limiting dilution Antibody purification 
1 CFHR2(3,4) 43/192 46/219 30/46 2/30* 2/2 CFHR2-63a†, CFHR2-157b Pre-Phase V 
                  
1 CFHR3(4,5) 51/192 41/153 17/98 2/17* 1/2 CFHR3-144a 
CFHR3-144a-H7 (HSL-
1) 
                  
1 CFHR4 10/192 5/21 - - 0/5 - - 
2 CFHR4 23/192 2/53 - - 1/2 CFHR4-33, CFHR4-55a Pre-Phase V 
1 CFHR4(4,5) 42/192 10/81 5/10 0/5 - - - 
                  
1 CFHR5 14/192 5/66 1/5 - 0/1 CFHR5-80b†† - 
2 CFHR5 15/192 5/29 - - 0/5 - - 
1 CFHR5(8,9) 24/192 9/39 3/9 0/3 - - - 
2 CFHR5(8,9) 61/192 64/292 50/64 2/2* 4/6** CFHR5-68a, CFHR5-86a Pre-Phase V 
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4.2.2 Phase II screening: Cell fusion and screening of mAbs against the immunising antigen 
Hybridomas were initially selected by examining the ability of cell culture supernatant, to detect the 
immunising antigen by ELISA (Phase II-a). Initial Phase II-a screening identified: 43 CFHR2; 51 CFHR3; 
75 CFHR4; and 114 CFHR5 positive wells from 1, 1, 3 and 4 cell fusions, respectively. Individual 
colonies of hybridoma cells were picked from positive wells and placed into separate wells containing 
hybridoma competent media. Supernatants from wells containing individual colonies were again 
screened by ELISA against the immunising antigen once cells became confluent (Phase II-b).  From 
the Phase II screening: 46/219 CFHR2 clones, 41/153 CFHR3 clones, 17/155 CFHR4 clones and 
83/426 CFHR5 clones were taken forward into Phase III screening to determine mAb specificity. 
4.2.3 Phase III screening: Determining the specificity of mAbs against CFH and CFHRs 
Due to the high sequence identity between CFH and the CFHRs, and the demonstrated cross 
reactivity of avaliable polyclonal antibodies and mAbs (Figure 4.1), additional screening by both ELISA 
and western blotting was used to determine the specificity of mAbs produced by each clone [Skerka, 
C. 2013]. Initially, culture supernatants from all Phase II-b positive hybridoma clones were screened 
by ELISA against the C-terminal CCP domains of CFH and CFHR1-CFHR5, when the immunising 
antigen was composed of C-terminal CCP domains. Screening of anti-peptide mAbs against CFHR4 
was performed by western blotting against NHS as no full length recombinant CFHR4 was available 
for screening (Phase III-c screening), while anti-peptide CFHR5 mAbs were analysed for recognition 
of full length recombinant CFHR5 (provided by Matthew Pickering). Plates were coated with 5 μg/ml 
of either recombinant protein or peptide, and blocked with 3% skimmed milk with 0.05% Tween 20 
prior to screening with hybridoma supernatants. From the Phase III-a screening: 30/46 CFHR2 clones, 
17/41 CFHR3 clones, 5/10 CFHR4 clones (raised against CFHR4(4,5)), 1/5 CFHR5 clone (anti-peptide) 
and 53/73 CFHR5 clones (raised against CFHR5(8,9)) were specific for the immunising antigen by ELISA. 
Representative examples of the specificity of mAbs raised against CFHR2-CFHR5 are shown in Figure 
4.5. CFHR32 (i.e. clone 2 generated against CFHR3) cross-reacted with CFHR4 (Figure 4.5f) while 
CFHR3168 cross-reacted with CFH and all CFHRs (Figure 4.5g). Cross-reactive mAbs were further 
characterised as they can be valuable for certain applications. 
69 
 
Figure 4.5: Specificity of mAbs during Phase III-a screening 
ELISA plates were coated with the two C-terminal CCP domains of CFH and CFHR1-CFHR5 or peptides (ENSRAKSNGM for 
CFHR4 and IAGVNIKTLLKLSG for CFHR5) at a concentration of 5 μg/ml. Results of ELISA analysis of hybridoma clones (A) 
CFHR2157b, (B) CFHR3144a and (C) CFHR568b which specifically recognise the immunising antigen. Anti-peptide mAbs (D) 
CFHR455a, and (E) CFHR580b recognise the peptide used for immunisation. Hybridoma clones (F) CFHR32 and (G) CFHR3168 
cross-react with CFHR4, and CFH/CFHR1-CFHR5, respectively. Error bars are SEM of two independent experiments. 
 
To confirm the specificity of the hybridomas, mAbs were also assessed for their ability to recognise 
recombinant C-terminal CCP domains of CFH and CFHRs by western blotting when generated by 
immunising with their two C-terminal CCP domains (i.e. CFHR2-CFHR5, Figure 4.6, Phase III-b). 
Proteins were diluted to a final concentration of 10 μg/ml in 2x sample buffer and resolved on 16% 
polyacrylamide gels, prior to transferring proteins to PVDF membranes by semi-dry transfer. Proteins 
were detected with mAbs in hybridoma culture supernatants diluted 1:2 with 1% skimmed milk/ PBS. 
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From the Phase III-b screening; 2 of 4 CFHR2 clones (CFHR263a and CFHR2157b), 2 of 17 CFHR3 clones 
(CFHR3144a and CFHR3184c), and both CFHR5 clones (CFHR568a and CFHR586a) specifically detected the 
C-terminal CCP domains of CFHR2, CFHR3 and CFHR5 respectively (Figure 4.6). In western blot Phase 
III-b analysis, CFHR32 cross-reacted with CFHR4, and CFHR3168 recognised CFH and CFHR1-CFHR5 
(Figure 4.6). Not all positive clones identified in Phase II-b were screened for their specificity. Once 
hybridomas producing CFHR-specific mAbs were identified, no further hybridomas were analysed 
for that CFHR. 
 
Figure 4.6: Specificity of novel mAbs during Phase III-b screening 
Western blot analysis showing the recognition of recombinant two C-terminal CCP domains of CFH and CFHR1-CFHR5 by 
mAbs from generated hybridoma clones. CFHR263a, CFHR2157b, CFHR3144a, CFHR3184c, CFHR568b and CFHR586a specifically 
recognise the immunising antigen whereas, CFHR32 and CFHR3168 cross-reacts with CFHR4, and CFH/ CFHR1-CFHR5, 
respectively. 
 
Hybridoma clones were also analysed by western blotting for recognition of CFHRs in NHS (Figure 
4.7, Phase III-c). Previous analysis of CFHRs in serum with non-specific antibodies indicated that 
CFHRs are often detected as multiple bands by western blot analysis, consistent with post-
translational modification of CFHRs [Skerka, C. 2013]. Samples of NHS were examined by western 
blot analyses using the mouse anti-human CFH mAb, OX24. Results confirmed that this mAb 
recognises both CFH (approximately 155kDa) and CFHL, an alternative splice variant of CFH (of 
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approximately 37kDa) (Figure 4.7a) [Sim, E. 1983. Ripoche, J. 1988]. Epitope mapping has 
demonstrated that CFHOX24 recognises CCP domain 5 of CFH [Sim, E. 1983]. Therefore it is unlikely 
that CFHOX24 will cross-react with CFHR1-CFHR5, as the related proteins do not have CCP domains 
related to CCP domain 5 of CFH.  
CFHR2157b recognised two bands in NHS by western blotting consistent to the molecular weight of 
two glycosylation forms of CFHR2 previously detected; a single glycosylation form of approximately 
24kDa, CHFR2, and a double glycosylation form of approximately 29kDa, CHFR2α that have been 
described (Figure 4.7b) [Skerka, C. 1992]. A similar staining pattern was observed for CFHR263a (data 
not shown). Four glycosylation variants of CFHR3 have been previously described, CFHR3, CFHR3α, 
CFHR3β and CFHR3γ [Skerka, C. 1993]. CFHR3144a recognised three bands between the molecular 
weights of 35-46kDa in NHS consistent with the glycosylation forms CFHR3α, CFHR3β and CFHR3 
(Figure 4.7c). Of note, no protein band was detected with CFHR3144a using sera from an individual 
with a homozygous CFHR3/CFHR1 deletion, indicating that this hybridoma produces a mAb which is 
specific for CFHR3.  
Two isoforms of CFHR4 have previously been described; the long isoform (CFHR4A) has nine CCP 
domains resulting from an internal duplication of CCP domains 1-3 (CCP domains 5-7 of CFHR4A), 
whereas the alternative splice variant, CFHR4B, has five CCP domains [Józsi, M. 2005]. Bands 
consistent with both isoforms of CFHR4 were detected in NHS using CFHR455a at approximately 86 
and 42kDa for CFHR4A and CFHR4B, respectively (Figure 4.7d). A third band of unknown identity was 
also detected at 240kDa (Figure 4.7d). Two potential glycosylation forms of CFHR5, CFHR5 (62kDa) 
and CFHR5α (55kDa) were detected with CFHR568a (Figure 4.7e) with limited cross-reactivity of other 
proteins in NHS with the exception of bands at 200 and 240kDa [Murphy, B. 2002. Goicoechea de 
Jorge, E. 2013]. 
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Figure 4.7: Recognition of CFH and CFHR2-CFHR5 in NHS 
(A) CFHOX24 specially recognises CFH and CFHL, (B) while two potential glycosylation forms of CFHR2 were recognised by anti-CFHR2157b, (C) and three of the four potential glycosylation forms of CFHR3 are 
recognised by anti-CFHR3144a. (D) Anti-peptide mAb CFHR455a detected two bands corresponding to the molecular weight of CFHR4A and CFHR4B but also a third band of approximately 240kDa. A similar sized 
band was also detected by (E) CFHR568a which also detects two potential glycosylation forms of CFHR5.
73 
4.2.4 Phase IV: Screening of anti-human CFHR mAbs cloned by limiting dilution 
Specific hybridoma mAb clones for each antigen identified in Phase III screening was further 
characterised in Phase IV analysis. Therefore, hybridomas producing specific mAbs were cloned by 
limiting dilution to ensure that the mAbs were derived from a single hybridoma rather than a mixed 
population. Hybridoma cell cultures were diluted to 5 cells/ml and plated at a concentration of 
approximately 1 cell per well in 96-well tissue culture plates. Plates were then screened by light 
microscopy for the growth of single colonies; wells containing multiple colonies were discarded. 
Single colonies were expanded into 24-well plates containing hybridoma competent media prior to 
reanalysing antibody specificity by ELISA. Two colonies for each hybridoma were then expanded in 
T-25 flasks, and the cell lines stored. A summary table of hybridomas that were successfully cloned 
by limiting dilution is shown in Table 4.2. 
An anti-peptide mAb CFHR580b showed weak reactivity against full length recombinant CFHR5 by 
ELISA (Figure 4.5e); however this mAb did not recognise any proteins in NHS by western blot analysis. 
Serum concentrations of CFHR5 have been estimated to range between 0.05-0.09 μM, Therefore 
CFHR5 could be below the detection limit of the assay [McRae, J.L. 2005; Goicoechea de Jorge, E. 
2013]. CFHR580b was successfully cloned by limiting dilution and found to have an IgMκ isotype; mAb 
isotype was determined using a mouse isotyping kit (AbD Serotec, UK). Therefore, further anti-CFHR5 
mAbs were generated against CFHR5 using CFHR5(8,9) as the antigen; this yielded the specific mAbs, 
CFHR568a and CFHR586a, which recognise CFHR5 by ELISA and western blot analysis of NHS (Figures, 
4.5c, 4.6 and 4.7e), indicating the CFHR5 is not below the limit of detection. Both, CFHR568a and 
CFHR586a were successfully cloned by limiting dilution using 1% condimed in the cloning media. 
In summary, novel mouse monoclonals, CFHR2157b, CFHR3144a, CFHR455a and CFHR568a, which are 
specific for CFHR2-CFHR5 respectively, were generated and characterised in this study (summarised 
in Table 4.1). All four mAbs recognise the corresponding CFHR by ELISA (Figure 4.5) and western 
blotting (Figure 4.6), and potentially recognise different glycosylation forms in NHS (Figure 4.7). 
CFHR2157b, CFHR3144a and CFHR568a have an IgG1κ isotype whereas CFHR455a has an IgMκ isotype as 
determined using the mouse isotyping kit (AbD Serotec, UK). Two cross-reactive IgG1κ antibodies 
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with known specificity i.e. CFHR32-H5 and CFHR3168-B5 were also cloned by limiting dilution. These two 
mAbs were isolated as controls and for purifying CFH and CFHR1-CFHR5 from NHS. 
Phase IV mAbs 
Spleen 
number 
Fusion 
antigen 
Hybridoma 
clone number 
Specificity Isotype Applications tested 
1 CFHR2(3,4) 157b-F7 CFHR2 IgG1κ ELISA, WB 
1 CFHR2(3,4) 157b-H12 CFHR2 IgG1κ ELISA, WB 
1 CFHR3(4,5) 144a-H7 CFHR3 IgG1κ ELISA, WB, Flow cyt 
1 CFHR3(4,5) 144a-C5 CFHR3 IgG1κ ELISA, WB 
1 CFHR3(4,5) 2-H5 CFHR3 and CFHR4 IgG1κ ELISA, WB 
1 CFHR3(4,5) 2-G8 CFHR3 and CFHR4 IgG1κ ELISA, WB 
1 CFHR3(4,5) 168-B6 All CFHRs and CFH IgG1κ ELISA, WB 
1 CFHR3(4,5) 168-F6 All CFHRs and CFH IgG1κ ELISA, WB 
2 CFHR4 33-C6 - IgG2aκ ELISA 
2 CFHR4 33-G8 - IgG2aκ ELISA 
2 CFHR4 55a-H6 CFHR4 IgMκ ELISA, WB 
2 CFHR4 55a-H9 CFHR4 IgMκ ELISA, WB 
2 CFHR5(8,9) 68a-E4 CFHR5 IgG1κ ELISA, WB 
2 CFHR5(8,9) 68a-G8 CFHR5 IgG1κ ELISA, WB 
2 CFHR5(8,9) 86a-D3 CFHR5 IgG1κ ELISA, WB 
2 CFHR5(8,9) 86a-F8 CFHR5 IgG1κ ELISA, WB 
1 CFHR5 80b - IgMκ ELISA 
1 CFHR5 80b - IgMκ ELISA 
 
Table 4.2: Summary of characterised mouse anti-human CFHR mAbs cloned by limiting dilution 
All mAbs that were analysed through to Phase IV were examined by ELISA and western blotting to determine their 
specificity. mAbs cloned by limiting dilution were further characterised by confirmation of mouse isotype. CFHR433a and 
CFHR580b (grey) do not recognise any serum proteins. CFHR3144aH7 (blue) has been published under clone name HSL-1 
[Caesar, J. J. 2014], and recognises CFHR3 by flow cytometry.  
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4.2.5 Production and purification of HSL-1 (Phase V) 
GWAS identified SNPs in both CFH and CFHR3 that are associated with susceptibility to 
meningococcal disease [Davila, S. 2010]. CFH is the major fluid phase negative regulator of the AP 
whereas the function of CFHR3 has not been defined due to the lack of reagents [Weiler, J. M. 1976. 
Whaley, K. 1976. Pangburn, M. K. 1977. Skerka, C. 2013]. The novel anti-CFHR3 mAb, CFHR3144a-H7 
(designated HSL-1) with specificity for CFHR3 was analysed further, due to the association of CFHR3 
with meningococcal disease.  
Initially, the genes encoding the variable heavy chain (VH) and variable light chain (VL) of HSL-1 were 
amplified by V-region PCR and sequenced using conventional Sanger sequencing; data were analysed 
using DNASTAR Lasergene software (performed by Absolute Antibodies ltd.). The sequence of VH and 
VL is shown in Figure 4.8a and is consistent with functional VH and VL chains. Sequencing also 
confirmed the isotype of this mAb (IgG1κ). Furthermore, the Fab fragment of HSL-1 was generated 
by Absolute Antibodies, by transient transfection of HEK293 cells and purification of the mAb by 
nickel chromatography.  
The activity and specificity of the recombinant FAb fragment of HSL-1 was compared with the mAb 
from culture supernatants. ELISA plates were coated with 1 μg/ml of CFH(19,20), CFHR3(4,5), CFHR4(4,5) 
or BSA then incubated with two-fold dilutions of whole mAb or the Fab fragment (Figure 4.8b-c) from 
10 μg/ml. Both the mAb and FAb fragment of HSL-1 specifically recognised CFHR3(4,5) by ELISA (Figure 
4.8b-c). Detection of CFHR3(4,5) by HSL-1 FAb fragment was significantly reduced, compared to the 
mAb, (OD450 0.72 and 0.95 respectively, at 5 µg/ml). Potential explanations include differences in 
detection of mouse IgG by the secondary antibody, as the pAb secondary potentially has a higher 
avidity for full length IgG due to more binding epitopes, or lower affinity of the Fab fragment for the 
antigen. This has not been confirmed using secondary antibodies raised against mouse Fab 
fragments.  
For further downstream applications, HSL-1 was purified from large volumes (2-4 litres) of cell culture 
supernatant. Cells expressing HSL-1 were adapted for purification by sequential dilution into 
hybridoma recovery media prior to transferring hybridomas into RPMI-1640 with L-glutamine 
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supplemented with either FreeAdd (serum substitute) or 10% ultra-low bovine FBS.  Antibodies were 
purified using Pierce™ Protein G Agarose resin, and size exclusion chromatography. 
 
Figure 4.8: Recombinant Fab fragment of HSL-1 retains specificity for CFHR3 
Sequence of the variable heavy (VH) and variable light (VL) domains of HSL-1 (A); sequencing was performed by Absolute 
Antibody. ELISA analysis of HSL-1 whole IgG from tissue culture supernatant (B) or the purified Fab fragment of (C) against 
recombinant C-terminal CCP domains of CFH (black), CFHR3 (green) and CFHR4 (blue); BSA (red) was used as a negative 
control. ELISA plates were coated with proteins at a concentration of 1μg/ml. Error bars are SEM of three independent 
experiments. 
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4.3 Discussion 
This chapter describes the generation of a panel of mAbs against human CFHR2-CFHR5, which 
specifically recognise each of the closely related proteins. To validate antibodies produced here, the 
reactivity against both the immunising protein (CFHR2-CFHR5) and serum proteins was determined. 
Initially, high throughput screening of hybridomas was performed by ELISA and identified 46 CFHR2, 
41 CFHR3, 17 CFHR4 and 83 CFHR5 positive clones. However, many antibodies that recognise the 
immunising antigen have limited reactivity against the endogenous protein, or, in the case of closely 
related proteins, recognise more than one member of a protein family [Pulford, K. 2006]. Cross-
reactivity can often be predicted due to high sequence identity, as for the CFHRs, but antibodies can 
also recognise cross-reactive epitopes or structural conformations of proteins which are difficult to 
predict from the amino acid sequence [Pulford, K. 2006. Martins S. 2007]. Therefore all positive 
hybridomas were also tested for their ability to bind against recombinant C-terminal CCP domains of 
CFH and CFHR1-CFHR5 by ELISA and western blot analysis, whereas CFHR5 anti-peptide mAbs were 
screened with full length CFHR5 and CFH by ELISA. Screening of mAbs identified two CFHR2, two 
CFHR3, no CFHR4 and four CFHR5 clones that specifically recognised the respective CFHR. 
The specific recognition of the C terminal CCP domains from the corresponding CFHR does not 
guarantee that mAbs only bind the protein of interest. Therefore subsequent validation was 
performed using NHS, as the mAbs generated in this study will be used to determine levels of CFH 
and CFHRs in serum. Western blotting analysis was performed to demonstrate the molecular weight 
of proteins detected, to identify cross reaction with other proteins, and determine if mAbs can 
recognise known post-translational modifications e.g. glycosylation of CFHRs [Skerka, C. 1992. 
Skerka, C. 1993. Józsi, M. 2005. Murphy, B. 2002. Goicoechea de Jorge, E. 2013. Skerka, C. 2013].  
CFHR2157b detected two bands in NHS consistent with the described glycosylation forms of CFHR2; 
with the glycosylation site at Asn126 residing in CCP domain 2 [Skerka, C. 1992. Chen, R. 2009]. While 
CFHR3144a potentially detects 3 of 4 known glycosylation forms of CFHR3 [Skerka, C. 1993. Chen, R. 
2009]. The known glycosylation sites for CFHR3 are at positions Asn108, -205, -309, with another predicted 
glycosylation site at Asn185; three of these sites are within CCP domains 2-3, while Asn309 is within 
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CCP domain 5 [Chen, R. 2009]. As CFHR3144a may only detect three of the described glycosylation 
forms of CFHR3, the mAb binding site may overlap with the Asn309 glycosylation site. Alternatively, 
the Asn185 glycosylation site may not be modified in sera under these conditions. Furthermore, CCP 
domain 5 of CFHR3 and CFHR4 have a lower amino acid identity (93%) compared to CCP domain 4 
of CFHR3 and CFHR4 (98%). Therefore the CFHR3144a binding epitope might reside within CCP domain 
5 of CFHR3 [Skerka, C. 1993. Chen, R. 2009. Skerka, C. 2013].  
CFHR568a detected a second band by western blot analysis consistent with a predicted post 
translational modifications of CFHR5 at Asn126, -400 which reside in CCP domains 2 and 7 respectively 
[Murphy, B. 2002. Goicoechea de Jorge, E. 2013]. CFHR455a detected two predicted isoforms of 
CFHR4 as determined by the molecular weight of proteins identified in western blotting of NHS [Józsi, 
M. 2005].  
The mAbs generated in this study will be used in the development of assays, both sandwich ELISA 
and Bio-Plex, to estimate the relative circulating concentrations of CFHRs in serum in the future. 
Therefore the mAb binding site will need to be characterised by epitope mapping [Engvall, E. 1971; 
Houser, B. 2012]. Determining the mAb epitope on CFHRs will elucidate the mechanism of binding 
and predict the effect of glycosylation on protein recognition and therefore on protein concentration 
estimation in NHS. The effect of glycosylation on mAb recognition could also be assessed by the 
removal of N-linked glycans by glycosidases to determine if protein estimations and detection remain 
the same.   
Antibodies raised by immunisation with peptides generally have high specificity for the immunising 
antigen. However, synthesised peptides are generally not post-translationally modified and may not 
adopt their native conformations. Therefore the mAbs elicited by peptides may fail to recognise 
endogenous proteins [Forsström, B. 2015]. This may explain why peptides of CFHR4 and CFHR5 
yielded few positive hybridomas (13 in total), of which only one (CFHR455a) recognised endogenous 
CFHR4. The number of initial positive wells found for fusions after the immunisation with CFHR4 or 
CFHR5 peptides was lower than the number of positive wells generated with recombinant proteins 
(Table 4.1). Additionally, a significant number of Ig secreting hybridomas displayed no specificity for 
 79 
the peptide or protein (Table 4.1), and two anti-peptide mAb clones, CFHR455a and CFHR580b, have 
an IgM isotype. IgM antibodies are secreted by B2-lymphocytes and are part of the initial humoral 
response to exogenous antigens [Henry, C. 1968. Baumgarth, N. 1999]. After antigen stimulation, 
B2-lymphocytes undergo clonal expansion, and in the presence of T-helper cells in splenic germinal 
centres, are subject to an isotype switch to IgG and the production of memory B cells [Bretscher, P. 
1970. Lopes-Carvalho, T. 2004. Carsetti, R. 2004]. IgM occurs predominately as cyclic pentamers 
(960kDa) or hexamers (1150kDa) and are more susceptible to degradation than IgGs [Randall, T. D. 
1990]. These properties make IgM antibodies more challenging to purify and unstable [García-
González, M. 1988. Middaugh, C. R. 1977]. IgM antibodies generated in response to an antigenic 
stimulus are generally monospecific but have lower affinities (10-7-10-9 mol-1 s-1) for antigens 
compared to IgG; in vivo this lower affinity is compensated by higher avidity [Baumgarth, N. 1999]. 
For these reasons and the lack of recognition of CFHR5 in NHS, it was decided to not characterise 
the IgM CFHR580b further. Analysis of CFHR455a showed specificity for CFHR4A and CFHR4B in NHS; 
therefore CFHR455a will be further characterised to establish its specificity. If appropriate, the IgM 
heavy chain could be engineered to express an IgG heavy chain. Additionally, the CFHR4 peptide, 
ENSRAKSNGM, can be used to help determine mAb specificity by absorbance assays. Of note, 
subsequent CFHR5 fusions, obtained after immunisation with recombinant protein, successfully 
generated CFHR5 specific IgG mAbs, CFHR568a and CFHR586a. 
CFHR455a recognises bands corresponding to the predicted molecular weights of both previously 
described isoforms of CFHR4 (CFHR4A and CFHR4B) while CFHR568a recognises bands corresponding 
to two predicted glycosylation forms of CFHR5 [Skerka, C. 1997. Józsi, M. 2005. Murphy, B. 2002]. 
However, mAbs CFHR455a and CFHR568b also recognise a non-specific band at approximately <250kDa 
and 200kDa respectively. Serum is a complex mixture consisting of an estimated 325-490 distinct 
circulating proteins with albumin, transferrin, haptoglobulin, and immunoglobulins being some of 
the most abundant [Pieper, R. 2003. Tirumalai, R. S. 2003]. It is therefore possible that proteins 
aggregate during SDS-PAGE if not fully denatured [Marshall, T. 1984]. Samples were boiled at 100oC 
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for 10 minutes in sample buffer prior to loading. Reducing the denaturation temperature may reduce 
aggregate formation.  
Specificity screening of CFHR2157b, CFHR455a and CFHR568a by western blot analysis of NHS (Figures 
4.7b, d and e) was performed prior to mAbs being cloned by limiting dilution; therefore screening 
should be repeated with tissue culture supernatants from cloned hybridomas, or preferably purified 
mAbs to reduce potential background recognition of serum proteins from other antibodies. Initial 
western blots of NHS using CFHR3 had higher background staining with an additional band, not 
corresponding to the predicted molecular weight of the different glycosylation forms of CFHR3, 
detected at approximately 230kDa. After cloning the mAbs by limiting dilution subsequent western 
blots of NHS had reduced non-specific binding therefore cross-recognition of serum proteins by 
other antibodies in FCS or antibodies in the supernatant would be the most likely explanation for 
recognition of non-specific bands. It was not possible to clone CFHR263a by limiting dilution. During 
clonal expansion, hybridomas are diluted to the single cell level and media is supplemented with BM 
Condimed H1; this hybridoma cloning supplement contains a mixture of growth factors and 
cytokines from Phorbol 12-myristate 13-acetate (PMA) stimulated mouse lymphoma cell lines 
[Rathjen, D. A. 1986]. Although clones were identified following dilution on two occasions, none of 
the clones generated supernatants that recognise the immunising antigen by ELISA. This indicates 
that CFHR263a was not a clonal hybridoma. It is possible that CFHR2-negative hybridoma(s) 
outcompeted any positive CFHR263a clones during growth. However, testing of further CFHR2 
hybridomas identified CFHR2157b which specifically recognises CFHR2 and was successfully cloned by 
limiting dilution. 
Recognition of the recombinant CFHRs and the presence of multiple bands of the molecular weight 
corresponding to different post-translational modifications or splice variants of CFH and CFHR1-
CFHR5 are initial steps in validating CFHR mAbs. However, the specificity of mAbs has not been 
demonstrated unequivocally or in other applications, such as flow cytometry and 
immunohistochemistry. The binding affinity of mAb for CFH and CFHR1-CFHR5 can be determined 
by surface plasmon resonance (SPR), and specificity could be further demonstrated by flow 
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cytometry by conjugating recombinant CFH and CFHR1-CFHR5 to labelled polystyrene beads to 
analyse mAb reactivity. Ideally, the specificity of mAbs could be demonstrated using sera from 
patients with defined deletions, e.g. ΔCFHR3/CFHR1 and ΔCFHR1/ CFHR4, although deletions of 
CFHR2 and CFHR5 have not been described [Skerka, C. 2013] 
Antibodies generated in this chapter will be used to study the biological function of the CFHRs and 
to determine the circulating concentrations of these proteins in NHS. For assay development and 
further downstream applications, mAbs need to be purified from tissue culture supernatants. Both 
mouse IgG and bovine IgG have high affinity for Protein G. Therefore contaminating bovine IgG needs 
to be removed from the tissue culture supernatants prior to mAb purification [Richman, D. D. 1982]. 
In the first instance HSL-1 was adapted to chemically defined, serum free tissue culture media. HSL-
1 hybridoma cells did not grow well in serum replacement media, and had reduced mAb production 
(from 15 mg/L to 3 mg/L). To increase the concentration of mAbs produced by this hybridoma, cells 
were transferred into high expression system Integra™ flasks (CELLine CL350, IBS Integra Biosciences, 
Switzerland). Integra™ CELLine flasks enable cells to reach high density for maximum mAb secretion 
[Trebak, M. 1999].  
Currently, there are no available antibodies which specifically recognise CFHR1, and none were 
generated during this study. This lack of reagents is most likely due to the high nucleotide identity of 
CCP domains 1-2 of CFHR1 with the N-terminal two domains of CFHR2 and CFHR5 (nucleotide 
sequence identity ranges from 85-100%, Figure 1.4). Furthermore the C terminal CCP domains 3-5 
of CFHR1 are 97-100% identical to CCP domains 18-20 of CFH (Figure 1.4). Analysis of the residues 
which are different between CFHR1 with CFHR2, CFHR5 and CFH are predicted to not be surface 
exposed, therefore antibodies would have to recognise a structural epitope or only be effective 
against the denatured protein. 
In summary the high degree of amino acid sequence identity between CFH and CFHR proteins has 
hampered the study of CFHR function. Cross reactivity of reagents has meant that purification of 
CFHRs from human serum and determining their physiological concentrations have been 
challenging. This study generated four, novel mAbs, CFHR2157b, CFHR3144a, CFHR455a and CFHR568a, 
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which are specific for CFHR2-CFHR5 respectively. These mAbs are likely to recognise multiple, 
glycosylation forms of the CFHRs, and can be utilised to study CFHR function in the general 
population as well as their role in human disease. 
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5. COMPETITION BETWEEN HOST MOLECULES INFLUENCES 
SUSCEPTIBILITY TO MENINGOCOCCAL DISEASE 
5.1 Introduction 
N. meningitidis is a major cause of bacterial meningitis and sepsis worldwide [Stephens, D. S. 2007]. 
The annual number of cases is estimated to be 1.2 million, with an overall incidence of 1-3 per 
100,000 of the population in Europe and North America [Rouphael, N. G. 2012. Yazdankhah, S. P. 
2004]. Invasive disease incidence rates can rise to 500-1,000 per 100,000 of the population during 
epidemics in sub-Saharan Africa [Yazdankhah, S. P. 2004. Maiden, M. C. 1998. Greenwood, B. M. 
1987]. However, for most individuals N. meningitidis is a commensal of the respiratory tract with 
carriage rates estimated to vary from 10 to 35% in the general population [Cartwright, K. A. 1987. 
Caugant, D. A. 1994. Stephens, D. S. 1999. Claus, H. 2005]. High rates of meningococcal carriage have 
been reported in closed or semi-closed populations, particularly among military recruits and 
university students where carriage rates can be higher than 70% [Caugant, D. A. 1992. Neal, K. R. 
2000. Caugant, D. A. 2009].  
The mechanisms underlying why some individuals develop invasive disease while others become 
asymptomatic carriers are incompletely understood. Individuals with rare, inherited deficiencies in 
components of the AP and TP have a markedly increased risk of developing invasive meningococcal 
disease, with complement deficiencies of C5 to C9 associated with a 7,000 to 10,000 fold increased 
risk compared to the general population [Figueroa, J. E. 1991. Ram, S. 2010]. The association of 
complement and invasive meningococcal disease is also highlighted in those receiving Eculizumab 
which inhibits C5 cleavage, and is associated with an elevated risk of developing meningococcal 
disease [Dmytrijuk, A. 2008. Kelly, R. J. 2011. Bouts, A. 2011]. Furthermore, a GWAS demonstrated 
that SNPs in CFH and the downstream gene, CFHR3 are associated with meningococcal disease 
[Davila, S. 2010. Biebl, A. 2015]. 
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CFH is the major fluid phase negative regulator of the AP recruited by N. meningitidis, inhibiting host 
complement activation and promoting survival in human blood [Weiler, J. M. 1976. Whaley, K. 1976. 
Pangburn, M. K. 1977. Madico, G. 2006. Schneider, M. C. 2006]. Almost all N. meningitidis isolates 
express the major CFH receptor, fHbp, which binds CFH at high affinity [Masignani, V. 2003. 
Lucidarme, J. 2011. Schneider, M. C. 2009]. fHbp is a variable protein, 
(http://pubmlst.org/neisseria/fHbp/), which can be divided into three variant groups that have >85% 
amino acid sequence identity within groups, but lower sequence identify between groups 
[Masignani, V.  2003. Brehony, C. 2009]. fHbps from all variant groups bind CFH at similar affinities 
with  KDs in the nanomolar range [Johnson, S. 2012. Caesar, J. J. 2014].  
While the role of CFH is well understood, the function of CFHR3 has yet to be elucidated [Madico, G. 
2006. Schneider, M. C. 2006].  The CFHRs are a group of proteins that are structurally similar to CFH 
but, unlike CFH, lack complement regulatory domains  (CCP 1-4) that mediate co-factor for FI and 
decay accelerating activity [Díaz-Guillén, M. A. 1999. Skerka, C. 2013]. Recent structural studies have 
identified a conserved dimerisation motif in CFHR1, CFHR2, and CFHR5 which are required for the 
formation of homo- and hetero-dimers, whereby dimerisation increases the avidity of CFHRs for C3b 
[Goicoechea de Jorge, E. 2013]. CFHR1, CFHR2 and CFHR5 can compete with CFH for tissue-bound 
complement fragments and act as antagonists to modulate complement activation [Goicoechea de 
Jorge, E. 2013. Tortajada, A. 2013].  
The aim of this chapter was to investigate the interaction between CFHR3 and N. meningitidis, and 
to characterise the biological consequences of this interaction to determine how CFHR3 might 
influence an individual’s likelihood of developing meningococcal disease.  
 
  
85 
 
5.2 Results 
5.2.1 CFHR3 binds N. meningitidis in an fHbp-dependent manner 
fHbp binds to CFH via CCP domains 6 and 7 (CFH(6, 7)) leading to high affinity interactions [Schneider, 
M. C. 2009]. CFH(6, 7)  binds to fHbp by mimicking GAG binding via charged chains at positions H337 
and R341 of CFH CCP domain 6; substitution of either of these amino acids with Ala leads to a ten-
fold reduction of CFH binding affinity to fHbp (KD 2.7 μM) [Prosser, B. E. 2007. Schneider, M. C. 2009]. 
The amino acid sequence analysis of the first two CCP domains of CFHR3 (CFHR3(1,2)), are 91% and 
87% identical to CFH(6, 7), respectively (Figure 1.4). Sequence alignments of CFHR3 CCP domain 1 and 
CFH domain 6 show that the residues important for fHbp interactions with CFH, R337 and H341, are 
conserved in CFHR3, suggesting that CFHR3 might bind fHbp. Therefore, binding of CFHR3 to N. 
meningitidis M1239 and M1239Δfhbp was analysed by flow cytometry using mAb HSL-1, which 
specifically recognises CFHR3 (Chapter 4). N. meningitidis M1239 expresses V3.28 fHbp [Masignani, 
V. 2003]. CFHR3 levels in serum are estimated to be between 50–80 µg/ml (1–1.6 µM); therefore 
NHS was initially used as a source of CFHR3 [Fritsche, L. G. 2010]. Following incubation with NHS, 
CFHR3 was detected on the surface of N. meningitidis M1239, but not M1239Δfhbp (p=0.005) (Figure 
5.1). Furthermore, no CFHR3 binding was detected following incubation of M1239 or M1239Δfhbp 
in sera from an individual homozygous for a combined deletion of CFHR3 and CFHR1 
(ΔCFHR3/CFHR1) (Figure 5.1). Taken together these results indicate that CFHR3 binds to the surface 
of N. meningitidis in an fHbp-dependent manner. 
5.2.2 Development of an assay to investigate the effect of CFHR3 on bacterial survival 
Having demonstrated that CFHR3 binds to fHbp on the surface of N. meningitidis, the next step was 
to determine the functional consequences of CFHR3 binding by examining the effect of surface 
bound CFHR3 on complement-mediated lysis. Previously, CFHR1 was reported to prevent formation 
of the AP C5 convertase (C3bBbC3b) by inhibiting binding of C3b to the AP C3 convertase (C3bBb) 
[Heinen, S. 2009]. However, recent evidence demonstrates that CFHR1, CFHR2 and CFHR5 act as 
antagonists of CFH by competing with CFH for tissue-bound C3b, promoting complement activation 
[Goicoechea de Jorge, E. 2013]. Therefore to investigate the effect of CFHR3 on complement-
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mediated bacterial lysis, a serum assay was established so that after incubation in NHS approximately 
80% of N. meningtidis survived. With these conditions, any potential reduction in bacterial survival 
after addition of exogenous CFHR3 should be detectable. 
 
Figure 5.1: N. meningitidis binds CFHR3 on its surface in an fHbp-dependent manner 
Flow cytometry analysis of CFHR3 binding to (A, B) N. meningitidis M1239, and (C, D) M1239Δfhbp. Shaded area indicates 
results from bacteria incubated with PBS, solid black lines show bacteria incubated in NHS, and solid blue lines show 
bacteria incubated in CFHR3 deficient sera (ΔCFHR3/CFHR1). (B, D) Data presented as the mean fluorescence intensity in 
arbitrary units (AU). Error bars indicate ± SEM of three independent experiments and p-values were calculated using a two-
tailed unpaired t-test; ***, p < 0.001; **, p < 0.01; and ns >0.05. 
Initially, N. meningitidis M1239 was incubated in NHS (Figure 5.2 A) for increasing lengths of time (0-
60 minutes) over a range of serum concentrations (0-75%) to determine the effect on bacterial 
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survival. The number of viable bacteria were measured by plating onto solid media and counting the 
number of colony forming units (CFU). A reduction in N. meningitidis survival was observed with 
increasing length of incubation of bacteria in the presence of NHS up to 60 minutes (Figure 5.2 A). 
Of note, no difference in survival of bacteria was observed following incubation in heat-inactivated 
NHS (HI-NHS) (Figure 5.2 B). For all subsequent serum survival assays, bacteria were incubated in the 
presence of serum for 30 minutes, as beyond this time there were limited differences in bacterial 
survival. 
As approximately 20% of bacteria survived following incubation in 35% NHS over 30 minutes (Figure 
5.2 A), N. meningitidis M1239 and M1239Δfhbp were incubated in serum concentrations ranging 
from 0% to 35% (Figure 5.2 C). In the presence of higher serum concentrations, there was decreased 
N. meningitidis survival as observed in Figure 5.1 A, while M1239Δfhbp was more susceptible to 
complement-mediated lysis than M1239 as expected (Figure 5.2 C).  Approximately 80% bacterial 
survival was observed following 30 minute incubation in 5% NHS for N. meningitidis M1239; these 
conditions were used in subsequent experiments. 
To ascertain the effect of CFHR3, the survival of N. meningitidis M1239 and M1239Δfhbp was 
evaluated after pre-incubating bacteria in a range of CFHR3(1,2) concentrations (0.01 µM to 5 µM) for 
ten minutes prior to exposing bacteria to NHS. Binding of CFHR3 to the meningococcus is mediated 
by CFHR3(1,2) which are homologous to CFH(6,7) [Caesar, J. J. 2014]. Therefore the effect of CFHR3(1,2)  
on bacterial survival was analysed. Pre-incubation in increasing concentrations of CFHR3(1,2) 
enhanced the susceptibility of N. meningitidis M1239 to complement-mediated lysis relative to 
bacteria incubated with no protein (Figure 5.2 D). Of note, the response of N. meningitidis M1239 to 
complement-mediated lysis after pre-incubation with CFHR3(1,2) was biphasic, indicating that there 
are potentially two subpopulations of bacteria even though the original population was clonal. The 
first subpopulation is rapidly killed whereas a second population is more resistant to complement-
mediated lysis until higher CFHR3(1,2) concentrations enhance bacterial lysis. This phenomenon is 
typically observed in the emergence of ‘persistence’ after exposure to antibiotic treatment [Balaban, 
N. Q. 2004]. Moreover, pre-incubating M1239Δfhbp with CFHR3(1,2) had no effect on bacterial 
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survival (Figure 5.2 E) and CFHR3(1,2) did not affect the survival of M1239 or M1239Δfhbp in the 
absence of complement (Figure 5.2 D-E). Therefore the addition of CFHR3(1,2) reduces N. meningitidis 
resistance to complement in a dose-dependent and fHbp-dependent manner.  
 
Figure 5.2: Optimisation of serum assays 
Serum survival of N. meningitidis M1239 analysed after different incubation times (indicated) in (A) NHS or (B) HI-NHS over 
a range of serum concentrations (0-75%). Data are expressed as survival relative to the number of CFU without NHS in PBS 
at time point 0. (C) Survival of N. meningitidis M1239 (filled circles) and M1239Δfhbp (unfilled circles) after incubation with 
a range of NHS concentrations (0-35%) for 30 minutes, approximately 80% of bacteria survive following a 30 minute 
incubation in 5% NHS. Survival of N. meningitidis (D) M1239 and (E) M1239Δfhbp in the presence of 5% NHS (black circles 
and line) or PBS (blue circles and line) following pre-incubation in different concentrations of CFHR3(1, 2). Data are presented 
as percent survival relative to bacteria incubated without serum and CFHR3(1,2). Error bars are ±SEM of three independent 
experiments. 
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5.2.3 N. meningitidis susceptibility to complement mediated lysis is altered by the 
acquisition of CFHR3 
To further examine the biological consequences of N. meningitidis binding CFHR3, the effect of pre-
incubating N. meningitidis with full length or domains of CFHR3 was analysed in serum assays. 
Subsequent experiments were performed with an exogenous protein concentration of 1 µM, as this 
concentration of CFHR3(1,2) had a significant impact on N. meningitidis survival (p = 0.0118) compared 
with no CFHR3. Pre-incubation of full length CFHR3 or CFHR3(1,2) resulted in significantly reduced 
survival of N. meningitidis M1239 in serum (two tailed t-test p = < 0.0001 and p = 0.0161, 
respectively) (Figure 5.3 A); In contrast, CFHR3(3,4) had no effect on bacterial survival compared with 
no protein control (p = 0.8191). Furthermore, the addition of CFHR3 or domains of CFHR3 had no 
effect on bacterial survival in the presence of HI-NHS (Figure 5.3 A). Furthermore, CFHR3(1,2) or  
CFHR3(3,4) did not affect the survival of N. meningitidis M1239Δfhbp after incubation in NHS or HI-
NHS but the addition of full length CFHR3 resulted in significantly reduced bacterial survival in the 
absence of fHbp (two tailed t-test p = 0.001) (Figure 5.3 B). 
 
Figure 5.3: CFHR3 increases susceptibility of N. meningitidis to complement-mediated lysis 
Sensitivity of N. meningitidis strains (A) M1239 and (B) M1239Δfhbp to complement-mediated lysis after pre-incubation 
with 1 µM CFHR3, CFHR3(1,2), CFHR3(4,5), or PBS. (A, B) Faded symbols are bacteria incubated in HI-NHS. Data presented as 
percentage survival relative to bacteria incubated in HI-NHS without exogenous CFHR3. Line shows the mean of three 
independent experiments, each with three technical replicates with individual results indicated as symbols. Significance 
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was calculated using a two-tailed unpaired t-test when compared to the no protein control; ****p < 0.0001; ***p < 0.001; 
*p < 0.05; ns p > 0.05. 
5.2.4 Generation of N. meningitidis isogenic strains expressing different fHbp variants 
fHbp is a highly variable lipoprotein [Masignani, V. 2003. Brehony, C. 2009]. To determine if sequence 
variation of fHbp affects binding of CFHR3 and consequently alters the serum sensitivity of N. 
meningitidis, M1239Δfhbp was complemented with different fhbp alleles (i.e. V1.1, V1.14, V2.22, 
V3.28 and V3.28T286A fHbp). The gene encoding fhbp was ligated into PGCC4 complementation vector 
prior to transformation into M1239Δfhbp at an ectopic site, in the intergenic region between 
NEIS0480 and NEIS0481, under the control of an IPTG inducible promoter; positive clones were 
selected on plates containing erythromycin [Mehr, I. J. 1998]. V3.28T286A fHbp has decreased CFH 
binding compared to the wild-type protein. The threonine residue at position 286 of V3.28 fHbp is 
located at the CFH:fHbp interface and so V3.28T286A fHbp was consequently used as a control 
[Johnson, S. 2012]. Expression and surface localisation of fhbp alleles after induction with IPTG was 
examined by flow cytometry analysis (Figure 5.4). For strains expressing the introduced V1.1 and 
V1.14 fhbp alleles, fHbp expression was detected with an anti-V1.1 fHbp pAb (Figure 5.4 A-B), 
whereas V2.22, V3.28 and V3.28T286A expressing strains were examined with anti-Ghfp pAb (Figure 
5.4 C-D) [Johnson, S. 2012. Jongerius, I. 2013]. fHbp was expressed and localised on the surface of 
all strains with an introduced fhbp allele but not detected on the surface of M1239Δfhbp (Figure 5.4). 
Apparent differences in detected expression levels of fHbp on the surface of complement M1239 
strains are likely to be caused by differences in the recognition of fHbp sequence by the antibodies 
used.  
5.2.5 Development of Alternative Pathway serum assays to assess the functional 
consequences of CFHR3 binding 
To further examine the biological consequences of binding CFHR3 on N. meningitidis and determine 
if fHbp sequence is likely to influence CFHR3 binding at the bacterial surface, an AP assay was 
established to exclude the potential influence of antibodies against different fHbps in sera. The CP 
and LP pathways were inactivated in sera by the addition of 10 mM EGTA, which specifically chelates 
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calcium, which is necessary for the formation of the C1 complex by the association of C1q and C1r2s2; 
Ca2+ is also necessary for the association of MBL with the MASPs [Des Prez, R. M. 1975]. The AP is 
activated in the presence of 5mM MgCl2 causing spontaneous hydrolysis of C3 and is non-specific as 
C3b deposition can occur on any surface unprotected by complement regulators [Des Prez, R. M. 
1975].
 
Figure 5.4: Characterisation of isogenic N. meningitidis expressing different fHbps 
Flow cytometry analysis of N. meningitidis M1239, and isogenic strains with either (A, B) anti-V1.1 fHbp sera or (C, D) anti-
GHfp sera. Detection of surface localised V1.1 (A-B, dark blue), V1.14 (A-B, light blue), V2.22 (C-D, green), V3.28 (C-D red) 
and V3.28T286A (C-D unfilled red) fHbp. Grey shaded area shows the plot for M1239Δfhbp. (B, D) Data presented as arbitrary 
units from the mean fluorescence of FACS Calibur FL-4 channel. Error bars are ± SEM of three independent experiments. 
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To evaluate the susceptibility of N. meningitidis to AP mediated lysis, N. meningitidis H44/76 (V1.1 
fHbp) and M1239 (V3.28 fHbp) were incubated in NHS concentrations ranging from 0% to 75% with 
the addition of EGTA/ MgCl2 (Figure 5.5 A). The percentage survival was calculated by comparing the 
number of CFU recovered after incubation in NHS compared with the number of CFU obtained after 
incubation without serum. The percentage survival of both N. meningitidis M1239 and H44/76 
reduced with increasing serum concentration as expected (Figure 5.5 A). Furthermore, M1239 was 
more sensitive to AP-mediated lysis than H44/76, with percentage survival of, 49.1% and 89.2 
respectively in 75% NHS (Figure 5.5 A). Of note, H44/76 was more resistant to AP-mediated lysis in 
the presence of NHS at all NHS concentrations examined, therefore M1239 was used in subsequent 
AP serum assays.  
N. meningitidis M1239 was incubated in NHS (Figure 5.5 B) or HI-NHS (Figure 5.5 C) for increasing 
lengths of time (0-60 minutes) over a range of serum concentrations (0-75%) with only the AP active. 
In contrast to assays with all the complement pathways active, (Figure 5.2 A), there was no significant 
decrease in bacterial survival in AP assays beyond 15 minutes incubation (Figure 5.5 B). Moreover, 
there was no difference in the number of bacteria recovered after incubation in HI-NHS over 60 
minutes (Figure 5.5 C). Next, the survival of N. meningitidis M1239, M1239Δfhbp and M1239Δfhbp 
isogenic strains (V1.1, V1.14, V2.22, V3.28 and V3.28T286A) was assessed in the AP assay with a range 
of serum concentrations (0-75%) in the presence of EGTA/Mg2+ to determine the concentration of 
NHS required for 80% bacterial survival (Figure 5.2 D). As expected, there was a decrease in N. 
meningitidis survival observed with increasing NHS concentrations, and M1239Δfhbp was more 
susceptible to AP mediated lysis than M1239 (Figure 5.5 D). Interestingly, N. meningitidis M1239 
fhbp complemented isogenic strains were more sensitive to AP mediated lysis than both M1239 and 
M1239Δfhbp. Furthermore, M1239Δfhbp::V3.28T286A, which expresses a non-functional fHbp, had 
significantly reduced survival in AP serum assays compared to M1239Δfhbp (Figure 5.5 B, p = 0.0493). 
Of note, approximately 80% bacterial recovery of N. meningitidis M1239 was seen in AP assays 
following a 30 minute incubation in 25% NHS. Subsequent experiments to investigate the effect of 
sequence variants of fHbp on N. meningitidis survival were performed under these conditions. 
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Figure 5.5: Optimisation of AP assays 
(A) Survival of N. meningitidis M1239 (black line) and H44/76 (grey line) in AP survival assays using a range of NHS 
concentrations (0-75%) for one hour. Survival of N. meningtidis M1239 in AP assays analysed at different incubation times 
(indicated) in either (B) NHS or (C) HI-NHS over a range of serum concentrations (0-75%); data expressed as the percent 
survival compared with the number of CFU in the absence of NHS at time point 0. (D) Survival of N. meningitidis M1239 
(black), M1239Δfhbp and fHbp isogenic strains (indicated) in AP assays over a range of NHS concentrations (0-70%). 
Approximately 80% bacterial survival is seen following a 30 minute incubation in 25%-35% NHS. Data presented as percent 
survival relative to bacteria incubated in HI-NHS for 30 minutes. Error bars are ± SEM of three independent experiments. 
94 
 
5.2.6 fHbp sequence affects strain sensitivity to complement mediated lysis after 
incubation with CFHR3 
Binding affinities of CFH and CFHR3 with fHbp have been determined for 25 naturally occurring fHbps 
from clinical isolates of N. meningitidis. The results demonstrate that V2 and V3 fHbp have no 
selectivity for CFH or CFHR3 (average KDs 1.8 nM and 2.4 nM, respectively) [Caesar, J. J. E. 2014]. 
However, V1 fHbp had lower affinities for CFHR3 compared with CFH (average KD for CFHR3, 8.9 nM) 
[Caesar, J. J. E. 2014]. To determine if the functional consequences of CFHR3 binding to N. 
meningitidis is affected by fHbp sequence, the effect of CFHR3, CFHR3(1,2) and CFHR3(4,5) on bacterial 
survival of N. meningitidis fhbp isogenic strains was examined in AP assays (Figure 5.6 A-C). N. 
meningitidis expressing V3.28 fHbp was more sensitive to AP-mediated lysis following pre-incubation 
of CFHR3 (Figure 5.6 A) or CFHR3(1,2) (Figure 5.6 B) compared with bacteria expressing V1.1 fHbp (p 
= < 0.0001 and 0.9974, respectively) consistent with the preferential affinity of V1.1 fHbp for CFH 
compared with CFHR3. Bacteria expressing either V1.14 or V2.22 fHbp had intermediate survival 
(Figure 5.6 A-B). Irrespective of the fHbp sequence, pre-incubation of N. meningitidis M1239 with 
full length CFHR3 (Figure 5.6 A) led to decreased bacterial survival compared with CFHR3(1,2) (Figure 
5.6 B), [p values, 0.9996 to < 0.0001]. Of note, bacteria expressing V3.28T286A, which has previously 
been shown to have decreased binding affinity for CFH, were unaffected after pre-incubation with 
CFHR3(1,2) (Figure 5.6 B) [Johnson, S. 2009]. Interestingly, pre incubation of full length CFHR3 with N. 
meningitidis expressing V3.28T286A led to an increase in sensitivity (p = 0.0019) to AP-mediated lysis 
(Figure 5.6 A). Furthermore, pre-incubation of bacteria expressing any fHbp variant with CFHR3(4,5) 
had no significant impact on bacterial survival compared to no protein (Figure 5.6 C). Taken together, 
the results demonstrate fHbp sequence influences the survival of N. meningitidis in the presence of 
CFHR3 in AP assays.  
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Figure 5.6: Survival of N. meningitidis in AP assays is affected by the fHbp sequence  
AP-mediated bacterial lysis of N. meningitidis M1239 isogenic strains expressing V1.1 (dark blue), V1.14 (light blue), V2.22 
(green), V3.28 (red) and V3.28T286A (unfilled red) fHbp in the presence of 1 µM of (A) CFHR3, (B) CFHR3(1,2) or  (C) CFHR3(4,5). 
Faded symbols show results of survival of bacteria incubated with no exogenous protein. Line shows mean of three 
independent biological experiments. Data presented as percent survival relative to bacteria incubated for 30 minutes in 
HI-NHS without exogenous protein. Significance was calculated by comparison with no protein control (faded symbols) 
using two‐way ANOVA multiple comparisons; p values; ****, p < 0.0001; ***, p < 0.001; **, p < 0.01; ns p > 0.05. 
 
5.2.7 CFHR3 competes with CFH for binding of N. meningitidis fHbp 
As CFHR3 binds to N. meningitidis in an fHbp-dependent manner (Figure 5.1) and potentially 
occupies the same binding sites as CFH (Figure 5.6 B), the impact of CFHR3 on CFH binding N. 
meningitidis was assessed by flow cytometry. N. meningitidis M1239 incubated in ΔCFHR3/CFHR1 
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sera binds high levels of CFH on the bacterial surface (Figure 5.7 A, C). However, addition of 
increasing concentrations (up to 1 µM) of CFHR3 results in a significant, dose-dependent reduction 
in bound CFH (Figure 5.7 A, C) and a dose-dependent increase in surface bound CFHR3 (Figure 5.7 B, 
C). With the addition of 1 μM of CFHR3 the level of bound CFH on the surface of N. meningitidis is 
approximately 50% lower than observed without CFHR3.  
In summary, CFHR3 competes with CFH for fHbp on the meningococcal surface, and increases the 
sensitivity of N. meningitidis to complement-mediated lysis. Furthermore, the sequence of fHbp can 
influence sensitivity to AP-mediated lysis, with V1 fHbp expressing strains the least sensitive to AP-
mediated lysis Therefore, an individual’s risk of developing meningococcal disease is likely to be 
affected by the relative concentrations of circulating CFH and CFHR3, and the sequence of fHbp on 
the meningococcal surface. 
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Figure 5.7: CFH and CFHR3 compete for binding to fHbp 
Flow cytometry analysis of N. meningitidis M1239 demonstrates that addition of increasing concentrations of CFHR3 (from 
0 μM - light blue to 1 μM - black) to CFHR3-deficient sera (ΔCFHR3/CFHR1) leads to decreasing levels of CFH (A and C) and 
increasing levels of CFHR3 (B and C) on the bacterial surface. Binding was detected using (A) anti-CFH mAb (OX24) or (B) 
anti-CFHR3 mAb (HSL-1). Grey shaded area indicates bacteria incubated with PBS. (C) Data presented as a percentage of 
the maximum florescence in arbitrary fluorescence units for sera without CFHR3 for CFH, and with 1 µM additional CFHR3 
for CFHR3. Statistical significance analysed with one‐way ANOVA multiple comparisons; ± S.E.M are shown, p-values; ****, 
p < 0.0001; ***, p < 0.001; **, p < 0.01; ns p > 0.05.  
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5.3 Discussion 
Work in this chapter demonstrates that CFHR3 binds to N. meningitidis in an fHbp-dependent 
manner, and that CFHR3 can compete with the negative complement regulator, CFH, for the same 
molecule on the bacterial surface. Higher levels of surface bound CFHR3 are likely to promote 
complement activation by acting as an antagonist of CFH and competing for surface bound C3b, 
leading to increased sensitivity of N. meningitidis to complement mediated lysis (Figure 5.3) [Caesar, 
J. J. E. 2014]. Sequence differences in fHbp variants also affect the susceptibility of N. meningitidis to 
AP-mediated lysis; bacteria expressing V1 fHbp were less susceptible to lysis than bacteria expressing 
V2 or V3 fHbp. Therefore host susceptibility to meningococcal disease may be influenced by the 
relative circulting serum concentrations of CFH and CFHR3, and by variation in fHbp sequence in 
infective strain. 
Understanding the biological function of CFHR proteins has been hampered by the lack of available 
reagents as many antibodies cross-react with other members of the protein family (Figure 4.1). Flow 
cytometry analysis with mAb HSL-1, generated and characterised in Chapter 4, demonstrates that 
CFHR3 in NHS binds to the surface of N. meningitidis in an fHbp-dependent manner (Figure 5.1 A-B). 
This interaction is mediated by high affinity binding between CFHR3(1,2) and fHbp (KD 4nM), similar to 
the values obtained with CFH and fHbp [Caesar, J. J. 2014]. This finding is consistent with the high 
amino acid sequence identity between CFHR3(1,2) and CFH(6,7) (91% and 85% identity for the CCP 
domains, respectively). Of note, Ala substitutions in V1, V2 and V3 fHbp that reduce CFH-fHbp 
binding also impact CFHR3-fHbp interaction, indicating that CFH and CFHR3 share a common, 
overlapping binding site on fHbp [Caesar, J. J. 2014]. Two other meningococcal proteins, NspA and 
PorB2 have been suggested to bind CFH by CCP domains 6 and 7, but binding to these proteins has 
only been shown in the absence of fHbp [Lewis, L. A. 2010. Lewis, L. A. 2013]. Futherwork could 
investigate whether CFHR3 can bind to these other proteins. However, there is no evidence to 
indicate that CFHR3 binds to any protein other than fHbp on the surface of N. meningitidis as the 
Δfhbp did not bind CFHR3 (Figure 5.1) 
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Initial studies proposed that CFHRs regulate the TP, by inhibiting formation of the C5 convertase, 
C3bBbC3b, by binding to C3b [Heinen, S. 2009]. Other studies have suggested that CFHRs act as 
regulators of the AP, but were performed under non-physiological conditions [Hellwage, J. 1999. 
Fritsche, L. G. 2010. McRae, J. L. 2005].  However, recent findings demonstrate that CFHR1, CFHR2, 
and CFHR5 are antagonists of CFH, and compete with CFH for tissue bound C3b, promoting 
complement activation [Goicoechea de Jorge, E. 2013]. Work here also shows that CFHR3 is a 
competitive antagonist of CFH at the meningococcal surface. 
Pathogens bind both CFH (Table 1.1) and CFHRs (Table 1.2), with B. burgdorferi selectively binding 
CFH or CFHRs via different receptors on the bacterial surface [Haupt, K. 2007. Siegel, C. 2010]. Here 
the effect of CFHR3, or domains of CFHR3 on survival of N. meningitidis in the presence of NHS was 
examined. Addition of CFHR3 or CFHR3(1,2)  decreased survival of N. meningitidis in a dose-dependent 
and fHbp-dependent manner (Figure 5.2 D-E). Furthermore, the addition of CFHR3(4,5) did not affect 
bacterial survival. Potential explanations for this include the inability of CFHR3(4,5) to compete with 
CFH or to localise to the bacterial surface without the CFHR3-fHbp interaction via CFHR3(1,2) (Figure 
5.3 B).  However, full length CFHR3 decreased survival of N. meningitidis significantly more than 
CFHR3(1,2) suggesting that CFHR3(4,5) may compete for surface bound C3b when attached to the 
bacterial surface. Therefore CFHR3 might have two roles influencing survival of N. meningitidis in 
serum; competition with CFH for fHbp via CFHR3(1,2) and competition with C3b via CFHR3(4,5). 
However, addition of CFHR3 to M1239Δfhbp reduced bacterial survival to a similar extent as M1239 
(Figure 5.3 B) which may be due to an increased opsonisation of M1239Δfhbp resulting in high 
deposition of C3b on the bacterial surface; consequently higher concentrations of CFHR3 are bound 
on the bacterial surface by CFHR3:C3b interactions [Madico, G. 2006].  
fHbp is expressed by almost all clinical isolates of N. meningitidis and is a variable protein, which can 
be categorised into three variant groups [Brehony, C. 2009. Lucidarme, J. 2011]. fHbps belonging to 
the same variant group have approximately 85% amino acid identity, with approximately 60% 
identity between different variant groups [Brehony, C. 2009]. Previous investigations have 
highlighted that fHbps from different variant groups bind CFH with affinities in the nanomolar range 
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[Johnson, S. 2012]. However, isogenic N. meningitidis strains expressing different fHbp variants had 
different sensitivities to AP-mediated lysis after the addition of CFHR3 or CFHR3(1,2) (Figure 5.6 A-B) 
consistent with evidence that sequence variation of fHbp affects the binding affinity for CFHR3 
[Caesar, J. J. 2014]. Examination of the relative binding affinities of fHbp variants for both CFH and 
CFHR3 showed that V1 fHbp can partially discriminate between CFH and CFHR3, with V1 fHbps 
displaying between 5-20 fold increased affinity for CFH than CFHR3; V2 and V3 fHbp had equal 
binding affinities for both proteins [Caesar, J. J. 2014]. Of note, isogenic N. meningitidis expressing 
V1, V2 and V3 fHbps were more susceptible to complement mediated lysis after addition of CFHR3 
(Figure 5. 6 A). The difference in the ability of fHbps to discriminate between CFH and CFHR3 might 
explain why V1 fHbps are the most prevalent fHbp in clinical isolates, accounting for approximately 
54-70% of cases [Masignani, V. 2003. Fletcher, L. D. 2004. Jacobsson, S. 2006. Beernink, P. T. 2007. 
Murphy, E. 2009. Brehony, C. 2009]. 
Variation in the CFH/CHFR gene locus on human chromosome 1q32 has been linked to susceptibility 
to meningococcal disease [Davila, S. 2010. Biebl, A. 2015]. A deletion of ΔCFHR3/CFHR1 is also 
associated with the development of anti-factor H auto-antibodies in haemolytic uremic syndrome 
(DEAP HUS) [Holmes, L. V. 2013. Zipfel, P. F. 2007]. However the molecular mechanisms underlying 
host susceptibility to meningococcal disease in the general population is not well understood and 
the causative polymorphisms/deletions associated with the SNPs identified in the GWAS are not 
known. Therefore, further work will focus on examining the relative levels of CFH and CFHR3 
between individuals with meningococcal disease and control groups and whether the relative levels 
are different in cases where the infective strains expresses a V1 fHbp compared with V2 and V3 
fHbps. 
Work presented here shows that CFHR3 and CFH directly compete for fHbp on the bacterial surface, 
therefore it is likely that relative serum levels of CFH and CFHR3 affect meningococcal survival in 
serum and influence disease susceptibility. Individuals with increased CFH or decreased levels of 
CFHR3 in the circulation may have increased CFH bound on the bacterium and may be at increased 
risk of meningococcal disease. In contrast, decreased CFH or increased CFHR3 levels would result in 
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higher concentrations of bound CFHR3, and may decrease susceptibility to meningococcal disease. 
Of note, the frequency of ΔCFHR3/CFHR1 is highest in Africa (54.7% in Nigeria) where there is a high 
incidence of meningococcal disease and lowest (0%) in individuals from Japan and South America 
[Holmes, L. V. 2013]. It will be interesting to examine the genetic basis of meningococcal 
susceptibility in patients from Africa, where epidemic disease occurs every 5-15 years [Wall, E. C. 
2014]. These studies provide a mechanistic basis for the GWAS that identified CFHR3 as being 
involved in susceptibility to meningococcal disease in the general population. GWAS studies, 
including the work on N. meningitidis, do not assay copy number variation. Therefore it will be 
important in the future to determine whether the ΔCFHR3/CFHR1 deletion and other polymorphisms 
are associated with changes in susceptibility to meningococcal disease. 
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6. CHARACTERISATION OF FHBP FROM NEISSERIA CINEREA AND 
POTENTIAL IMPLICATIONS OF VACCINATION AGAINST MENB 
6.1 Introduction 
The bacterial genus Neisseria includes two major human pathogens, N. meningitidis and N. 
gonorrhoeae [Knapp J. S. 1988. Smith, N. H. 1999]. N. meningitidis is an asymptomatic commensal of 
the human nasopharynx in approximately 10-40% of the general population but can transverse the 
epithelial layer and cause systemic disease [Stephens, D. S. 2007]. Non-pathogenic Neisseria species 
can also colonise the human oral cavity and/ or nasopharynx of healthy individuals [Gold, R. 1978. 
Knapp, J. S. 1988].  
Capsular polysaccharide-conjugated vaccines have been developed for protection against some 
serogroups of N. meningitidis i.e. A, C, W and Y, while outer membrane vesicle (OMV) vaccines have 
been employed to combat epidemic disease outbreaks caused by a single clone [Vipond, C. 2012. 
Kelly, C. 2007]. Neither of these approaches have been successful against endemic serogroup B 
strains of N. meningitidis, which still cause significant numbers of meningococcal disease cases in 
Europe and the USA. This is due to concerns of inducing autoimmunity, as the 2-8 linked polysialic 
acid of the serogroup B capsule is identical to a modification of human N-CAM1 [Finne, J. 1983. Finne, 
J. 1987. Jennings, H. J. 1981], while OMV vaccines offer limited cross protection [Fredriksen, J. H. 
1991. Holst, J. 2009. Tappero, J. W. 1999. Tondella, M. L. 2000]. Recently developed meningococcal 
vaccines against serogroup B N. meningitidis are composed of multiple protein antigens to enhance 
immunogenicity and cross protection [Giuliani, M. M. 2006]. Two, recently licensed vaccines, 
Bexsero® and Trumemba®, both contain fHbp [Masignani, V. 2003. Fletcher, L. D. 2004]. 
fHbp is a 27 kDa surface lipoprotein expressed by almost all disease isolates of N. meningitidis and 
elicits SBA, a known correlate of protection against the meningococcus [Masignani, V. 2003. Fletcher, 
L. D. 2004. Lucidarme, J. 2011. Gotschlich, E. C. 1969]. fHbp can be classified into one of three variant 
groups (V1, V2 or V3), based on its amino acid sequence [Fletcher, L. D. 2004. Brehony, C. 2009]. 
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fHbps within the same variant groups generally can induce cross protection due to high amino acid 
sequence identity, whereas there is little or no cross protective immunity between variant groups 
[Masignani, V. 2003]. fHbp promotes survival of N. meningitidis in human blood by binding CFH at 
high affinity via CCP domains 6 and 7 [Madico, G. 2006. Schneider, M. C. 2006. Schneider, M. C. 
2009]. In addition, CFHR3 competes for binding to fHbp and acts as a competitive antagonist of CFH, 
whereby surface bound CFHR3 decreases meningococcal survival (Chapter 5). 
Recent genome analysis of 80 strains of pathogenic and commensal Neisseria found fhbp in all N. 
meningitidis (n=27) and N. cinerea isolates (n=5) examined [Muzzi, A. 2013]. fhbp was also present 
in all N. gonorrhoeae (n=17) and N. polysaccharea (n=7) included in the study, although most of the 
fhbp genes in these species contain a frame shift mutation; this frame shift has been shown to render 
the protein unable to bind CFH in N. gonorrhoeae, isolate F62 [Hadad, R. 2012. Jongerius, I. 2013. 
Muzzi, A. 2013]. N. cinerea fhbps have a significant nucleotide identity with V1 fhbp, whereas N. 
gonorrhoeae and N. polysaccharea harbour homologues of V3 fhbp [Muzzi, A. 2013]. The commensal 
Neisseria spp. have been speculated to serve as reservoirs for virulence-associated alleles as high 
rates of genetic exchange can potentially occur due to the diversity of commensal Neisseria spp. on 
human mucosal surfaces [Marri, P. R. 2010. Stabler, R. A. 2005. Sáez Nieto, J. A. 1998]. For example, 
N. cinerea contains two genes for the major Tfp subunit, pilE, which is required for virulence, 
although in contrast to N. meningitidis, PilE is not involved in bacterial association with epithelial cells  
[Wörmann, M. E. 2016]. Although other virulence associated genes, including fhbp, opa, and nadA 
have been identified in the genome of N. cinerea, their expression and function have not been 
studied [Toleman, M. 2001. Muzzi, A. 2013].  
Previous evidence indicates that commensal Neisseria spp. can induce immunity against the 
meningococcus. For example, colonisation with N. lactamica is thought to offer immunity against N. 
meningitidis [Gold, R. 1978. Cann, K. J. 1989. Snyder, L. A. 2006]. Moreover, human challenge with 
N. lactamica, have identified salivary IgA and serum IgG antibodies that cross react with N. 
meningtidis within four weeks of carriage; non-carriers and the control group did not develop 
antibodies against N. lactamica or N meningitidis [Evans, C. M. 2011]. Furthermore, inoculated 
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individuals who were colonised by N. lactamica were protected against subsequent acquisition of N. 
meningitidis [Evans, C. M. 2011]. The presence and conservation of fhbp in commensal Neisseria 
shown by Muzzi et al. and the shared bacterial niche in the human nasopharynx between N. 
meningitidis and N. cinerea raises the issue of whether implementation of protein-based vaccines 
containing V1 fHbp could impact the nasopharyngeal flora. 
Therefore, the aim of this study was to investigate the expression and function of N. cinerea fhbp 
and to evaluate the immunogenicity of Bexsero® against N. cinerea.  
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6.2 Results 
6.2.1 N. cinerea fHbp is predicted to be structurally similar to meningococcal fHbp.  
Previous studies have identified a homologue of fhbp in the N. cinerea genome with the fhbp locus 
conserved compared to N. meningitidis [Muzzi, A. 2013]. Genome sequences of five N. cinerea 
isolates, CCUG 346 T, CCUG 5746, CCUG 25879, CCUG 27178 A, and CCUG 53043, were obtained 
from the PubMLST Neisseria BIGSdb database (http://pubmlst.org/neisseria/). All isolates contain 
fhbp with a predicted signal peptide, conserved lipobox, and a variable linker sequence (Figure 6.1). 
 
Figure 6.1: Sequence alignment of N. meningitidis fHbp V1.1 with N. cinerea fHbp from (http://pubmlst.org/) 
Black boxed residues show sequence variation of fHbp and white boxed residues show identical residues compared with 
N. meningitidis V1.1 fHbp sequence. Grey boxed residues show residues conserved in all strains. Sequence analysis 
indicates a conserved signal motif (blue box), lipobox (green box) and variable linker sequence (purple box). 
 
There was a high nucleotide sequence identity between N. cinerea fhbp with the meningococcal fhbp 
V1.1 (approximately 95%). Phylogenetic analysis indicates that all N. cinerea fhbps belong to the 
variant 1 family (Muzzi, A. 2013). fhbp from N. cinerea isolate, CCUG 346 T was further characterised 
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as this strain is genetically transformable [Wörmann, M. E. 2016].  Comparison of the predicted 
amino acid sequence of fhbp from N. cinerea CCUG 346 T with N. meningitidis V1.1 fHbp revealed 
six nonsynonymous substitutions in N. cinerea fhbp, of which one residue is in the signal peptide 
(Figure 6.2A). To evaluate the impact of amino acid substitutions, a structural model of N. cinerea 
fHbp was generated using V1.1 fHbp (Schneider, PBD: 2W80) as the threading template (Figure 6.2B 
and Supplementary Information Figure SI.1). Three of the residues unique to N. cinerea fHbp, (H243, 
H269 and D282) are in the C terminal barrel and predicted to be distinct from the CFH:fHbp interface. 
However, residues R193 and E267 of N. cinerea fHbp reside at the CFH:fHbp interface and could 
potentially alter this key host pathogen interaction. The close proximity (less than 4 Å) of these 
residues with CFH residues, S366 and N338 respectively, has the potential to lead to additional salt 
bridges, so could increase the binding affinity of CFH to N. cinerea fHbp compared with V1.1 fHbp.  
6.2.2 Functional characterisation of N. cinerea fHbp.  
Initially binding of fHbp from N. cinerea and N. meningitidis to CFH was determined by far western 
blot analysis using CFH from NHS. Previous investigations have shown that an Ile to Ala substitution 
at position 311 of V1.1 fHbp (V1.1I311A fHbp) significantly decreases the binding affinity to CFH(6, 7) 
(Johnson, S. 2012); therefore this non-functional protein was used as a control. N. cinerea fHbp, V1.1 
fHbp and V1.1I311A fHbp were purified as recombinant proteins and detected by anti-V1.1 fHbp 
(Figure 6.3A). Both N. cinerea fHbp and V1.1 fHbp bind CFH by far western analysis, whereas far 
western analysis demonstrates that V1.1I311A fHbp had no detectable CFH binding (Figure 6.3A). To 
further characterise this interaction, the binding affinity of N. cinerea fHbp was determined for 
CFH(6,7) by SPR. Results show that N. cinerea fHbp binds CFH(6,7) with similar affinities as V1.1 fHbp, 
with  KDs of 3.5 nM ± 0.5 and 3.0 nM ± 0.5, respectively  (Figure 6.3B-C), indicating the substitutions 
in N. cinerea fHbp do not affect its ability to bind CFH. Next, the level of CFH binding to N. cinerea 
fHbp and V1.1 fHbp was analysed by ELISA using full length recombinant CFH (Figure 6.3D). ELISA 
data was consistent with results from both far western and SPR analyses, with no significant 
difference in CFH binding to N. cinerea fHbp and N. meningitidis V1.1 fHbp (p > 0.05 by two-tailed t 
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test) over a range of concentrations (Figure 6.3E). Taken together, these results demonstrate that N. 
cinerea fHbp binds CFH and that this interaction is mediated by CCPs 6 and 7.  
Initial functional characterisation of N. cinerea fHbp (Figure 6.3) and fHbp surface localisation 
experiments (Figure 6.5) were performed by Katy Poncin, University of Namur, under my direct 
supervision at the University of Oxford during an internship for her MSc. 
 
 
Figure 6.2: N. cinerea fHbp is predicted to be structurally similar to N. meningitidis fHbp 
(A) Sequence alignment of N. meningitidis V1.1 fHbp and N. cinerea fHbp. Blue boxed residues show amino acid differences. 
(B) Predicted structure of N. cinerea fHbp (grey ribbon) generated with the I-TASSER server and V1.1 fHbp (blue ribbon) 
[Schneider, PBD: 2W80]. Figure drawn using Pymol. Residues in red (shown as ball-and-stick representations) are different 
in N. cinerea fHbp compared to V1.1 fHbp. Residues Arg193 and Glu267 (red) are near to the interface of fHbp with CFH 
(expanded view, green ribbon). 
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Figure 6.3: N. cinerea fHbp binds CFH at high affinity 
(A) Recombinant fHbp from N. cinerea CCUG 346 T, N. meningitidis V1.1 fHbp and V1.1I311A fHbp analysed by western blot 
using polyclonal anti-V1.1 fHbp sera. N. cinerea fHbp and V1.1 fHbp bind CFH by far western analysis with NHS as the source 
of CFH. Molecular masses shown in kDa and Coomassie blue staining of proteins as the loading control. (B) SPR analysis of 
N. cinerea fHbp binding to CFH(6, 7) (concentrations indicated) with 1:1 Langmuir fit (black lines). (C) Calculated KD values 
for CFH(6, 7) binding to N. cinerea fHbp and V1.1 fHbp; NBD, no binding detected. X2, chi-squared test of independence. (D) 
ELISA of full length CFH binding to N. cinerea fHbp, V1.1 fHbp and V1.1I311A fHbp. (E) Significance of CFH binding by ELISA 
analysed 5 µg/ ml-1 CFH. Error bars are ± SEM of three independent experiments, p values (***, p < 0.001; ns, p > 0.05) 
calculated using a two-tailed unpaired t-test. H.L. conceived and designed experimental plan, experiments were performed 
by K.P. ad data analysed by both H.L. and K.P. 
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6.2.3 N. cinerea isolates express fHbp on the bacterial surface.  
Next, the expression of fHbp by N. cinerea isolates was analysed using polyclonal mouse sera raised 
against V1.1 fHbp which cross reacts with N. cinerea fHbp from CCUG 346 T (Figures 6.3A). fHbp was 
detected at approximately 27 kDa in all five N. cinerea isolates by western blot analysis of whole cell 
lysates from these strains (Figure 6.4A). Moreover, N. meningitidis H44/76, H44/76Δfhbp and five N. 
cinerea isolates were analysed for their ability to bind full length CFH using NHS. Far western analyses 
demonstrates that N. meningitidis H44/76 and N. cinerea isolates are able to bind CFH; no CFH 
binding was detected for N. meningitidis H44/76Δfhbp (Figure 6.4A). Next, an fhbp deletion strain of 
N. cinerea CCUG 346 T was constructed (N. cinerea CCUG 346 TΔfhbp) by insertional inactivation 
with a kanamycin resistance cassette to determine if binding of CFH to N. cinerea is fHbp-dependent. 
Analysis of the wild-type N. cinerea and the Δfhbp strain demonstrated no expression of fHbp in the 
Δfhbp, while far western blot analysis demonstrates that CFH binding to N. cinerea is dependent on 
fHbp expression (Figure 6.4B). N. meningitidis H44/76 and H44/76Δfhbp were used as positive and 
negative controls, respectively.  
 
Figure 6.4: Functional fHbp is expressed by all N. cinerea strains examined 
(A) Western blot analysis of fHbp expression using anti-V1.1 fHbp sera against whole cell lysates of N. cinerea strains 
(indicated), N. meningitidis H44/76 and H44/76Δfhbp. Far western analysis, using NHS as the source of CFH, demonstrates 
that fHbp from N. cinerea binds CFH; RecA used as a loading control. (B) Western and far western analyses demonstrate 
that binding of CFH to N. cinerea is dependent on fHbp expression.  
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To determine whether N. cinerea fHbp is localised on the surface of bacteria, flow cytometry analysis 
was performed using anti-V1.1 fHbp sera to detect fHbp on the surface of wild-type N. cinerea, CCUG 
346 T and CCUG 346 TΔfhbp (Figure 6.5A-B); N. meningitidis, H44/76 and H44/76Δfhbp were 
examined as positive and negative controls (Figure 6.5C-D). The results demonstrate that fHbp is 
present on the surface of N. cinerea CCUG 346 T and N. meningitidis H44/76 but not CCUG 346 
TΔfhbp or H44/76Δfhbp (two tailed t test p = < 0.0001 and p = 0.0183) (Figure 6.5B, D). Taken 
together these results show that in N. cinerea fHbp is surface localised and N. cinerea fHbp binds 
CFH at a similar affinity to meningococcal V1.1 fHbp. 
 
Figure 6.5: N. cinerea fHbp is present on the bacterial surface 
Flow cytometry analysis with anti-V1.1 fHbp sera demonstrates surface localisation of fHbp on (A-B) N. cinerea (black-solid 
line) and (C-D) N. meningitidis (blue-solid line). fHbp was not detected on the surface of (A-B) N. cinerea Δfhbp (black-
dotted line) and (C-D) N. meningitidis Δfhbp (blue-dotted line). (A, C) Grey shaded area indicated bacteria incubated in the 
absence of sera. (B, D) Error bars are ± SEM of three independent experiments; Significance was calculated using a two-
tailed unpaired t-test; ****, p < 0.0001; and *, p < 0.05. H.L. conceived and designed experimental plan, experiments were 
performed by K.P. and data analysed by both H.L. and K.P. 
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6.2.4 Binding of CFH promotes complement resistance of N. cinerea.  
Both NspA and PorB2 of N. meningitidis have previously been shown to bind CFH and promote serum 
survival of N. meningitidis [Lewis, L. A. 2010; Lewis, L. A. 2013]. Initially, the ability of N. cinerea to 
recruit CFH to its surface was analysed by flow cytometry. N. cinerea CCUG 346 T and CCUG 346 
TΔfhbp were incubated in HI-NHS as a source of CFH, or in CFH depleted sera (HI-CFH depleted). CFH 
binding was detected with an anti-CFH mAb (OX24) which recognises CCP domain 5 of CFH (Figure 
6.6) [Sim, R. 1983]; fluorescence was quantified as the geometric mean fluorescence intensity. 
Bacteria incubated with PBS, instead of HI-NHS, were used as a negative control. Following 
incubation with HI-NHS, CFH was detected on the surface of N. cinerea, CCUG 346 T (Figure 6.6A-B), 
but not the fhbp mutant, CCUG 346 TΔfhbp (two tailed t-test p=0.0002) (Figure 6.6C-D). 
Furthermore, no CFH binding was detected to either strain following incubation with HI-CFH 
depleted sera (Figure 6.6). Taken together these results demonstrate that CFH binds to the surface 
of N. cinerea in an fHbp-dependent manner. 
Next, the functional consequences of binding CFH on the bacterium was evaluated in serum survival 
assays. N. cinerea CCUG 346 T and CCUG 346 TΔfhbp were incubated in a range of NHS 
concentrations (0-20%) for 30 minutes to evaluate the effect of serum concentration on survival. 
The percentage survival of strains in NHS was calculated by comparing the number of CFU recovered 
from bacteria incubated in PBS.  N. cinerea CCUG 346 T was more resistant against complement-
mediated lysis than CCUG 346 TΔfhbp over a range of serum concentrations. For example, 54.3% 
and 31.24% survival was observed for CCUG 346 T and CCUG 346 TΔfhbp, respectively at 5% NHS 
(two tailed t test p = 0.0161) (Figure 6.7A). Furthermore, we examined whether these differences in 
survival were observed in the absence of the CP and LP by adding 10 mM EGTA and 5 mM MgCl2 
(Des Prez, R. M. 1975). The enhanced resistance of N. cinerea CCUG 346 T compared to CCUG 346 
TΔfhbp to complement-mediated lysis was still observed when only the AP was active (67.1% and 
58.55% survival was observed for CCUG 346 T and CCUG 346 TΔfhbp, respectively at 10% serum 
concentration, (two tailed t test p = 0.491) (Figure 6.7B); although the enhanced resistance of N. 
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cinerea CCUG 346 T compared to CCUG 346 TΔfhbp to complement-mediated lysis was not 
significant in AP only complement assays. 
 
Figure 6.6: N. cinerea recruits CFH to its surface in a fHbp-dependent manner 
Flow cytometry analysis of CFH binding to (A-B) N. cinerea CCUG 346 T and (C-D) N. cinerea CCUG 346 TΔfhbp. Shaded area 
indicates results from bacteria incubated with PBS, solid green shows bacteria incubated in HI-NHS, and broken green 
shows bacteria incubated in HI-CFH-depleted sera. (B, D) Data presented as the mean fluorescence intensity. Error bars 
indicate mean ± SEM of three independent experiments and p-values calculated using a two-tailed unpaired t-test; ***, p 
< 0.001; and ns >0.05. 
Results in Chapter 5 demonstrate that CFHR3 can bind to fHbp with this interaction mediated by CCP 
domains 1-2, and that CFHR3 competes for binding to fHbp with CFH on the meningococcal surface. 
Competition of CFHR3 for fHbp renders N. meningitidis more susceptible to complement-mediated 
lysis. Therefore, the effect of CFHR3 on N. cinerea survival in serum was examined using CFHR3(1,2) 
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which binds fHbp. Furthermore, the effect of CFHR3(4,5) on bacterial survival was examined as 
CFHR3(4,5) is known to bind C3b but not fHbp [Caesar, J. J. 2014]. N. cinerea CCUG 346 T and CCUG 
346 TΔfhbp survival was measured following pre-incubation in a range of CFHR3(1,2) concentrations 
(0.01 µM to 5 µM) for ten minutes prior to incubating bacteria in 3% NHS. This serum concentration 
was selected as approximately 80% of N. cinerea CCUG 346 T survives after incubation in 3% NHS for 
30 minutes (Figure 6.7A). Similar to N. meningitidis, CCUG 346 T was more susceptible to 
complement-mediated lysis after pre-incubation with CFHR3(1,2) (Figure 6.8A). Moreover, pre-
incubation of CCUG 346 T Δfhbp with CFHR3(1,2) had no effect on bacterial survival indicating that the 
effect of CFHR3 on bacterial survival is fHbp dependent (Figure 6.8B). For example, 70.69% and 
96.8% survival was observed for CCUG 346 T and CCUG 346 T Δfhbp respectively after pre-incubation 
with 1 µM CFHR3(1,2); percentage survival for these experiments was calculated relative to bacteria 
without pre-incubation with CFHR3(1,2) after 30 minutes incubation in NHS. Furthermore, CFHR3(1,2) 
did not affect survival of either CCUG 346 T or CCUG 346 TΔfhbp in HI-NHS (Figure 6.8A-B). Pre-
incubation of CCUG 346 T or CCUG 346 TΔfhbp with CFHR3(4,5) had no effect on bacterial survival 
(Supplementary Information Figure SI.2) indicating that CFHR3 CCP domains 1 and 2 are essential for 
mediating the interaction between fHbp and CFHR3.  
 
Figure 6.7: Serum survival of N. cinerea 
Percent survival of N. cinerea (filled circles) and N. cinerea CCUG 346 TΔfhbp (open circles) to (A) complement mediated 
lysis following 30 minute incubation in NHS (concentrations indicated) and to (B) lysis mediated by the AP (concentrations 
indicated). Survival was calculated relative to bacteria incubated in HI-NHS. 
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Figure 6.8: CFHR3 increases susceptibility of N. cinerea to complement mediated lysis 
Survival of  (A) N. cinerea CCUG 346 T (filled circles) and (B) CCUG 346 TΔfhbp (open circles) in the presence of 3% NHS 
(black) or HI-NHS (blue) following pre-incubation in different concentrations of CFHR3(1,2) (indicated). Data presented as 
survival relative to bacteria incubated in the absence of serum and CFHR3(1,2). Error bars are ± SEM of three independent 
experiments. 
 
6.2.5 Mice immunised with Bexsero® elicit a serum bactericidal activity response which is 
comparable to mice immunised with fHbp alone.  
The introduction of sub-unit vaccines against N. meningitidis containing fHbp has the potential to 
impact commensal species such as N. cinerea which expresses fHbp (Figure 6.4A) [Masignani, V. 
2003; Fletcher, L. D. 2004; Muzzi, A. 2013]. To examine whether immune responses elicited by 
licensed meningococcal vaccines could mediate SBA against N. cinerea, mice were immunised with 
Bexsero®, V1.1 fHbp and N. cinerea V1.110 fHbp, and the resulting sera examined for SBA against N. 
cinerea. Non-immune serum, generated by immunising mice with adjuvant alone, was used as a 
negative control. Initially the antibody responses elicited by Bexsero® were analysed by assessing the 
ability of sera to recognise V1.1 fHbp, present in Bexsero®, and N. cinerea V1.110 fHbp by ELISA. 
Interestingly, there was no significant difference in the recognition of V1.1 and V1.110 fHbp by sera 
from mice immunised with V1.1 fHbp, N. cinerea fHbp, or Bexsero® (p = 0.7572, 0.2751 and 0.8965, 
respectively) (Figure 6.9A-C). Sera from mice immunised with V1.1 or V1.110 fHbp did not recognise 
BSA whereas mice immunised with Bexsero did react with BSA at lower serum dilutions which may 
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be due to more complex mixture of proteins in the vaccine (Figure 6.9A-C). Of note, non-immune 
sera did not recognise V1.1 fHbp, V1.110 fHbp, or BSA (Figure 6.9D). 
 
Figure 6.9: Immunisation with Bexsero® elicits immune responses against N. cinerea 
ELISA analysis of sera raised against (A) V1.1 fHbp, (B) V1.110 fHbp, (C) Bexsero® and (D) non-immune sera (three-fold 
dilutions from 1/300) against recombinant V1.1 fHbp (black triangles) and V1.110 fHbp (blue triangles); BSA (red circles) 
was used as a control. (E) Western blot analysis of whole cell lysates (strains indicated) or recombinant V1.1 fHbp and 
V1.110 fHbp, fHbp is recognised by sera from mice immunised with recombinant fHbp or Bexsero®. 
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Next, the ability of pooled sera and individual mice sera to recognise fHbp was analysed by western 
blot analysis against  whole cell lysates of N. cinerea CCUG 346 T and N. meningitidis H44/76 as well 
as recombinant V1.1 fHbp and V1.110 fHbp (Figure 6.9E; Supplementary Information Figure SI.3). 
Sera from groups immunised with fHbp V1.1 or N. cinerea fHbp detected a single band in wild-type 
strains corresponding to the expected size for fHbp (approximately 27 kDa), while no protein was 
detected in the Δfhbp knockout strains. However, sera from mice immunised with Bexsero® detected 
multiple protein bands which could be attributed to immune responses against other antigens in the 
OMVs in the vaccine. However, a band of approximately 27 kDa (corresponding to the approximate 
molecular weight of fHbp) was no longer detected in Δfhbp knockout strains. Furthermore, as 
expected antibodies elicited by V1.1 fHbp, V1.110 fHbp and Bexsero® also recognised V1.1 fHbp and 
V1.110 fHbp by western blot analysis (Figure 6.9E; Supplementary Information Figure SI.3)  
Next the potential impact of immunisation with Bexsero® on N. cinerea survival was examined by 
measuring SBA against the bacterium (Table 6.1). In an SBA, the ability of antibodies to initiate 
bacterial lysis is measured by adding dilutions of antibodies (usually in the form of heat-inactivated 
immune serum) to bacteria in an exogenous source of complement (either baby rabbit complement 
or human serum). Currently, an SBA titer ≥8 in the presence of baby rabbit complement is used as 
the threshold for meningococcal vaccine efficacy, which has been correlated with protection from 
meningococcal disease [Borrow, R. 2006]. Of note, polysaccharide conjugate vaccines against 
serogroup C elicit SBA and a lead to a significant reduction in carriage of serogroup C meningococci 
strains and a decrease in invasive serogroup A disease by 89-94% [Balmer, P. 2002. Maiden, M. 2008. 
Campbell, H. 2009]. Furthermore, introduction of a polysaccharide conjugate vaccine against 
serogroup A meningococci in Africa has almost eliminated serogroup A meningococcal disease 
through the reduction of carriage and induction of herd immunity [Sow, S. 2011. Sambo, L. 2015. 
Kristiansen, P. A. 2012]. A correlation between the SBA and reduction in serogroup B carriage has 
yet to be established and is under further investigation [Read, R. C. 2014]. 
 The polysaccharide capsule is a key virulence factor of N. meningitidis and isolates which do not 
express polysaccharide capsule are more susceptible to complement-mediated lysis [Drogari-
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Apiranthitou, M. 2002; Ram, S. 1999]. Genome analysis of N. cinerea indicate that N. cinerea lack 
expression of polysaccharide capsule as the key capsule biosynthesis genes are not present [Kim, J. 
J. 1989; Marri, P. R. 2010]. Therefore, N. cinerea were expected to be more susceptible to 
complement-mediated lysis. Consistent with this, approximately 50% bacterial survival was observed 
after incubation with 12% NHS for N. meningitidis (Figure 5.2C) whereas 50% survival was observed 
for N. cinerea after incubation in 5% NHS (Figure 6.7A). Prior to analysing the SBA from immunised 
mice, the concentration of rabbit complement was optimised (Supplementary Information Figure 
SI.4). N. cinerea was incubated in a range of complement dilutions from 0 to 1:64. At a 1:10 dilution 
of rabbit complement, in SBA buffer, and after a 60-minute incubation, 91.8% N. cinerea survival was 
observed (Supplementary Information Figure SI.4). This concentration of complement was used in 
subsequent SBA assays.  
Immunisation with V1.1 fHbp and Bexsero® elicited SBA titres of 128 against N. cinerea CCUG 346 T 
but no SBA was detected against CCUG 346 TΔfhbp, indicating that the main vaccine target against 
N. cinerea on the bacterial surface is fHbp. Of note, N. cinerea CCUG 346 T complemented with N. 
cinerea V1.110 fHbp under an IPTG inducible promotor, had a higher SBA titre (256) using sera from 
mice immunised with Bexsero® than wild-type N. cinerea. This is correlated with the higher 
expression levels of fHbp in the complemented compared to the wild-type N. cinerea strain 
(Supplementary Information Figure SI.5). Furthermore, no SBA was detected against N. cinerea CCUG 
346 TΔfhbp with V1.1 fHbp, V1.110 or Bexsero®. In contrast, mice immunised with V1.110 fHbp did 
not elicit SBA against either the wild-type N. cinerea CCUG 346 T or the Δfhbp mutant. However, 
mice immunised with V1.110 fHbp elicited an SBA titre of 512 against N. cinerea CCUG 346 T 
complemented with the homologous fHbp suggesting that N. cinerea fHbp either does not elicit a 
strong immune response or that N. cinerea fHbp is expressed at low levels on the bacterial surface. 
Moreover, no SBA was observed against N. cinerea CCUG 346 T, CCUG 346 TΔfhbp or CCUG 346 
TΔfhbp::V1.110 fhbp using non-immune mouse sera. In conclusion, immune responses elicited by 
Bexsero® recognise N. cinerea fHbp and have SBA against N. cinerea.  
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Strain fHbp variant SBA elicited by 
    V1.1 fHbp V1.110 fHbp Bexsero® 
CCUG 346 T V1.110 128 NBT 128 
CCUG 346 TΔfhbp - NBT NBT NBT 
CCUG 346 TΔfhbp::fhbp V1.110 128 512 256 
 
Table 6.1: Serum bactericidal titres of pooled sera from mice immunised with recombinant fHbp, Bexsero® or control mice 
against N. cinerea strains 
No bactericidal titre (NBT). 
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6.3 Discussion 
fHbp is a key virulence factor for the meningococcus and binds the negative complement regulator, 
CFH, promoting bacterial survival in human blood [Madico, G. 2006. Schneider, M. C. 2006. 
Schneider, M. C. 2009]. Its importance as a vaccine candidate is evident as fHbp is a major 
component of two recently licensed meningococcal B vaccines, Bexsero® and Trumenba® 
[Masignani, V. 2003. Fletcher, L. D. 2004]. Data in this chapter shows that fHbp expression is not 
restricted to pathogenic N. meningitidis isolates but this antigen is also expressed by the commensal, 
N. cinerea. N. cinerea fHbp binds CFH at high affinity, and promotes resistance of N. cinerea to 
complement-mediated lysis. Furthermore, sera raised against Bexsero® had SBA against N. cinerea 
expressing fHbp. Therefore immunisation with Bexsero® has the potential to affect the survival of N. 
cinerea, a component of the nasopharyngeal flora. 
Previous work has analysed the expression and function of fHbp in pathogenic Neisseria [Madico, G. 
2006; Schneider, M. C. 2006]. fHbp is a highly variable protein which can be grouped into three 
distinct variants based on its amino acid sequence [Brehony, C. 2009]. Recent analysis of the genome 
sequence of commensal Neisseria spp. indicated that fhbp was present in N. polysaccharea and N. 
cinerea, with the latter showing high amino acid identity with V1 meningococcal fhbp (95%). Using 
SPR, N. cinerea fHbp bound CFH(6,7) with KDs in the nM range, that was similar to the affinity of CFH 
with V1.1 fHbp from N. meningitidis indicating that high affinity binding of CFH to the surface of the 
bacterium is not only involved during survival in the bloodstream but could aid colonisation and 
persistence in the human nasopharynx. In serum survival assays wild-type N. cinerea, which express 
fHbp, had enhanced survival compared to the fHbp knockout although the differences in survival 
were less pronounced than in N. meningitidis H44/76 [Madico, G. 2006]. Furthermore, the difference 
in survival of N. cinerea was not significant at most serum concentrations. In contrast to N. 
meningitidis, N. cinerea do not express a polysaccharide capsule, a major meningococcal virulence 
factor, as they lack the capsule biosynthesis genes and are consequently more susceptible to 
complement-mediated lysis [Kim, J. J. 1989. Marri, P. R. 2010]; this is evidenced by the serum 
concentration resulting in 50% bacterial lysis (LD50) being approximately 5% whereas it has been 
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previously been demonstrated that N. meningitidis H44/76 requires 40% NHS for LD50 [Madico, G. 
2006]. Therefore, to further examine the functional consequences of N. cinerea CCUG 346 T binding 
CFH, bacteria should be pre-incubated in purified recombinant CFH prior to the addition of CFH-
depleted sera to evaluate the difference in serum survival as demonstrated previously [Schneider, 
M. C. 2006]. Pre-incubation with recombinant CFH would reduce competition with the known CFH 
antagonist, CFHR3, potentially making the assay more sensitive to differences in survival between 
the wild-type N. cinerea and the Δfhbp mutant [Caesar, J.J. 2014]. 
High affinity interactions between fHbp and CFH have evolved for N. meningitidis and N. cinerea 
which inhabit the nasopharynx, but not for N. gonorrhoeae. Indeed, a frame shift mutation in the 
nucleotide sequence at position 40 of ghfp disrupts the lipobox resulting in the loss of surface 
localisation of GHfp [Jongerius, I. 2013]. Furthermore, sequence changes in the ORF of ghfp abolish 
CFH binding [Jongerius, I. 2013]. GHfp has been shown to bind siderophores in vitro, although the 
precise function of this protein in the gonococcus has yet to be established even though GHfp is 
highly conserved unlike meningococcal fHbp [Veggi, D. 2012; Hadad, R. 2012; Jongerius, I. 2013]. 
Furthermore, N. gonorrhoeae has been shown to bind CFH via surface expressed PorB.1 which is 
abundantly expressed on the gonococcal surface [Ram, S. 1998. Ngampasutadol, J. 2008].  
For N. meningitidis, most work investigated the role of CFH on serum survival [Madico, G. 2006; 
Schneider, M. C. 2006]. However, disease is an evolutionary dead-end for the meningococcus. 
Therefore bacteria must be adapted for colonisation of the nasopharynx, which is its natural habitat. 
The mechanisms by which N. meningitidis and N. cinerea recruit CFH compared with N. gonorrhoeae 
might reflect differences in concentrations of CFH at these sites and the level of other complement 
proteins. Low levels of CFH have been detected in urothelial cells with higher levels detected in 
kidney tubules, while CFH could not be detected on respiratory epithelial cells of the nasopharynx 
by immunohistochemistry [Uhlén, M. 2015]. However, N. meningitidis is exposed to high levels of 
CFH in serum, 116–562 μg/mL (0.7–3.6 μM) in a healthy Caucasian population, while the amount of 
CFH in the respiratory tract is significantly lower, with levels in saliva ranging from 0.007-0.059 g/mL 
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(0.04-0.38 nM) [Esparza-Gordillo, J. 2004. Sofat, R. 2013]. Furthermore, complement proteins, 
including C3b, may be present in plasma exudates of the nasopharyngeal mucosa from the abundant 
sub-epithelial microvessels [Persson, C. G. 1991. Kaul, T. N. 1982].  Levels of C3 in nasopharyngeal 
secretions are estimated to be approximately 6.6% (4.2-20.2%) of serum C3 levels, (range from 0.1-
0.3 mg/mL compared to serum levels of 1.5-2.1 mg/mL), indicating that there is a significant level of 
complement in the nasopharynx [Prellner, K. 1985]. Therefore high affinity interactions with CFH 
might be required to protect against complement activation on mucosal surfaces due to low 
availability of this important complement regulator [Esparza-Gordillo, J. 2004. Sofat, R. 2013]. CFH 
binding to meningococcal fHbp was previously estimated to have the highest affinity of any known 
CFH ligand, with KDs in the low nanomolar range; N. cinerea also binds CFH at a similar affinity, which 
suggests that fHbp is required for colonisation [Schneider, M. C. 2009. Johnson, S. 2012]. 
Binding of CFH is important for colonisation of other bacteria which inhabit the nasopharynx, 
including S. pneumoniae. Binding of CFH by CCP domains 8-11 and CCP domains 19-20 to PspC of S. 
pneumoniae significantly increases bacterial attachment to host epithelial and endothelial cells by 
acting as a molecular bridge between the bacterium and host cell [Hammerschmidt, S. 2007]. There 
are other examples of host molecules including vitronectin, fibronectin, and plasminogen acting as 
molecular bridges to enable bacteria to engage host cells [Virji, M. 1994. Singh, B. 2010. 
Dziewanowska, K. 2000. Sumitomo, T. 2016]. Moreover, the Arg-Gly-Asp at the C-terminus of CCP 
domain 4 of CFH was shown to mediate attachment of S. pneumoniae to epithelial cells via 
interactions with integrins to induce uptake of pneumococci into epithelial cells [Hellwage, J. 1997. 
Hammerschmidt, S. 2007]. A similar role for CFH acting as a molecular bridge has also been described 
for Streptococcus pyogenes [Pandiripally, V. 2003]. Similar mechanisms might influence colonisation 
of N. meningitidis and N. cinerea. 
Asymptomatic colonisation of the oropharynx and nasopharynx by N. lactamica has been well 
documented in children, and has been suggested that colonisation by commensal Neisseria protects 
children from developing meningococcal disease through induction of natural immunity [Gold, R. 
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1978. Cann, K. J. 1989. Cartwright, K. A. 1987]. A live N. lactamica human challenge study indicated 
that colonisation by N. lactamica may reduce colonisation by N. meningitidis by eliciting 
opsonophagocytic antibodies or competing with N. meningitidis on mucosal surfaces [Evans, C. M. 
2011]. A subsequent study, in which 149 individuals were inoculated with N. lactamica, 
demonstrated a significant reduction in N. meningitidis carriage in the challenge group after 8 weeks 
in participants colonised by N. lactamica (24.2 and 14.7% nasopharyngeal carriage of N. meningitidis) 
vs the control group (22.4 to 23.6% nasopharyngeal carriage of N. meningitidis) suggesting that 
bacterial competition on mucosal surfaces was likely to be the mechanism for the reduction on 
carriage and acquisition of N. meningitidis [Deasy, A. M. 2015]. Therefore, N. lactamica could 
compete with N. meningitidis for the same binding sites on mucosal surfaces, including CEACAMs and 
PAFr which are proposed receptors for Opa and Tfp, respectively [Toleman, M. 2001. Virji, M. 1996a 
Virji, M. 1996b. Jen, F. E. 2013]. However, N. cinerea lacks opa gene homologues and has been shown 
to bind epithelial cells independently of Tfp expression [Marri, P. R. 2010. Wörmann ME. 2016]. 
Future investigations should aim to identify molecules involved in initial adhesion which are 
independent of Tfp. N. cinerea lacks the capsule biosynthesis locus and therefore adhesins which 
mediate intimate attachment of bacteria to host cells may have a larger impact than in N. meningitidis 
[Kim, J. J. 1989. Marri, P. R. 2010]. MspA and NadA of N. meningitidis have been shown to mediate 
intimate attachment to epithelial cells and gene homologues have been identified in N. cinerea but 
the expression and function of mspA and nadA have yet to be confirmed [Wörmann ME. 2016. Muzzi, 
A. 2013]. Furthermore, the potential role of N. cinerea fHbp in mediating binding to epithelial cells 
by utilising CFH as a molecular bridge, as shown for S. pneumoniae and S. pyogenes, has yet to be 
analysed. 
Genome analysis indicated that fhbp was present in all N. cinerea isolates. Western and Far western 
analysis showed that fHbp is expressed by all five N. cinerea isolates examined and bound CFH. Of 
note, fhbp is not present in other commensal Neisseria spp. with the exception of N. polysaccharea, 
although the majority of N. polysaccharea isolates have a frameshift in the ORF potentially producing 
a truncated protein [Muzzi, A. 2013]. This was in contrast to a recent genome analysis of the 
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commensal Streptococcal species, Streptococcus mitis, which showed that the CFH binding protein 
of S. pneumoniae, PspC, was absent despite the close relatedness of the two species [Denapaite, D. 
2010]. Further comparative analysis of the genome sequences of Staphylococcus epidermidis with 
Staphylococcus aureus has also identified that the gene encoding a CFH-binding protein of S. aureus, 
SdrE, is absent from the genome of S. epidermidis [Gill, S. R. 2005. Sharp, J. A. 2012]. The absence of 
SdrE from S. epidermidis may be due to differences in its biological niche compared to S. aureus. S. 
aureus commonly colonises mucosal surfaces of the respiratory tract, whereas S. epidermidis is part 
of the skin flora and might not be exposed to complement at this site [Gill, S. R. 2005. Smith, E. J. 
2011]. There are limited data investigating the role of CFH binding to commensal bacteria even 
though there is increasing evidence to indicate that CFH and CFH binding may be important for 
colonisation. Therefore future work to elucidate these mechanisms of CFH binding in commensal 
species should provide further insights into host-pathogen interactions and colonisation. 
Bexsero®, a multi component vaccine consisting of fHbp fused to GNA2091, NadA, NHBA fused to 
GNA1030, and OMVs from NZ98/24, was recently licensed against serogroup B meningococci and 
implemented in the UK infant vaccination schedule [Oster, P. 2005]. Conjugate vaccines against N. 
meningitidis have been highly successful at reducing carriage of this pathogen but will not affect 
commensal Neisseria spp. as they target the capsular polysaccharide which is not present in the 
commensal species [Trotter, C. L. 2004. Balmer, P. 2002]. Limited data is currently available which 
assess the impact of Bexsero® on carriage, although a study of 2,954 18-24 year olds suggested that 
Bexsero® could reduce carriage [Read, R. C. 2014]. In the study, 987 participants were assigned to a 
control group and 979 participants received two doses of Bexsero®. Prior to immunisation 31% of the 
control group and 33% of the participants who received the Bexsero® immunisation were positive for 
meningococcal carriage. Three months after the second dose of Bexsero®, participants showed a 
significant reduction in carriage of N. meningitidis (18.2% reduction in carriage) compared to the 
control group which was independent of meningococcal serogroup [Read, R. C. 2014]. 
The antigens included in the Bexsero® vaccine have been shown to induce SBA against a panel of N. 
meningitidis isolates [Pizza, M. 2000. Masignani, V. 2003]. SBA is an accepted immunological correlate 
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of protection against meningococcal disease and rabbit SBA titres of ≥8 are considered to be 
protective [Gold, R. 1978. Borrow, R. 2005]. Mice immunised with Bexsero® elicited SBA against N. 
cinerea. Moreover, the SBA titres obtained with Bexsero® were similar to mice immunised with fHbp 
alone. Sequence analysis of N. cinerea indicates that fhbp, GNA2091 and GNA1030 are present in all 
N. cinerea isolates whereas only fragments of nadA, with low sequence identity to meningococcal 
nadA4, are present in some N. cinerea isolates [Muzzi, A. 2013]. NHBA was not found in any N. cinerea 
isolate analysed [Muzzi, A. 2013]. GNA2091 and GNA1030 do not induce SBA against N. meningitidis 
but are included in the vaccine as they act as adjuvants and increase immune responses. The lack of 
SBA responses against N. cinerea without fhbp indicates that immunisation with fHbp is enough to 
induce effective immune responses against N. cinerea.  
Although SBA is the ‘gold standard’ correlate of protection against N. meningitidis, induction of SBA 
against N. cinerea does not necessarily mean that immunisation with Bexsero® will affect carriage of 
this species [Gold, R. 1978]. As IgG and complement are present on mucosal surfaces and in plasma 
exudates on epithelial surfaces [Robert-Guroff, M. 2000. Persson, C. G. 1991. Reichhardt, M. P. 2016], 
it is possible that induction of SBA against fHbp could affect the nasopharyngeal flora, especially 
bacteria expressing fHbp such as N. meningitidis and N. cinerea. SBA were performed using lower 
dilutions of complement for N. cinerea (1:10) compared with N. meningitidis (1:6). Furthermore, as 
N. cinerea lack capsule and expresses fHbp, N. cinerea may be more susceptible than N. meningitidis 
to immune responses against surface proteins elicited by Bexsero® i.e. bactericidal antibodies. 
Therefore, it will be interesting to evaluate the impact of Bexsero® on carriage of commensal 
Neisseria as well as the meningococcus. Furthermore, this study has not eliminated the possibility of 
N. cinerea inducing a bactericidal immune response in individuals colonised by the bacterium or 
assessed the impact of colonisation by N. cinerea on meningococcal carriage which could be the focus 
of further investigation. 
Data in this chapter shows that not only does N. cinerea possess a fhbp gene but that fHbp is localised 
on the surface of the bacterium and accessible to mucosal surfaces. Moreover, Bexsero® elicits 
bactericidal antibodies against N. cinerea, with SBA responses similar those following immunisation 
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with fHbp alone. Given that meningococcal fHbp can elicit bactericidal antibodies against N. cinerea, 
N. cinerea could potentially elicit specific mucosal and serum antibody responses as previously 
demonstrated by cross-reactive antibodies against N. meningitidis following carriage by N. lactamica 
and therefore could be a source of natural immunitiy against the meningococcus [Evans, C. M. 2011]. 
Furthermore, carriage of commensal Niesseria species, including N. cinerea, may contribute to 
protection against meningococcal carriage and disease via direct competition in the nasopharynx as 
evidenced by reduced carriage of N. meningitidis in individuals colonised by N. lactamica although 
the impact of N. cinerea carriage on carriage of N. meningitidis has yet to be elucidated. [Evans, C. 
M. 2011. Deasy, A. M.]. Implementation of vaccines containing fHbp have the potential to affect the 
commensal nasopharyngeal flora which could alter the species which are naturally acquired and 
carried on the nasopharyngeal mucosa. If commensal Neisseria carriage is terminated through the 
introduction of fHbp containing vaccines, i.e. Bexsero®, other bacterial species could occupy a vacant 
niche and could potentially include other pathogens e.g. N. meningitidis which are not covered by 
available vaccines. Therefore the impact of multi-component vaccines on commensal Neisseria 
species should be assessed in future carriage studies. 
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8. SUPPLEMENTARY INFORMATION 
 
 
SI 1: N. cinerea fHbp is predicted to be structurally similar to N. meningitidis fHbp. 
(A) Predicted structure of N. cinerea fHbp (grey ribbon) generated with the I-TASSER server and V1.1 fHbp (blue ribbon) 
[Schneider, PBD: 2W80] and (B) predicted structure of N. cinerea fHbp bound to CFH (green ribbon). Figure drawn using 
Pymol. Residues in red (shown as ball-and-stick representations) are different in N. cinerea fHbp compared to V1.1 fHbp. 
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SI 2: CFHR3(4,5) does not influence susceptibility of N. cinerea to complement mediated lysis. 
Survival of  (A) N. cinerea CCUG 346 T (filled circles) and (B) CCUG 346 TΔfhbp (open circles) in the 
presence of 3% NHS (black) or HI-NHS (blue) following pre-incubation in different concentrations of 
CFHR3(4,5) (indicated). Data presented as percent survival relative to bacteria incubated in the 
absence of serum and CFHR3(4,5). 
 
SI 3: Immunogenicity of individual mouse sera 
Sera of individual mice from groups immunised with V1.1 fHbp, N. cinerea fHbp and Bexsero® 
recognises N. cinerea CCUG 346 T, N. meningitidis MC58 and H44/76 fHbp and detects recombinant 
V1.1 and V1.110 fHbp as determined by western blot analysis. 
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SI 4: Optimisation of rabbit complement concentration for N. cinerea SBA assays. 
(A) Survival of N. cinerea CCUG 346 T (black bars) and CCUG 346 T Δfhbp (grey bars) after incubation in a range of rabbit 
complement dilutions (neat to no complement, as indicated). Red line indicates 100% bacterial survival. Approximately 
90% bacterial survival is seen following incubation in 1:9 dilution of rabbit complement after 60 minutes incubation. Data 
presented as percent survival relative to bacteria incubated in no rabbit complement for 60 minutes. Error bars are ± SEM 
of three independent experiments. 
 
 
SI 5: Characterisation of isogenic N. cinerea expressing the homologous fHbp. 
(A) Flow cytometry analysis of N. cinerea CCUG 346 T (black), and isogenic strain expressing V1.110 fHbp (blue) using anti 
V1.1 fHbp sera. Grey shaded area shows the plot for CCUG 346 T Δfhbp. (B) Data presented as arbitrary units from the 
mean fluorescence of FACS calibur FL-4 channel.  
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9. Publication: Competition between antagonistic complement 
factors for a single protein on N. meningitidis rules disease 
susceptibility. Caesar JJ. et al. (2014) Elife 
 
 
